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Abstract
This thesis documents work directed towards the development of a novel cancer therapeutic 
that uses a synthetic polymer to deliver a pro-apoptotic peptide into the cytosol of cancer 
cells and in turn induce death by apoptosis. This was approached by (1) testing the ability 
of a range of synthetic polym ers (poly(2-alkyl acrylic acid)s (PAAAs) and poly[ 1 - 
(dimethylamino)ethyl methacrylate] (pDM AEM A)) to facilitate the release of molecules 
from endosomes to the cytosol, (2) conjugating a pro-apoptotic peptide (Bad(140-165)) to a 
suitable endosomal-disruptive polymer, and (3) testing the ability of the polymer-peptide 
conjugate to enter the cytosol following endocytosis and to trigger apoptosis.
PAAAs were shown to be endocytosed into cells and transported to late endosomes, where 
acidification of the lumen by the membrane H+-ATPase triggered polymer-mediated vesicle 
disruption and release of endosomal contents to the cytosol. pDMAEMA was shown to 
induce rapid necrosis and to be endocytosed into cells where it induced morphological 
changes in late endosomes/lysosomes. However, pDMAEMA did not have the ability to 
disrupt endosomes, and was thus not used in further experiments. In addition, the very high 
toxicity of pDMAEMA could also pose a significant risk of bystander cell damage in 
cancer therapies. A hydrazide-linker (X) was synthesised and conjugated to PAAAs. 
Results showed that (1) the membrane disruptive ability of PAAAs was retained following 
conjugation with hydrazide linker, and (2) the carboxcyclic-hydrazide bond incorporated 
within the linker was stable at pH 7 but not at pH 5. Finally, PAAA-X was conjugated to 
Bad(140-165) to form PAAA-X-Bad(140-165). Immunofluorescence assays showed that 
PAAA-X-Bad( 140-165) partially co-localised with early endosomes and induced disruption
of endosomes and release of their contents into the cytosol in a time-dependent manner. 
Surprisingly, cell viability was retained following uptake of PAAA-X-Bad(140-165). The 
reasons why apoptosis was not induced following uptake of PAAA-X-Bad(140-165) are 
currently unknown, however possibilities include incomplete cleavage of the linker and/or 
insufficient release of Bad( 140-165) into the cytosol. Future experim ents, such as 
increasing the number of linkers and/or Bad(140-165) molecules attached to molecules of 
PAAA, may aid in the understanding of why apoptosis was not induced.
As an adjunct to studies of the effects of polymers and PAAA-X-Bad(140-165) on cells, a 
new technique was developed to measure mitochondrial permeability transition (MPT) in 
intact cells. In this method, calcein is introduced into cells by pinocytic loading. Polarised 
mitochondria are visualised as darkened voids within a bright green fluorescent cytosol. 
MPT is measured as an in-filling of calcein fluorescence into these darkened voids. This 
method is free of disadvantages associated with earlier developed techniques and will be 
valuable in studies of MPT in intact cells. However, unfortunately, technical limitations 
prevent the use of this method to measure MPT in cells undergoing apoptosis.
Taken together, results presented in this thesis provide a firm foundation for the future 
development of a novel cancer therapeutic that (1) directly targets cancer cells, (2) induces 
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This chapter gives a review of the current understanding of apoptosis. Details of the 
molecules and processes involved and the mechanisms of regulation are described. The 
development of pH-sensitive polymers and their use in cancer therapies are then 
described. The final section of this chapter describes a novel cancer therapeutic, 
involving pH-sensitive polymers that directly target cancer cells and induce death by 
apoptosis.
1.1 Apoptosis
Apoptosis, or programmed cell death, represents a physiological form of cell death and 
is thought to be involved in every homeostatic and pathological process in the body 
(Gastman, 2001; Wilson, 1998). It is the dominant form of cell death especially in the 
organs and tissues of the immune system and is genetically controlled by an internally 
encoded suicide program (Steller, 1995; White, 1993).
The apoptotic pathway is divided into three functionally distinct phases: initiation, 
execution and degradation. During the initiation phase the cell receives a death-inducing 
signal, which can result from various chemical and biological agents (Gastman, 2001). 
Examples of initiating signals include a shortage of nutrient supply or ligation of death 
signal-transmitting receptors (Kroemer et al., 1997). Apoptosis can be initiated by many 
different pathways but it is in the execution phase where these different signals are 
translated into a common molecular pathway. During the execution phase a ‘point of no 
return’ is passed and the cells become irreversibly programmed to die (Kroemer et al., 
1995; Kroemer et al., 1997). The final degradation phase is accompanied by a distinct 
set of morphological and physiochemical changes including:
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1. Cellular and nuclear shrinkage, which is accompanied by internucleosomal DNA 
fragmentation (Patel et al., 1996; Vander Heiden et al., 1997).
2. Protein degradation and blebbing of the membrane into apoptotic bodies (which 
contain intact cytoplasmic organelles and nuclear fragments). This occurs just 
before phagocytosis by macrophages or adjacent cells (Shi, 2001; Villa et al., 1997), 
preventing the leakage of noxious cellular contents into the surrounding tissue. 
Figure 1.1 depicts major cytostructural changes that occur during apoptosis.
3
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Figure 1.1: The major cytostructural changes that occur during apoptosis. (1) Shows a 
normal cell. In the early stages of apoptosis the cytoplasm starts to condense, the 
chromatin becomes very dense and compact, forming uniform, fine granular masses on 
the nuclear envelope, and the nuclear and cellular outlines become mildly ruffled and 
convoluted (2). This is then followed by rapid chromatin condensation and convolution 
of the nuclear and cellular outlines. The nucleus breaks up into discrete membrane 
enclosed fragments, and the cell buds to produce membrane-bound apoptotic bodies 
containing well-preserved organelles (3). The apoptotic bodies are phagocytosed by 
adjacent cells (4) and degraded within lysosomal vacuoles (5) to form compact debris 
(6) (Adapted from Kerr, 1995).
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1.2 Organelles Involved in Apoptosis
In the evolution o f eukaryotic cells, m itochondria have for a long time played a 
prominent role (Scheffler, 2001). They (1) are essential for cellular energy metabolism 
(Rutter and Rizzoto, 2000), (2) reduce and detoxify free radicals, such as reactive 
oxygen species (ROS) (Mignotte and Vayassiere, 1998), (3) serve as a cellular calcium 
buffer (Orth and Schapira, 2001), and (4) are sites of electron transport and generators 
of cellular ATP (Harris and Thompson, 2000). A growing body of evidence from many 
independent research groups, now supports a role for m itochondria as crucial 
participants in the induction and execution phases of apoptosis (Finucane et al., 1999; 
W ilson, 1998; Green and Reed, 1998; Kroem er et al., 1998; Bernardi et al., 2001; 
Desager and Martinou, 2000, Gottlieb et al., 2000; Parone et al., 2002).
In recent years, several controversial reports have suggested that lysosomes may also 
play a crucial role in apoptosis, particularly in the initiation phase. In a number of cell 
types, apoptosis is associated with an early destabilisation of lysosomal membranes and 
subsequent release of lysosomal enzymes into the cytosol (Terman et al., 1999; Neuzil 
et al., 1999; Roberg et al., 1999). It was suggested that rupture of the lysosomal 
membrane may be an early upstream event in apoptosis (Antunes et al., 2001). Despite 
these recent findings, the involvem ent o f lysosom es in apoptosis is still poorly 
understood (see section 1.7), and probably because of this, not generally accepted 
(Hengartner, 2000).
It has also been suggested that the endoplasm ic reticulum  may be involved in the 
execution phase, independent of m itochondria (Ng et al., 1997). Ng et al. (1997) 
suggested that caspase-m ediated generation of an N-terminal 20 kDa fragm ent of the
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human protein p28 Bap31 in the endoplasm ic reticulum  induces apoptotic nuclear 
changes. It is also possible that other organelles may be involved. For example, Mancini 
and colleagues (2000) have suggested that the Golgi complex may be involved in the 
execution phase, while Li et al. (2000) suggest the involvement of the nucleus in the 
execution phase. However, to date, evidence is limited and further research will be 
needed to confirm these suggestions.
1.3 Proteins Involved in Apoptosis
Extensive research has revealed many of the crucial components involved in apoptosis, 
however ongoing research indicates the potential for many more. Some of the vital 
components of the apoptotic pathway discovered to date include: (1) cytosolic-based 
proteins such as caspases and inhibitor of apoptosis (IAP) fam ily proteins and (2) 
m itochondria-associated proteins such as Bcl-2 fam ily proteins, cytochrom e c, 
Smac/DIABLO, apoptosis inducing factor (AIF) and Omi/HtrA2.
1.3.1 Cytosolic Proteins
1.3.1.1 Caspases
Caspases (cysteinyl aspartate-specific proteinases) are a family of intracellular cysteine 
proteases that cleave substrates adjacent to aspartic acid residues and that can 
themselves be activated by cleavage at similar sites (M ignotte and Vayssiere, 1998; 
Green and Evan, 2002). They are produced in cells as catalytically inactive zymogens 
and are activated by either truncation or dimerization. Three general mechanisms of 
caspase activation have been described thus far:
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1. Processing by an upstream caspase -  This type of activation results from pro- 
caspases being exposed to a previously activated caspase. It is the simplest mechanism 
of caspase activation and is used specifically for the activation of downstream caspases, 
such as caspase-3, -6 and -7.
2. Induced Proximity -  Muzio et al. (1998) suggest that the formation of a death- 
inducing signalling complex (DISC), comprised of tightly clustered specific ligands 
(e.g. Fas), receptor molecules, adaptor proteins (e.g. FADD) and pro-caspase-8, is 
sufficient to allow the pro-enzyme molecules to mutually cleave and activate each other, 
thereby producing active caspase-8.
3. Association with regulatory subunits -  This activation process is the most complex. 
The only known example involves the formation of a large complex, comprised of 
Apaf-1, cytochrome c, ATP and pro-caspase-9. The specific combination of these 
proteins results in the activation of caspase-9, however, the exact mechanism of 
activation remains unclear (Hengartner, 2000).
Over a dozen caspases have been identified and are divided into three subgroups, based 
on their substrate preference, extent of sequence homology and structural similarities 
(Hengartner, 2000). Table 1.1 shows the groupings of all known caspases. The cysteine 
containing sequence glutam ine-alanine-cysteine-arginine-glycine (QACRG) is a 
conserved motif common to all caspases; if the cysteine is mutated, then the proteases 







Structurally related to group I 
Structurally related to group II
Caspase-1, -4, -5 
Caspase-2, -3, -7 
Caspase-6, -8, -9,-10 
Caspase-11, -12,-13 
Caspase-14
Table 1.1: -  Caspases and their subgroups (Gastman, 2001).
1.3.1.2 IAPS
The inhibitor of apoptosis (IAP) family of proteins inhibit the enzymatic activity of 
mature caspases (Miller, 1999). In the past few years several distinct IAPs have been 
identified, all of which exhibit anti-apoptotic activity. Table 1.2 summarises the known 
IAPs. All IAPs contain a highly conserved functional region known as the baculovirus 
IAP repeat (BIR), which contains approximately 80 amino acids folded around a zinc 
atom (Shi, 2001). Most IAPs have more than one BIR region, with the various BIR 
domains exhibiting different functions. Caspase inhibition occurs through precise 
interactions between the BIR domains of IAPs and the mature caspase.
XIAP BRUCE Survivin ML-IAP
CIAP-1 CIAP-2 NAIP Livin
Apollon





In recent years, extensive research has been conducted on the Bcl-2 family proteins, as 
they have been strongly implicated as important regulators of apoptosis. A primary 
mechanism by which these proteins regulate apoptosis is probably by controlling 
cytochrome c release, however, further research is needed to determine the exact 
function of these specialised proteins. A number of Bcl-2 family members have been 
identified and are summarised in Table 1.3. Each family member contains at least one of 
the four conserved functional regions called Bcl-2 homology domains (BH1-BH4), 
schematically shown in Figure 1.2. These domains enable the different members of the 
family to form homo- or hetero-dimers with each other, thereby enhancing or 
antagonising their functions (Mignotte and Vayssiere, 1998; Kelekar et al., 1997). They 
are divided into three different groups based on Bcl-2 homology and function. The anti- 
apoptotic members, such as Bcl-2, harbour at least three, but generally four, BH 
domains, while the pro-apoptotic members have between one and three BH domains. 
The pro-apoptotic group is subdivided into two groups -  those with only one BH 
domain and those that possess up to three domains. Many of the pro-apoptotic family 
members, such as Bax, Bid and Bad, are synthesised in the cytosol, however, following 
an apoptotic stimulus, they undergo a conformation change and are translocated to 














Table 1.3 : Functional groupings of Bcl-2 family members (B-cell leukemia/lymphoma 
2). (Gastman, 2001; Cory and Adams, 2002).









Figure 1.2: Schematic representation of the BH domains contained within the Bcl-2 




Cytochrome c is a 12.3 kDa extrinsic membrane protein, normally associated with the 
outer surface of the inner membrane of mitochondria (Gastman, 2001). It is encoded by 
a nuclear gene and is translated by cytosolic ribosomes as apocytochrome c. 
Apocytochrome c is subsequently translocated into mitochondria where a haeme group 
is attached covalently to form holocytochrome c (Yang et al., 1997; reviewed by 
Waterhouse et al., 2002). The release of holocytochrome c from mitochondria has been 
implicated as one of the critical steps in apoptosis; much debate continues over the 
mechanism and the order of events that lead to the release of the protein. The Bcl-2 
proteins are thought to be involved in this process. This is supported by Gross et al. 
(1999) and others, who have shown that the addition of pro-apoptotic Bcl-2 family 
members to isolated mitochondria is sufficient to induce cytochrome c release, whereas 
the over-expression of anti-apoptotic Bcl-2 family proteins inhibits cytochrome c 
release. In addition to Bcl-2, mitochondrial lipids (e.g. cardiolipin) have also been 
suggested to be involved in the release of cytochome c. Cardiolipin is thought to induce 
the detachment of cytochrome c from the inner mitochondrial membrane (Ott et al., 
2002).
1.3.2.3 Smac / DIABLO
Smac (second mitochondria-derived activator of caspases), also known as DIABLO 
(direct IAP binding protein with low pi) is a recently discovered mitochondrial protein. 
It is comprised of 239 amino acids, including an N-terminal 55 residue-long targeting 
sequence that is cleaved upon transport into mitochondria (Du et al., 2000; Verhagen et 
al., 2000, Reed, 2002). During apoptosis, Smac/DIABLO is released, in conjunction 
with cytochrome c, from the intermembrane space of mitochondria. However, it is yet to
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be determined if these two proteins are released by the same mechanism. Smac interacts 
with multiple IAPs, thereby preventing their inhibitory effect on both initiator and 
effector caspases (Chai et al., 2000). The interaction between Smac and various IAPs is 
thought to involve the four N-terminal residues of Smac and the BIR domains of the 
IAPs (Liu et al., 2000; Wu et al., 2000).
1.3.2.4 Omi/HtrA2
The serine protease Omi is the most recent mitochondrial protein implicated in 
apoptosis to be identified. Like Smac, Omi is localised predominantly in the 
intermembrane space of mitochondria but is released into the cytosol, in conjunction 
with Smac and cytochrome c, during apoptosis (Hegde et al., 2002). As yet, it is not 
known if Omi, cytochrome c and Smac are released by the same mechanism (Martins et 
al., 2002). In the cytosol, the N-terminal 133 amino acids are cleaved from the rest of 
the protein and mature Omi protein is generated (van Loo et al., 2002). To date the 
function of Omi remains unclear, however, it is thought to interact with the BIR 
domains of IAP proteins, thereby promoting caspase activity (van Loo et al., 2002; 
Martins et al., 2002; Verhagen et al., 2002). Hegde et al. (2002) have also shown that 
Omi can induce cell death in mammalian cells independent of caspases, Apaf-1 or IAP, 
via its serine protease activity; they suggest that it may be involved in a caspase- 
independent mechanism of cell death.
1.3.2.5 AIF
AIF (apoptosis inducing factor) is a 50 kDa protein which is normally confined to the 
intermembrane space of mitochondria but translocates to the nucleus following 
induction of apoptosis (Susin et al., 1999a; Daugas et al., 2000). Once inside the
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nucleus, it induces chromatin condensation and cleavage of DNA into 50 Kb fragments, 
however the mechanism involved remains unresolved (Ye et al., 2002). AIF has now 
been shown to induce caspase-independent peripheral chromatin condensation and 
DNA fragmentation when added to purified nuclei. In addition to its apoptogenic action 
on nuclei, AIF can also participate in the regulation of apoptotic mitochondrial 
permeabilisation (reviewed by Cande et al., 2002).
1.4 Pathways Involved in Apoptosis
There are two major apoptotic pathways known to date: the intrinsic pathway, which is 
initiated by mitochondria, and the extrinsic pathway, initiated by cell surface receptors. 
The extrinsic pathway, or death receptor pathway, is triggered by members of the death 
receptor family, such as CD95 and tumour necrosis factor receptor 1 (TNFR1). The 
binding of a specific ligand to these receptors results in the formation of a death- 
inducing signalling complex. This complex, together with an adaptor molecule known 
as FADD (Fas-associated death domain protein), associates with multiple pro-caspase-8 
molecules to cause caspase-8 activation (Hengartner, 2000). The activation of caspase-8 
in turn activates other downstream caspases and causes apoptotic death (Figure 1.3).
The intrinsic pathway occurs in response to a wide range of death stimuli, including the 
activation of tumour suppressor proteins and oncogenes (Shi, 2001). It is thought that 
these diverse pathways converge on mitochondria, possibly via the action of pro- 
apoptotic Bcl-2 proteins. This is followed by the release of many proteins from the 
interm em brane space, such as cytochrom e c, AIF (Lorenzo et al., 1999), 
Smac/DIABLO (Du et al., 2000; Verhagen et al., 2000) and several pro-apoptotic
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caspases, including pro-caspase-2,-3, and -9 (Loeffler and Kroemer, 2000). Exactly how 
these proteins are released and the order of release is still greatly debated and will be 
discussed later (Sections 1.5 and 1.6). Once in the cytosol, cytochrome c is thought to 
bind tightly with Apaf-1; this binary complex then associates with dATP or ATP and 
pro-caspase-9 to form a complex known as the apoptosome (Zou et al., 1999; Saleh et 
al., 1999; Green and Evan, 2002), which in turn activates pro-caspase-9 to form 
caspase-9. Interestingly, caspase-9 remains bound to the apoptosome as a holoenzyme, 
as caspase activity is only retained while it is bound in this conformation (Rodriguez 
and Lazebnik, 1999). The holoenzyme caspase-9 activates caspase-3 and subsequent 
apoptotic events (Hengartner, 2000; Desagher and Martinou, 2000). The final events 
include the activation of DNA fragmentation factor 45 (DFF45) which, when activated, 
functions as a nuclease and degrades chromatin into nucleosomal fragments.
The intrinsic and extrinsic pathways converge at the level of caspase-3 activation. The 
activation of caspase-3 is inhibited by IAP proteins, which are themselves antagonised 
by Smac/DIABLO following release from mitochondria (Hengartner, 2000). These 
pathways are linked by the action of Bid, a pro-apoptotic Bcl-2 family member (Yin, 
2000). The activation of caspase-8, in the extrinsic pathway, increases the pro-death 
activity of Bid and its translocation to mitochondria, where it promotes release of 
cytochrome c and Smac (Yin 2000; Li et al., 2002). Figure 1.3 schematically represents 


































Figure 1.3: Schematic representations of the two major pathways of apoptosis. In the 
extrinsic pathway, death receptor ligands bind to death receptors and in turn activate 
caspase 8 and further downstream caspases, thereby causing apoptotic death. In 
contrast, the intrinsic pathway can be triggered by various cell death stimuli, which 
cause mitochondria to release proteins, such as cytochrome c. This then triggers a 
cascade of events, including the activation of caspases and DNA fragmentation 
(Adapted from Gastman, 2001).
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1.5 Mitochondria and Apoptosis
Mitochondria are now accepted as key players in the execution phase of apoptosis. The 
culmination of results from many independent research groups has led to this 
conclusion. Some of these results are summarised below:
1. Kroemer and others (reviewed by Loeffler and Kroemer, 2000) have shown that 
mitochondrial membrane permeabilization often precedes the signs of advanced 
apoptosis and necrosis, irrespective of the cell type or death-inducing stimulus. 
They have also shown that inhibition of m itochondrial membrane 
permeabilization by specific pharmacological interventions (i.e. agents acting on 
mitochondrial proteins) prevents or retards cell death.
2. Balakirev and Zimmer (1998) reported major changes to mitochondrial integrity 
prior to the classical sign of apoptosis, and also mitochondrial depolarisation 
preceded DNA fragmentation.
3. Pastorino et al. (1998) and Zamzami et al. (1998a,b) have shown that the Bcl-2 
family of proteins act on mitochondria to regulate apoptosis.
4. Green and Kroemer (1998), Kroemer and Reed (2000) and Boya et al. (2001) 
have shown that several pro-apoptotic signals converge on mitochondria to 
induce mitochondrial membrane permeabilisation and this phenomenon is under 
the control of Bcl-2 related proteins.
5. Gilmore et al. (2001) have shown that pinocytic loading of the pro-apoptotic 
mitochondrial protein cytochrome c in to intact cells induces activation of 
caspase-3 and -9  like enzymes, and a loss of mitochondrial depolarisation 
coincident with an increase in mitochondrial permeability.
6. Numerous proteins, such as Smac, Omi and cytochrome c, which have
downstream apoptotic functions, are primarily localised in mitochondria (Du et
16
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al., 2000; Verhagen et al., 2000; van Loo et al., 2002; Martins et al., 2002;
Verhagen et al., 2002).
Two models for the involvement of mitochondria have been proposed:
1. The first model was initially proposed by Kroemer et al. (1997) and involves the 
phenomenon referred to as mitochondrial permeability transition (MPT). MPT results in 
the opening of mega channels or pores (permeability transition pores-PTP), which are 
formed under specific conditions at points where the inner and outer membranes of 
mitochondria touch. The opening of the pores allows for the equilibration of ions and 
respiratory substrates (<1500 Da) between the cytosol and the mitochondrial matrix, 
leading to the reduction of mitochondrial transmembrane potential (Axpmit) (Mignotte 
and Vayssiere, 1998). results from the asymmetric distribution of protons and 
other ions on either side of the inner mitochondrial membrane, which gives rise to a 
chemical (pH) and electrical gradient which is essential for mitochondrial function 
(Kroemer et al., 1997). Following water moves into the mitochondrial matrix,
causing swelling and the outer mitochondrial membrane is broken (Sklachev, 1996). As 
a result, mitochondrial proteins (cytochrome c, AIF, Smac and Omi) are released into 
the cytosol, promoting caspase activation and triggering DNA fragmentation and 
chromatin condensation (Ferri and Kroemer, 2001) (Figure 1.4). This MPT-dependent 
model has been supported by studies of many cell types in response to various toxic 
stimuli (Zamzami et al., 1997; Petit et al., 1996; Boise and Thompson, 1997; Hirsh et 




2. The second model of mitochondrial involvement in apoptosis proposes the release of 
mitochondrial proteins through an MPT-independent mechanism (Liu et a l ,  1997). 
Many studies have suggested that cytochrome c release occurs in the absence of or prior 
to mitochondrial depolarisation (Goldstein et al., 2000; Kluck et al., 1997). For 
example, in Jurkat and FL5.12 cells, the release of cytochrome c was shown to coincide 
with swelling of the outer mitochondrial membrane. This change was apparent before 
the loss of Wmit, which is normally associated with MPT (Kluck et al., 1997). To date, 
four alternative mechanisms have been suggested for the MPT-independent release of 
mitochondrial proteins, however none of these have been established. These include: (1) 
formation of a lipid-pore complex in the outer mitochondrial membrane (Vander Heiden 
et al., 1997), (2) Bcl-2 family members (e.g. Bax) forming channels in the outer 
mitochondrial membranes, thereby allowing cytochrome c and other proteins to be 
released but not damaging mitochondria (Shimizu et al., 1999; Antonsson et al., 1997), 
(3) direct action of upstream caspases on mitochondria (Susin et al., 1997) and (4) Bcl-2 
family members (e.g. Bax), in conjunction with mitochondrial permeability transition 
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Figure 1.4: Schematic representation of two models of the involvement of mitochondria 
in apoptosis. In model 1, PTP open causing MPT, collapse of Wmit swelling of 
mitochondria and release of mitochondrial proteins, such as cytochrome c, into the 
cytosol. This is followed by caspase activation and DNA fragmentation. In model 2, 
mitochondrial proteins are released by an MPT-independent mechanism. Many MPT- 
mdependent mechanisms have been proposed, including (1) formation of a lipid-pore 
complex, (2) Bax proteins forming large pores in the outer mitochondrial membrane and 
releasing proteins, (3) caspases acting directly on mitochondrial membranes, and (4) 
Bax forming pores in conjunction with VDAC.
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1.6 Regulation of Apoptotic Pathways
Slight alterations in the apoptotic process can have drastic consequences. For example, 
abnormal down-regulation of apoptosis is a contributor to cancer and autoimmune 
diseases, whereas up-regulation of cell death is implicated in neurodegenerative 
disorders such as Alzheimer’s disease (Thompson, 1995). Therefore, the apoptotic 
process must be highly regulated. In a wide variety of cell types, Bcl-2 and Bcl-2- 
related proteins are critical in preventing cells from undergoing apoptosis induced by 
various stimuli. The mechanism(s) by which these proteins modulate apoptosis is not 
yet known but several theories have been proposed:
1. One of the unique characteristics of the Bcl-2 family members is their ability to form 
homo- and hetero-dimers. One of the first theories advanced to account for the effects of 
Bcl-2 family members on apoptosis focussed on the interaction between Bax and Bcl-2 
related proteins. Sedlak et al. (1995) reported that the formation of Bax homo-dimers 
promotes apoptosis and the formation of hetero-dimers between Bcl-2 related proteins 
and Bax prevents apoptosis in murine FL.5.12 cells. However, in some cell systems, the 
binding of Bax to Bcl-2 was not sufficient to prevent apoptosis (Knudson and 
Korsmeyer, 1997). It was suggested that the process of hetero-dimerization may inhibit 
apoptosis by preventing the translocation of Bax to mitochondria (Gross et al., 1998; 
Nomura et al., 1999).
2. Bcl-2 and Bcl-xL may inhibit apoptosis by preventing the over-production of ROS 
and shifting the redox potential to a more reduced state. The mechanism for this effect is 
not known but it has been suggested that Bcl-2 may act in an antioxidant pathway 
(Mignotte and Vayssiere, 1998).
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3. Pro-apoptotic Bcl-2 proteins may also regulate apoptosis through interaction with 
caspases. In mammalian cells a complex between caspase-9, Bcl-xL Apaf-1 and 
cytochrome c is formed in many different types of cells induced to undergo apoptosis, 
including murine thymocytes (Hsu et al., 1997). Caspase-9 and Bcl-xL bind to distinct 
domains in the Apaf-1 molecule (Pan et al., 1998). It has been suggested that the 
formation of this complex may regulate mammalian cell death (Pan et al., 1998). 
Regulation is achieved by the binding of the Bcl-xL to Apaf-1, which blocks the ability 
of Apaf-1 to promote the activation of caspase-9, hence preventing activation of other 
caspases and DNA fragmentation. Bcl-2 related proteins such as Bax, Bak and Bik are 
able to disrupt the interaction between Bcl-xL and Apaf-1 by forming hetero-dimers 
with Bcl-xL (Pan et al., 1998: Mignotte and Vayssiere, 1998), allowing apoptosis to 
proceed.
4. Reed (1997) suggested that the Bcl-2 family inhibits apoptosis by inserting, following 
a conformational change, into the outer mitochondrial membrane, forming channels or 
even large holes. Muchmore et al. (1996) originally reported the ability of Bcl-xL to 
form channels with discrete conductances in synthetic lipid membranes. Recently, Zhai 
et al. (2000) and Basanez et al. (1999) showed that Bid and Bax are also able to form 
pores in liposomes and release encapsulated molecules such as cytochrome c. However, 
this pore forming ability does not establish a corresponding function in vivo. The 
synthetic membranes used in these studies do possess a similar negative charge to the 
outer mitochondrial membrane. Therefore, it is possible that Bcl-2 proteins and 
mitochondrial membranes might interact in a similar manner.
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5. It is hypothesised that the Bcl-2 family members may be involved in the formation of 
large pores through the recruitment and interaction of other outer mitochondrial 
membrane proteins. Bcl-2 family members have been shown to interact with a large 
mitochondrial protein called the voltage dependent anion channel (VDAC). In 
electrophysiological studies, Shimizu and colleagues (1999 and 2000) have shown that 
Bax and VDAC specifically interact in synthetic membranes to form novel ion 
channels, which are bigger than pores formed by VDAC or Bax alone.
6. It is possible that Bcl-2 family members may regulate the release of cytochrome c by 
controlling the opening and closing of the PTP and in turn MPT. The precise molecular 
composition of the PTP remains elusive, however, it is thought to be a multi-protein 
assemblage, incorporating proteins such as the VDAC, the adenine nucleotide 
translocator (ANT), the benzodiazapine receptor and cyclophilin D. Bax has been 
shown to interact specifically with two of these proteins, VDAC and ANT (Tsujimoto 
and Shimizu, 2000). Therefore, this model suggests that Bcl-2 family members, in 
particular Bax, may control MPT and the release of cytochrome c.
1.7 Lysosomes and Apoptosis
Lysosomes, together with late endosomes, are the main cellular compartment for intra­
cellular degradation and contain a large number of enzymes, particularly non-specific 
proteases. Accumulating evidence suggests that lysosomes, perhaps in conjunction with 
mitochondria, may be intimately involved in apoptosis. However, the role of lysosomes 
in apoptosis is still poorly understood.
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Many researchers believe that lysosomes are sturdy structures whose integrity remains 
intact until the final stages of cell death (reviewed by Antunes et al., 2001; Brunk and 
Svensson, 1999; Li et al., 2000; Helliquist et al., 1997), thereby contributing little to the 
process. Despite this common opinion, it is now known that in certain pathological 
situations, as well as in normal aging (Bi et al., 2000), lysosomal integrity may be 
compromised, causing leakage of lysosomal proteases into the cytosol. It has also been 
shown that minor lysosomal destabilisation produces degenerative alterations that are 
efficiently repaired by autophagocytic processes, suggesting that m inor lysosomal 
leakage m ight be a com m on and reversible occurrence (reviewed by Brunk and 
Svensson, 1999). Many independent research groups have now reported that partial 
rupture of lysosomes seems to be an early and consistent event preceding apoptosis, 
caused by a variety of agonists, including oxidative stress, growth factor withdrawal, 
FAS receptor ligation, and exposure to low density lipoprotein, photo-oxidative 
dam age, v itam in  E (in p articu la r a -to c o p h e ry l succinate) and a synthetic 
lysosom otrophic detergent, O -m ethyl-serine dodecylam ine hydrochloride (M SDH) 
(Roberg et al., 1999; Kagedakl et al., 2001; Antunes et al., 2001; Brunk and Svensson, 
1999; Hellquist et al., 1997; Neuzil et al., 1999; Li et al., 2000).
Rupture of lysosomal membranes is thought to result in the release of many hydrolytic 
proteases, for exam ple cathepsins, to the cytosol. Cathepsins are proteases that are 
present in nearly all animal cells (Roberg et al., 1999). They have various functions, 
however, their most interesting role in relation to the field of apoptosis is their ability to 
activate pro-caspases (G ardner et al., 1997). This activation may be upstream to the 
mitochondrial release o f cytochrom e c (Roberg, 2001). The precise m echanism  of 
caspase activation by cathepsins is currently not known. Kagedal and associates (2001)
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suggest that cathepsin D may activate caspases directly, through proteolytic interaction, 
or indirectly, through proteolytic attack on mitochondrial membranes, thereby ensuring 
the release of pro-apoptotic factors. Also, cathepsin B was previously shown to 
contribute to bile-salt induced apoptosis by a caspase-8-dependent process and is 
thought to be involved in the activation of specific proinflammatory caspases 
(Guicciardi et al., 2000; Schotte et al., 1998).
Oxidative stress induces apoptosis in many cell lines. In fibroblast cells, oxidative stress 
induces relocation of cathepsin D from lysosomes to the cytosol. This was observed to 
be an early event, preceding other apoptotic changes, such as the release of cytochrome 
c to the cytosol (Roberg et al., 1999). This sequence of events is consistent with 
lysosomes being involved in the initiation of apoptosis. Recently, Antunes et al. (2001) 
and Olejnicka et al. (1999) have reported lysosomal membrane rupture in Jurkat and 
NIT-1 cells following exposure to hydrogen peroxide. A similar sequence of events to 
that found in fibroblast cells was observed in both Jurkat and NIT-1 cells. Partial 
lysosomal membrane rupture was the initial event, followed by mitochondrial 
depolarisation, cytochrome c release and activation of downstream caspases. These 
events did not occur until 1-2 hours after the removal of hydrogen peroxide. Antunes et 
al. (2001) noted that following treatment of Jurkat cells with hydrogen peroxide the 
number of lysosomes decreased. This decrease is thought to result from a feed-back 
loop, where the early release of lysosomal enzymes feed-back to activate further 
lysosomal rupture. Interestingly, over-expression of Bcl-2 was found to inhibit this 
feed-back loop and further apoptotic changes in J774 cells following oxidative stress. It 
is possible that Bcl-2 somehow blocks down-stream events that result in later lysosomal
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rupture (Zhao et al., 2000) and cytochrome c release. Thus, this is another putative 
function for Bcl-2 (see Section 1.6).
Until recently, it was agreed in much of the published literature that death caused from 
lysosomal rupture was the result of direct pro-caspase activation by lysosomal 
proteases. However, some research groups were unable to detect caspase activation. 
Vandenabeele’s group argue that the primary role of released cathepsins may be related 
to an inflammatory response, as opposed to an apoptotic response. Their results suggest 
that lysosomal proteases, in particular cathepsin B, efficiently process pro-caspase 1 and
11 (caspases involved in inflammation) but only weakly process the precursors of 
caspase-2, -3, -6, -7 and -14. Stoka and colleagues (2001) have recently proposed an 
alternative model in which proteases released from lysosomes following lysosomal 
injury are involved in the activation of Bid. As previously discussed, Bid is a pro- 
apoptotic member of the Bcl-2 family that is typically activated by proteolysis. Stoka et 
al. (2001) reported the ability of proteases, such as cathepsin D, to cleave and activate 
Bid. Once Bid is activated, it is translocated from the cytosol to mitochondria, thereby 
causing release of cytochrome c (Stoka et al., 2001). It is currently unclear if proteases 
released from lysosomes directly activate caspases or specific members of the Bcl-2 
family. It may be that both the activation of caspases and Bid by proteases are required 
for the onset of apoptosis. Irrespective of the precise action of lysosomal proteases, the 
recent literature strongly suggests that lysosomal rupture may (at least under some 
conditions) be extremely important in the initiation of apoptosis. Figure 1.5 depicts a 















Figure 1.5: Proposed pathway of lysosomal involvement in apoptosis. Under some 
conditions, lysosomal rupture is thought to be an early event, preceding many apoptotic 
events such as cytochrome c/AIF release and caspase activation. It has been suggested 
that cathepsins may activate pro-caspases, thereby forming active caspases, or interact 
with Bcl-2 proteins to induce apoptosis, however, the exact mechanism is not known. 
Other undiscovered enzymes may also be involved (adapted from Zhao et al., 2000).
1.8 Cancer Therapeutics
As previously mentioned, dysfunctions of apoptosis have been implicated in the 
pathogenesis of many serious diseases, including cancer. Cancer is the second most 
common cause of death in highly developed countries (Szekeres and Novotny, 2002). 
For many years now, clinical treatment for cancer has typically involved chemotherapy,
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radiotherapy and surgery. Despite the extensive use of these therapies, there are still 
many disadvantages associated with them, such as a lack of specificity that often causes 
many harmful side effects (Luo and Prestwich, 2002). In addition, cell death caused by 
chemo- and radiotherapy is through an indirect mechanism, that is, cell death results 
from interference with DNA replication or metabolic processes, not by the direct 
induction of apoptosis (Baell and Huang, 2002). This mechanism of killing is 
sometimes insufficient to kill all cancer cells and, furthermore, makes it possible for 
cancers to develop radio-or chemo-resistant sublines that survive successive rounds of 
treatment and ultimately result in patient mortality (Ali et a l ,  1999; Igney and 
Krammer, 2002). Therefore, a need exists to develop therapeutic approaches that can 
overcome these disadvantages.
Over the last five years, a diverse range of experimental therapeutic strategies have been 
developed. Typically, these involve targeted delivery of anticancer drugs to cell surface 
proteins specifically expressed by tumour cells. These types of approaches have 
significant potential to improve efficacy and minimise toxicity to normal healthy cells 
(Kreitman, 1999; Trail and Bianchi, 1999; Luo and Prestwich, 2002). The most 
promising strategies involve monoclonal antibody (Mab) fragments, hormones or 
growth factors conjugated to drugs, toxins, radionuclides, enzymes, photosensitizers or 
cytokines. A small number of these are being trialled clinically. For example, the use of 
radio-labelled Mab 17-1A has resulted in improved survival of patients with Dukes C 
collateral cancer (Trail and Bianchi, 1999), while immunotoxins using anti-CD22 and 
anti-CD 19 Mabs have been used to target B-cell lymphoma and leukaemia (Kreitman, 
1999). Immunotoxins are constructs of either a plant or bacterial protein toxin bound to 
an antibody. Although these newly developed treatment methods signify a marked
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improvement in the area of cancer therapeutics, problems involving specificity, 
immunological reactions and the treatment of solid tumours still remain. Furthermore, 
the majority of these new treatments require parallel treatments in order to be 
successful.
A non-immunogenic complex that delivers the killing agent or toxin specifically to 
cancer cells in order to directly activate apoptosis, in the absence of bystander cell 
damage would be an ideal cancer therapeutic. Currently, there are few cancer 
therapeutics available that directly manipulate apoptosis. However, in the past few 
years, cancer research has started to focus on therapeutic agents that directly affect the 
apoptotic pathway. Mai et al. (2001) and Arap et al. (2002a) have recently reported a 
novel peptide (comprised of a protein transduction domain) which, when coupled to an 
antimicrobial peptide ((KLAKLAK)2) and injected, induces apoptosis. This conjugate, 
known as D PI, has greater efficiency than other potential therapeutics such as the 
immunotoxins. Unfortunately, disadvantages are still associated with it: for example (1) 
it can’t be used alone, other therapies would still be required, and (2) it must be injected 
directly into the tumour. Kessel and Horwitz (2001) also recently reported another 
synthetic an ti-tum our agent, X K 469, (2 -[4 -(7 -ch lo ro -2 -qu inoxaliny loxy ) 
phenoxypropionic acid), which induces apoptosis in solid tumours in vitro. These 
researchers suggested that this drug may induce apoptosis by interacting with the 
peripheral benzodiazepine receptor (which is thought to form part of the PTP); however, 
further experiments are required to confirm this.
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1.9 Potential Applications of Synthetic Polymers 
in Cancer Therapy
Despite continued efforts to find more potent and selective compounds for treating 
cancers, advances have been disappointing, particularly for the treatment of commonly 
occurring solid tumours (Duncan, 1997). Major limitations include the inability to (1) 
specifically target cancer agents to tumour sites, and (2) induce apoptosis only within 
cancer cells. Ideally, cancer drugs need to be concentrated preferentially in tumour cells, 
in order to maximise tumour cell death and minimise bystander cell damage.
In recent years many synthetic polymers have been investigated as potential drug 
delivery agents for cancer therapy, some of which are currently in clinical trials. These 
include pH-sensitive polymers, and HPMA (N-(2-hydroxypropyl)methacrylamide) and 
SMA (poly(styrene-co maleic acid/anhydride)) polymers.
1.9.1 pH-Sensitive Polymers
Linhardt and Tirrell (2000) investigated the behaviour of three polymers from a family 
of polymers referred as polyacrylic acids (Figure 1.6). These have a simple chemical 
structure with a carbon backbone conjugated to either a methyl (polymethylacrylic acid 
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Figure 1.6: Chemical structures of pH-sensitive polyacrylic acid polymers (A) 
polypropylacrylic acid (B) polyethylacrylic acid (C) polymethylacrylic acid (adapted 
from Kim and Tirrell, 1999).
The most striking feature of these polymers is their ability to disrupt membranes in a 
pH-sensitive manner. The pH is not constant throughout a cell for example, the pH 
within an endosome is lower than that of the cytosol by 1 or 2 pH units, depending on 
the stage of endosomal development (Murthy et al., 1999). Anti-tumour drugs 
introduced into cells are trafficked from early endosomes to late endosomes and 
eventually to lysosom es where they are degraded (M ukherjee et al., 1997). 
Unfortunately, this trafficking process prevents the release of the internalised drug into 
the cell cytosol, inhibiting its cytotoxic action. Endosome-destabilising peptides 
(Tolstikov et al., 1997) and pH-triggered bispecific antibodies (Raso et al., 1997 a and 
b) have previously been used to release internalised drugs into the cytosol. Linhardt, 
Tirrell and associates suggest that the variation of pH in endosomes and lysosomes must 
be considered when investigating possible delivery of cancer drugs in vivo (Linhardt et 
al., 1999). They suggest that the use of pH-sensitive polymers, such as PEAA and 
PPAA, would be ideal as part of a membrane-disruptive system which could enhance 
the release of drugs from endosomes into the cell cytosol. Such polymers would need to 
disrupt lipid bilayers at pH 6.5 and below but should be non-lytic at physiological pH 
(pH 7.4) (Murthy et al., 1999).
30
Chapter 1 Introduction
Despite the similar structures of PEAA, PMAA and PPAA, they have significantly 
different pKa values (Stayton et al., 2000). This results in each of the polymers 
disrupting membranes at different pH values (the “critical pH”). Linhardt et al. (1999) 
suggest that control of the critical pH can be attained either by altering the properties of 
the lipid bilayer or by variation of the polymer chain structure. Polymer side chains 
have been modified in length and chemical composition (by copolymerisation with 
methacrylic acid) (cited by Linhardt et al., 1999). In order to determine the critical pH, 
initial experiments were conducted using red blood cells (RBC). Synthetic polymers 
such as PEAA have also been shown to disrupt liposomes and synthetic vesicles (Meyer 
et al., 1998; Hughes et al., 1996). With RBC, PPAA produces maximum haemolysis at 
approximately pH 6.0, whereas maximum haemolysis for PEAA is reached at pH 5.0 
(Stayton et al., 2000). On a molar basis, PPAA is 15 times more effective than PEAA at 
pH 6.0 (Murthy et al., 1999).
Recently, Lackey and colleagues (1999) have demonstrated the ability of PPAA to 
retain haemolytic ability following conjugation with streptavidin. PPAA-streptavidin 
complexes not only retain the capacity to lyse RBC lipid bilayers at low pH but the 
haemolytic activity is similar to that of unmodified PPAA (Lackey et al., 1999). The 
ability of these synthetic polymers to lyse membranes at specific pHs and to retain this 
function after conjugation could be valuable in the development of novel polymer-based 
cancer therapeutics.
Another pH-sensitive polymer that has potential for use as a membrane-disruptive agent 
is pDMAEMA. pDMAEMA was originally described by Van de W etering and 
colleagues and has previously been used in gene therapy (Van de Wetering et al., 1999).
Chapter 1 Introduction
The ability of pDMAEMA to deliver genes into cells is consistent with it doing this by 
disrupting endosomes. The mechanism of putative pDMAEMA-mediated endosomal 
disruption is probably different from that of PAAA. At physiological pH, the polymer is 
partially protonated. However, Van de Wetering et al. (1999) suggests that, at low pH, 
the polymer acts as a ‘proton sponge’. They propose that, when inside endosomes, 
pDMAEMA causes massive ATPase-driven proton accumulation, which is followed by 
passive chloride influx into the endosomes to prevent the build up of a charge gradient. 
In this model water is then absorbed into endosomes as a result of the increased 
osmolarity (due to the uptake of protons and chloride ions), causing osmotic swelling 
and endosomal membrane rupture (Van de Wetering et al., 1999). However, there is no 
direct experimental evidence to support this model. There are very few previous studies 
that have examined the effects of pDMAEMA on intact cells. pDMAEMA has not 
previously been conjugated to other compounds, including anti-tumour agents. The 
ability of derivitized pDMAEMA to disrupt endosomes remains unknown.
1.9.2 HPMA and SMA Polymers
In recent years, extensive research has implicated HPMA and SMA synthetic polymers 
as potential cancer therapeutic agents, in particular for treating solid tumours (Maeda et 
al., 2001; Duncan et al., 2001). In vivo, many cancer drugs, in particular those of low 
molecular weight, rapidly penetrate many types of cells to cause extensive bystander 
cell damage. Furthermore, these drugs can be quickly removed from circulation via the 
action of the kidneys, thereby reducing tumour killing potential. Duncan (1997) and 
Etrych (1999) have shown that conjugating a potent anti-tumour agent to a polymeric 
carrier, such as HPMA or SMA, temporarily inactivates the drug and increases its 
distribution in the body, as the conjugate can only gain entry into cells via endocytosis.
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The increased circulation of the drug-polym er conjugate results in enhanced 
accumulation of the drug in tumours and thus enhanced cancer cell killing. This 
phenomenon is known as the enhanced permeability and retention effect (EPR - Figure
1.7) (Maeda et al., 2001; Duncan, 1997).
Figure 1.7: Schematic representation of the enhanced permeability and retention effect 
(EPR). A. Due to the higher permeability of tumour blood vessels, the drug-polymer 
conjugate is easily able to escape into the tumour. B. The low permeability of blood 
vessels in normal tissue prevents the drug-polymer conjugate from escaping to areas 
where it is not needed. C. Tumour tissues have poor lymphatic drainage and thus tend to 
retain drug-polymer conjugate (adapted from Duncan, 1997; Duncan et al., 1996).
HPMA has been conjugated to a variety of drugs but the most promising is doxorubicin 
(Dox), an anthracycline antibiotic with activity against a broad range of tumours 
(Seymour, 1991). Duncan (1997) reported studies of the first Dox-HPMA conjugate. 
HPMA and Dox were conjugated by a Gly-Phe-Leu-Gly-peptidyl side-chain, which is 
cleaved intracellularly by lysosomal thiol-dependent proteases, releasing free Dox into 
the cell. Proteases, like cathepsin B, are known to be present at higher levels in some 
human tumours. The Dox-HPMA conjugate, now known as PK1, is a 25 kDa complex
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which successfully capitalises on the EPR effect to concentrate up to 70 times more 
than free Dox in mouse melanoma tumours in vivo (Duncan, 1997; Pimm et al., 1996; 
reviewed by Luo and Prestwich, 2002). Pre-clinical tests revealed that PK1 was 5-10 
times less toxic than free Dox and displayed improved antitumour activity, particularly 
in solid tumour models (Duncan et al., 1992; Ulbrich et al., 1996). In recent years, PK1 
has been trialled on a broad range of tum ours, for example MAC 15A and M AC26 
(Loadman et al., 1999). These tum ours display distinctly different morphology and 
vasculature, leading to the suggestion that PK1 may have therapeutic potential for a 
variety of cancers. PK1 is currently undergoing Phase II evaluation for treatm ent of 
breast, colon and non-small cell lung cancer (Duncan et al., 2001).
Many variations of the simple PK1 construct, including changes in (1) the chemical 
bond used to produce the conjugate, (2) the overall mass of the conjugate, and (3) the 
structure and length of the spacers (Ulbrich et al., 1996) have been made, in order to 
improve the EPR effect and the toxicity to tumours. Etrych et al. (2001) constructed a 
conjugate between HPMA and Dox, using a hydrolytically unstable hydrazone linkage. 
This spacer is stable under physiological conditions (pH 7.4) but is hydrolytically 
degraded in mildly acidic environments (e.g. the lumen of endosomes at pH 5.0). Initial 
in vitro experiments indicate that the complex is relatively stable at physiological pH 
and that the drug activity increases under mildly acidic conditions (pH 5) (Etrych et al., 
2001). Compared with PK1, this conjugate is significantly more efficient at treating 
EL4T-cell lymphoma in mice (Ertych et al., 2001).
here are now at least seven HPMA polymer-drug conjugates that have entered phase 
M l clinical trials as anticancer agents, including N-(2-hydroxypropyl)methacrylam ide
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further 4 hours. For these latter experim ents, cells were analysed by confocal 
microscopy and flow cytometry.
3.2.2.6 Identification o f Intracellular Vesicles Disrupted by PAAA Polymers
Immunofluorescence assays were used to examine the morphology and distribution of 
both early and late endosomes and lysosomes following endocytosis of polymers. This 
enabled determination of the specific intracellular vesicle/s that the polymer/s disrupted. 
Monoclonal antibodies reactive with early endosomal antigen 1 (E E A l), lysosomal- 
associated membrane protein-1 (Lamp-1), and Golgin-97 were used. EEAl is thought to 
only be associated with early endosomes. Lamp-1 is associated with various vesicles, 
however, it seems to predom inately accum ulate in late endosom es and lysosomes 
(Akasaki, 1995). Anti-golgin-97 recognizes a 97 kDa protein called Golgin-97, which is 
a member of the granin family of proteins localised on the cytoplasmic face of the Golgi 
apparatus.
U937 cells were treated as described fo r m easuring the release of calcein from
endosomal vesicles (section 3.2.2.3), except that calcein was deleted from  the initial
incubation mixture. Following uptake, the cells were incubated for 4 hours at 37°C in
10% FB S/D M EM :F12 before p rocessing  fo r im m unofluorescence. In som e
experiments, polym ers were omitted from  the initial incubation buffer but 70 //M
MSDH (an acidotropic detergent known to disrupt lysosomes (Li et al., 2000)) was
added to the medium used for the subsequent 4 hour incubation. The cells were then
centrifuged fo r 5 m inutes at 300 g ,  resuspended in 0 .4  ml of 4% (w /v)
paraformaldehyde in PBS, pH 7.4, and incubated with shaking at room temperature for 
30 m inutes. The fixed cells w ere then w ashed w ith PBS and perm eabilised
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results, cited by Maeda et al., 2001). Also, encouragingly, SMANCS treatment has been 
associated with minimal side effects, the major one being a low-grade fever.
1.10 Development of a Novel Cancer Therapeutic
The recent development of pH-sensitive polymers (section 1.9.1) and consideration of 
what was known about apoptotic signal transduction pathways, particularly the 
involvement of Bcl-2 family members (sections 1.3.2.1 and 1.4) and lysosomes (section
1.7), led to the formulation of two strategies that offered the potential to develop new 
kinds of cancer therapeutics. These strategies were;
1. To test whether endocytosed pH-sensitive polymers would disrupt lysosomes 
and thereby induce apoptosis.
2. If strategy 1. was not feasible, to begin development of a trimolecular construct 
that was designed to be taken up by cancer cells via receptor-mediated 
endocytosis, and to subsequently release a pro-apoptotic peptide into the cytosol 
where it would induce apoptosis.
These strategies are further elaborated below.
1.10.1 Lysosomal Destabilisation
As previously discussed, partial destabilisation of lysosomal membranes is thought to 
be an early event in some apoptotic pathways. It was hypothesised that the gradual 
decrease in pH in endosomes/lysosomes might cause (1) endocytosed PAAAs to 
undergo a change to a m em brane-disruptive conformation or (2) endocytosed 
PDMAEMA to become a ‘proton sponge’ which would destabilise lysosomes and
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release their lumenal proteases into the cytosol to induce apoptosis. These hypothetical 
effect(s) of PAAAs and pDMAEMA on cells have not been studied before.
1.10.2 Development of a Pro-Apoptotic Trimolecular Construct
If polymer-mediated destabilisation of lysosomes is not feasible then the alternative 
approach adopted will be to develop a trimolecular construct, incorporating three 
components:
1. A killing peptide to induce apoptosis.
2. A targeting ligand that, by binding to a specific receptor on the surface of cancer 
cells, induces receptor-mediated endocytosis.
3. An endosomal disruptive polymer that will release the construct from endosomal 
vesicles into the cytosol.
Currently, very few cancer therapeutics target apoptosis directly. However, this is an 
ideal mode of killing because apoptotic cells are naturally engulfed and degraded by 
phagocytes, preventing the release of toxic cellular contents into adjacent healthy tissue. 
Thus, apoptotic killing would (1) result in a reduced number of side effects, and (2) 




Figure 1.8: The proposed trimolecular construct. The construct is designed to enter the 
target cell via receptor-mediated endocytosis. Once inside the endosome/lysosome, the 
polymer and the pH-sensitive linker are designed to facilitate release of a pro-apoptotic 
peptide into the cytosol.
In theory, this construct offers many potential advantages compared to other cancer 
therapeutics, including (1) efficient cell killing (i.e. direct induction of apoptosis in 
target cells), (2) high specificity - the combination of the action of the targeting ligand 
and the tendency of the polymer to accumulate at sites of solid tumours (via the EPR 
effect) would significantly reduce bystander cell damage, and (3) repeated cycles of 
treatment will be feasible, due to the construct being poorly immunogenic. A proposed 







Killing peptide acts on 
mitochondria to induce apoptosis
Figure 1.9: Proposed pathway of action of the trimolecular construct on a target cell. It 
is hypothesised that the construct will enter the cell via receptor-mediated endocytosis. 
Once inside an acidified endosome, the linker between the killing peptide and the 
polymer will be cleaved and the polymer will disrupt the endosomal membrane. The 
released killing peptide will then target mitochondria and induce apoptosis.
1.10.2.1 Pro-apoptotic Peptide
Bcl-2 family members are known to play an important role in the release of cytochrome
c from mitochondria, to initiate downstream apoptotic events. In recent years, it was
discovered that the BH3 domain is critical for hetero-dimerisation of Bcl-2 family
members and appears to be essential for death promoting activity (Polster et al., 2001).
Since this discovery, many BH3 peptides have been developed as potential apoptosis
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inducing agents. The Bad(140-I65) peptide, developed by Kelekar et al. (1997) was one 
of the first BH3 peptides to be synthesised. In vitro experiments showed that this 
peptide binds to Bcl-xLand induces characteristic features of apoptosis. Truncated forms 
of pro-apoptotic Bak and Bax consisting of only the BH3 region are also sufficient to 
induce apoptosis and antagonise the effects of anti-apoptotic members of the Bcl-2 
family of proteins in prostate carcinoma cell lines (Finnegan et al., 2001). Finnegan and 
co-workers believe that BH3 peptides interact with Bcl-2 at sites where pro-apoptotic 
proteins normally bind, thereby inhibiting binding of Bak and Bax-like proteins. As a 
result, BH3 peptides promote the formation of pro-apoptotic Bak/Bax homodimers, 
thereby inducing cell death. Polster et al. (2001) recently developed a Bax peptide, 
comprised of amino acids 53-86 that includes the BH3 domain.
Theoretically, if used in vivo to induce apoptosis of cancer cells, pro-apoptotic peptides 
have several advantages when compared with other toxic agents. Firstly, pro-apoptotic 
peptides must be introduced into the cytosol to have a cytotoxic effect. Since the peptide 
is membrane impermeable, it can’t easily enter the cytosol of non-target cells, thus 
limiting damage to adjacent, healthy cells. Second, once in the cytosol of a target cell, 
the peptide will remain there until it is naturally degraded (or the target cell membrane 
loses integrity). Finally, systemic exposure to the peptide is unlikely to elicit an immune 
response as it represents a human amino acid sequence. Therefore, a variety of recently 
developed BH3 peptides could be used as suitable killing agents in the proposed 
trimolecular construct.
To confirm that Bcl-2 peptides induce apoptosis in intact cells, processes associated 
w,th apoptosis (e.g. MPT) must be measured. Two techniques have previously been
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employed to measure MPT in intact cells, however both have significant disadvantages. 
Therefore a need exists for the development of a method to measure MPT in intact cells 
that is free of the disadvantages associated with the other techniques. The development 
of a novel technique to measure MPT in intact cells is discussed in chapter 6.
1.10.2.2 Targeting Ligand
Receptor-mediated endocytosis (RME) is the process by which a ligand makes contact 
with a specific receptor on the cell surface and elicits internalisation of the ligand within 
the cell. This type of uptake is highly efficient when cells display a high density of 
ligand-specific receptors (Duncan et al., 1996). Many receptors, including those for 
transferrin, low-density lipoprotein and growth factors have been proposed as 
candidates for tumour targeting and used in many experiments. The transferrin receptor 
has frequently been used in these studies. Transferrin is a 77 kDa human blood 
glycoprotein with a broad cellular distribution. It regulates iron availability in the body 
and mediates the transport and uptake of iron into cells, via RME (Ali et al., 1999; Luo 
and Prestwich, 2002). The number of transferrin receptors on the cell surface is in direct 
relationship to the amount of iron required by a cell. The iron requirement of most 
human cells is generally minimal hence few transferrin receptors are present on the 
plasma membrane. However, it has been found that rapidly dividing cells, like cancer 
cells, express transferrin receptors at significantly higher levels. This has led to the 
proposal that the transferrin uptake pathway could be exploited for targeted delivery of 
chemotherapeutic agents in vivo (Ali et al., 1999). Thus, transferrin would be a suitable 




Following RME, the trimolecular construct must be released from the endosome into 
the cytosol in order to cause mitochondrial changes and induce apoptosis. Non-viral (i.e. 
immunological compatible in vivo) and inexpensive endosomal disruptive agents would 
be ideal to use in the proposed trimolecular construct. Synthetic polymers, such as 
PAAAs and pDMAEMA have been suggested as possible endosomal disruptive agents.
1.10.2.4 Covalent Linkage Between Polymer and Peptide
It is likely that a pro-apoptotic peptide will have to be released from the construct to 
allow it to act on mitochondria and induce apoptosis. A wide variety of linkers that 
facilitate peptide release have previously been employed. The most popular are (1) 
spacers that are degraded by proteases such as cathepsins, and (2) a pH-sensitive linker 
that releases the drug on entry into acidic endosomes or lysosomes. Various acid- 
sensitive linkages, including the carboxylic-hydrazone, the c/s-aconityl and the trityl, 
have been investigated (Kratz et al., 1999). The carboxylic-hydrazone linkage system is 
the most extensively used and has produced promising results (Kratz et al., 1999). This 
type of linkage will be used in the initial studies described in this thesis.
1.11 Aims
The aims of this thesis were to:
1. Determine if any of the available pH-sensitive polymers can disrupt lysosomal 
membranes and thereby directly induce apoptosis.
If the polymers tested were incapable of this, then proceed to:
2. Identify the most efficient endosomal-disruptive polymer.
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3. Synthesise a hydrazide pH-sensitive linker and conjugate it with an endosomal- 
disruptive polymer.
4. Conjugate a linker-derivatised endosomal-disruptive polymer with a pro- 
apoptotic peptide.
5. Determine if the conjugate produced in 4. induces apoptosis in cultured cells.
6. Develop an improved technique to directly measure mitochondrial permeability 
transition in intact cells.
If results from 5. are promising, then (if time permits)
7. Conjugate transferrin to the conjugate formed in 5. (to form a trimolecular 
construct) and test its ability to be internalised via RME and kill cancer cells via 
apoptosis.
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Chapter 2 Materials and Methods
This chapter contains general materials and methods that were used throughout the 
work described in this thesis. Other chapter-specific materials and methods are 
described in the corresponding chapters.
2.1 Materials
Many general chemicals were purchased from Sigma (MO, USA). Details of chemicals 
purchased elsewhere are provided below.
2.1.1 Tissue Culture
Dulbecco’s Modified Eagles Medium: Hams F-12 (DMEM:F12) was from Life 
Technologies (MD, USA) and Foetal Bovine Serum (FBS) and Trypsin-EDTA were 
from Trace (Melbourne, Australia). N aH C03 was from Ajax (Sydney, Australia) and 
HEPES was from United States Biochemical Company (USB, OH, USA). Most cell 
lines used were obtained from the American Type Culture Collection (ATCC, MD, 
USA) and included: Jurkat (human leukemia T cells), U937 (human myelomonocytic 
cell), HL60 (human promelocytic leukima cells) and HeLa (human epitheloid 
carcinoma cells). Hek 293 (human embryonic kidney) cells were a kind gift from P. 
Poronick (University of Sydney, Sydney, Australia). Sterile Greiner Labortechnik 
plasticware was obtained from Interpath Services (Melbourne, Australia).
2.1.2 Purification of Annexin V
Acrylamide, tris(hydroxymethyl)aminomethane (Tris), and glycine were from ICN 
Biochemicals (Sydney, Australia). Bradford reagent, ammonium persulphate, FITC 
(fluorescein isothiocyanate), N ,N ,N ',N’-tetramethylethylenedaime (TEMED) were from
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Sigma (Syndey, Australia). N ,N ’methylene-bis-acrylam ide and sodium dodecyl 
sulphate (SDS) were from BDH (Dorset England). Annexin-V-FLUOS was from Roche 
(IN, USA). N-(2-hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid) (HEPES) was 
from United States Biochemical Corp. (OH, USA). DEAE-Sephacel was from 
Amersham Biotech (Melbourne, Australia). The Econo pump system was purchased 
from Bio-Rad (Sydney Australia). Ultrafree concentration devices were from Millipore 
(MA, USA). Hoeffer Scientific “Tall-Mighty-Small” Minicell (CA, USA) was used for 
electrophoresis of proteins. All other chemicals were of reagent grade and were from 
either Sigma (Syndey Australia) or Ajax Chemical Co. (Sydney Australia).
2.2 Methods
2.2.1 Tissue Culture
Cells were cultured in com plete medium, consisting of DMEM:F12 medium 
supplemented with 10% (v/v) FBS. The cells were incubated in a Forma Scientific 
humidified incubator at 37°C and 5% (v/v) COz. Passage of suspension cells involved 
most of the culture being discarded and replaced with complete medium twice a week. 
Passage of adherent cells was conducted similarly except that all the culture medium 
was discarded. Pre-warmed, sterile trypsin-EDTA was then added to the flask, ensuring 
that the base of the flask was covered. Cells were then incubated (37°C and 5% (v/v) 
C 02) for 2-3 minutes or until most of the cells became suspended. Following this, 
trypsin-EDTA was discarded and replaced with complete medium. All procedures were 
carried out in a laminar flow hood with sterile techniques and reagents.
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2.2.2 Flow Cytometry
A Becton Dickinson (CA, USA) FACSort flow cytometer and CellQuest software 
(version 3 .If) were used to analyse cells. A flow cytometer is an instrument used to 
analyse large numbers of cells collecting information about the size, granularity and 
fluorescence of each cell (Darzynkiewicz and Li, 1996). In the FACSort, cells are 
delivered upwards in a stream of liquid and are intercepted by a laser that excites the 
cells at 488 nm. As shown in Figure 2.1 the signals produced include forward scatter 
(FSC, relating to the size of the cell), side scatter (SSC, measuring the granularity of the 
cell), and three different fluorescent signals: FL1 (green fluorescence), FL2 (orange 
fluorescence) and FL3 (red fluorescence), all of which are measured by dedicated 
detectors (Darzynkiewic and Li, 1996). A series of three dichroic mirrors allows for the 
detection of three fluorescent signals. Dichroic mirrors discrim inate between 
wavelengths, allowing specific wavelengths to pass through but reflecting others (Carter 
and Meyer, 1994; Mechtold and Radbruch, 1992).
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Figure 2.1: A schematic diagram of the operation of a flow cytometer. A stream of cells 
is intercepted by a laser beam. The size, granularity and fluorescence of each cell are 
measured.
2.2.3 Confocal Microscopy
A Leica TCS SP confocal microscope mounted on a Leica DM IRBE inverted 
microscope (Leica Microsystems, Heidelberg, Germany) was used to analyse cells. 
Confocal microscopy is used to image either fixed or living tissues that have been 
labelled with one or more fluorescent probes. Confocal microscopes are built around a 
conventional microscope but use lasers rather than a lamp for a light source. They also 
have sensitive photomultiplier tube detectors (PMTs) that detect the points of light 
produced by the specimen and a computer to control the scanning mirrors and to 
facilitate the collection and display of images (Paddock, 1999). Images are subsequently 
stored and analysed via software. Leica TCS NT software was used (Version 1.6.587:
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Leica M icrosystems, Heidelberg, Germany). The images produced have greater 
resolution than those achieved by conventional microscopy. In all confocal image 
analyses signals collected were adjusted to remain within the linear range of the 
detectors.
2.2.4 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
A Hoeffer Scientific “Tall-Mighty-Small” vertical slab-casting unit connected to a Bio- 
Rad model 1000/500 power supply was used for electrophoresis. Melted agar (1%) was 
used to seal the bottom of the chamber. The separating gel (10% acrylamide) was 
placed in the chamber and allowed to set. The stacking gel was then added to the 
chamber. Immediately following loading of the stacking gel, a comb (used to form the 
sample wells) was placed in the top of the chamber. The stacking gel was then left to 
solidify while the comb was in place. Once the stacking gel was set, the comb was 
removed and the chamber placed in the electrophoresis unit.
For each sample, approximately 10 /^g of protein in PBS was mixed with an equal 
volume of sample buffer. Samples were then boiled for 5 minutes before loading into 
the wells. Running buffer (250 mM TRIS, 1.9 M Glycine, 1% SDS) was subsequently 
poured into the buffer chambers before the gel was electrophoresed at a constant 180 V 
until the dye front had reached the bottom of the gel (approximately 2 hours). Following 
completion of electrophoresis, gels were placed into a Coomassie Blue staining solution 
(0.1% Coomassie Blue, 40% methanol, 10% glacial acetic acid) and left to stain, on a 
platform rocker, for 1 to 1.5 hours. Gels were then destained using ‘destain’ solution 
(50% methanol, 50% glacial acetic acid) until the bands were clearly visible (data not 
shown).
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2.2.5 Bradford Assay
To a clean 96-well microtitre plate, 100 fi\ of BSA protein standards were added to the 
wells in the first three columns (setting up a triplicate series), in order of increasing 
concentration (i.e. from 0.05 mg/ml to 1 mg/ml) down the plate. To the next three 
columns, a series of binary dilutions of the “unknown” protein sample was performed 
down the plate (giving a final volume of 100 //1/well). To each well, 100 //I of Bradford 
reagent was added and mixed. The plate was incubated at room temperature until a blue 
colour developed in wells containing protein (usually between 5 and 60 minutes). The 
plate was subsequently read at 595 nm using a spectrophotometer. A plot of absorbance 
versus concentration for the BSA standards was generated and used to interpolate the 
concentration of “unknown” proteins.
2.2.6 Purification of Annexin V from Chicken Liver
Crude annexin V protein, isolated from chicken liver, was supplied by a previous 
colleague. It was isolated by homogenisation and density gradient centrifugation as 
described by Boustead et al. (1993). The crude annexin V protein was then purified by 
ion-exchange chromatography. A DEAE-Sephacel column was connected to an Econo 
pump system, including UV detector and chart recorder (running speed 2 cm/h). The 
column was equilibrated with 20 mM HEPES buffer pH 7.4. Following equilibration, 
the crude annexin V solution was passed over the column. The unbound protein was 
eluted and a linear gradient of 0-0.6 M NaCl in 20 mM HEPES buffer pH 7.4 was 
applied to the column. The column was eluted at 1 ml/min and 5 ml fractions were 
collected. Elution of annexin V was expected at 0.1 M NaCl (Clarke, 1998). Fractions 
were analysed by SDS PAGE (section 2.2.4) and annexin V was identified based on 
molecular weight. Fractions containing annexin V were pooled together and
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concentrated, using Ultrafree concentration devices (cut off 20 kDa) to a final volume of 
1.5 ml. The final concentration of the purified annexin V protein was determined by a 
Bradford protein assay (section 2.2.5).
2.2.7 Conjugation of Annexin V with FITC
An aliquot of a stock solution of FITC (40 mg/ml in DMSO) was added to the protein to 
give a final concentration of 250 /yg FITC per mg of protein. The reaction mixture was 
then incubated (protected from light) at room temperature for 2 hours on a platform 
rocker. Following incubation, the reaction mixture was placed in dialysis tubing and 
dialysed against several changes of PBS, pH 7.4, over 24 hours. Unconjugated FITC 
was removed from the reaction mixture by dialysis performed at 4°C protected from 
light. The protein concentration and the substitution ratio were determined by taking 
Azgo and A295 absorbance readings of the dialysed protein.
The protein concentration and substitution ratio (S.R.) were determined using the 
following formulas, respectively.
Iprotein] mg/ml = A280 -  (0.35 x A495) S.R. = 2.87 x A495
A280— (0.35 x A495) A280 — (0.35 x A495)
2.2.8 Staining Cells with Annexin V-FITC
Annexin V labelling solution was made by diluting 1:100 annexin V-FITC in annexin V 
buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, 5 mM CaCl2). lxlO 6 cells were 
centrifuged at 300 g for 5 minutes. The cells were resuspended in 1 ml of lx PBS and 
re-centrifuged. Cells were then drained thoroughly and resuspended in 50 jaI of the
51
Chapter 2 M aterials and Methods
annexin V labelling solution, followed by a 15 minute incubation at room temperature 
in the dark. Immediately before flow cytometric analysis of the cells, 500 |al of annexin 
V buffer was added to the cells. FSC, SSC and FL1 signals were acquired. Increased 
exposure of phosphatidylserine (PS) on the surface of the cells was measured by an 
increase in FL1. M anufacturer's instructions were followed when cells were stained 
using annexin-V-FLUOS.
2.2.9 Comparison of Annexin-V-FLUOS and Purified Annexin 
V Conjugated to FITC
The ability of purified annexin V conjugated to FITC (annexin V-FITC) to detect 
exposed PS was compared to annexin-V-FLUOS (commercial annexin V-FITC). U937, 
HL60 and Jurkat cells were induced to undergo apoptosis using three different stimuli, 
respectively: TNFa/cyclohexim ide (10 ng/ml and 10 /^g/ml respectively, 4 hours), 
etoposide (20 /^g/ml, 6 hours) and a-Fas antibody (100 ng/ml, 4 hours). Following 
incubations, cells were stained with either annexin-V-FLUOS or annexin V-FITC. Cells 
were also stained with PI to ensure that only viable cells were analysed (see section 
3.2.2.1). All experiments were performed in triplicate to ensure reproducibility. In all 
cases, annexin V-FITC and annexin V-FLUOS gave comparable detection of exposed 
PS. The results shown in Figure 2.2 are representative.
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FITC-Annexin V (Green Fluorescence)
M l values (%) Control Annexin V- 
FLUOS
Annexin V-FITC
U937 4.79 83.07 81.81
Jurkat 10.56 33.22 36.76
HL60 8.22 60.39 63.18
Figure 2.2: Flow cytometry histograms showing comparisons of annexin V-FLUOS 
(commercial annexin V-FITC) and annexin V-FITC. Comparable detection of PS, 





Poly(2-Alkylacrylic Acid) Polymers 
Deliver Molecules to the Cytosol by pH- 





In recent years, many attempts have been made to improve cancer therapy, for example, 
by the development of synthetic polymers as macromolecular carriers. Synthetic 
polymers have significant potential for the delivery of molecules and drugs to cells both 
in vitro and in vivo. They offer several advantages in therapeutic situations, including
(1) increased plasma half-life (because their size is above that required for renal 
exclusion), (2) controlled release of the drug at lower drug doses, and (3) enhanced 
accumulation of drugs at sites of solid tumours (due to the “enhanced permeability and 
retention” effect) (Luo and Prestwich, 2002).
Poly(2-alkylacrylic acid) (PAAA) polymers have recently been suggested as a possible 
delivery agent for anti-cancer drugs. Three PAAA polymers have been synthesized. 
Polypropyl(2-alkylacrylic acid) (PPAA), poiyethyl(2-alkylacrylic acid) (PEAA) and 
polym ethyl(2-alkylacrylic acid) (PMAA) are distinguished by the length of the 
hydrocarbon side chain. To date, few studies have examined the effects of PAAAs on 
intact cells. Murthy et al. (1999) have reported the ability of these polymers to disrupt 
red blood cells in a pH-dependent manner. The precise molecular mechanism(s) by 
which these polymers disrupt lipid bilayers is not known, although it is thought that the 
polymer undergoes a conformational transition from an expanded coil shape to a more 
complex shape upon acidification (Linhardt et al., 1999). This change in conformation 
is most likely related to the increased hydrophobic character when the many carboxylate 
ions become protonated at low pH. At low pH, partitioning of the polymer into cell 
membranes increases significantly, resulting in membrane rupture (Murthy et al., 1999). 
Cheung et al. (2001) have also shown that when PPAA is incorporated into lipoplexes
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(mixtures of lipids, DNA and PPAA) formed with dioleyltrimethylammonium propane 
(DOTAP) it facilitates the delivery of genes into cells.
Currently, the effects of PAAAs on nucleated mammalian cells are not known. It has 
been hypothesised that PAAAs may be endocytosed by cells into acidified vesicles and 
are there triggered by low pH to disrupt endosomes and release their contents to the 
cytosol. However, the ability of PAAAs to disrupt specific endosomal compartments, 
and the pH dependence of this action, has not previously been measured.
The following chapter investigates the effects on cells of constitutively endocytosed 
PAAAs. Cells continually endocytose materials and particles from their extracellular 
environment. The cell membrane invaginates and forms specific vesicles called early 
endosomes. The contents of early endosomes then transit to more acidic compartments, 
late endosomes and lysosomes. The toxicity and pH-dependent lytic activity of each 
polymer was initially determined. Further investigations were carried out to (1) test the 
ability of PAAAs to disrupt endosomes and/or lysosomes in cultured human cells, and
(2) determine whether this action was dependent upon vesicle acidification. Similar 
studies of pDMAEMA were also carried out; these results are presented in chapter 4. 
We predicted that if the PAAAs disrupted lysosomal membranes, apoptotic death would 
result (see section 1.7). Many independent research groups have shown that partial 
lysosomal rupture induces apoptosis; enzymes released from lysosomes are thought to 
produce this effect by interacting with proteins associated with mitochondria (Brunk 
and Svensson, 1999). If the PAAAs disrupt lysosomes and induce apoptosis it is 
feasible that they could themselves be used as cancer therapeutics.
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3.2 Materials and Methods
3.2.1 Materials
Poly(2-alkylacrylic acid) (PAAA) polymers were supplied by P. Stayton (University of 
Washington, WA, USA). Lipofectamine was from Invitrogen (Melbourne, Australia). 
Propidium iodide, acridine orange, bafilomycin and calcein were from Sigma (MO, 
USA). Monoclonal antibodies reactive with early endosomal antigen 1 (EEA1), 
lysosom al-associated membrane protein-1 (Lamp-1) and Golgin-97 were from 
Pharmingen-Transduction Laboratories (CA, USA). Alexa 488-conjugated goat-anti- 
mouse Ig, streptavidin-Alexa 546 and LysoTracker Yellow DND-68 were from 
Molecular Probes (OR, USA). O-methyl-serine dodecylamide hydrochloride (MSDH) 
was a kind gift from G. Dubowchik (Bristol-Myers Squibb. CT USA). The pEGFP-Nl 
plasmid, encoding enhanced green fluorescent protein, and the pCMVp plasmid, 
encoding |3-galactosidase, were obtained from Clontech (CA, USA). The pCat-EGFP 
plasmid, encoding green fluorescent protein was a generous gift from G. Gores (Mayo 
Medical School, Minnesota, USA). All other chemicals were of reagent quality and 





3.2.2.1 Viability of Cells Following Constitutive Endocytosis of Synthetic 
Polymers
The cytotoxicity of endocytosed PAAAs is unknown. The viability of cells was 
determined by staining cells with propidum iodide (PI), at intervals during 24 hours 
following uptake of PAAAs. PI is a cell-impermeant fluorescent stain. Loss of cell 
viability coincides with a decrease in membrane integrity, allowing PI to enter the cell 
and stain the DNA, which is detected as an increase in red fluorescence.
Cells (2x l06) were centrifuged (5 minutes, 300 g) and resuspended in 500 /A of polymer 
buffer (PB, 145 mM NaCl, 5 mM KC1, 0.5 mM HEPES) containing 200 /*g/ml polymer 
(added from a stock solution of 2 mg/ml in 0.1 M NaOH). Cell suspensions were 
incubated for 30 minutes at 37°C and then washed 3 times with DMEM:F12 before 
being resuspended in 10% FBS/DMEM:F12. Cells were then incubated for 24 hours at 
37°C. Cell viability was determined at 2, 4, 8 and 24 hours, following the initial 
incubation with polymer. Immediately before flow cytometric analysis, cells were 
stained with PI (1 //g/ml). 10,000 cells were analysed for each sample and FSC, SSC 
and FL3 signals were collected.
3.2.2.2 Confirming Endocytic Entry of Polymers into Cells
Endocytosis is the process by which all mammalian cells internalise macromolecules 
and particulates from the extracellular environment. Internalised materials are initially 
held within vesicles known as early endosomes. We reasoned that PAAAs, internalised 
by endocytosis, would be localised in early endosomes. To confirm this, we traced the
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initial movements of PEAA through the cell. This was achieved by biotinylating PEAA 
(b-PEAA, details below) and staining permeabilised cells with anti-EEAl antibody 
(EEA1 is used for the detection of early endosomes). b-PEAA was detected by 
streptavidin-Alexa 546 and anti-EEAl antibody was detected by Alexa 488-conjugated 
goat anti-mouse Ig antibody.
PEAA was biotinylated as follows; 5.1 mg PEAA was dissolved in 0.5 ml anhydrous 
dimethylsulfoxide (DMSO). This was mixed with biotin-x-hydrazide (0.7 mg dissolved 
in 0.5 ml anhydrous DMSO and 2 mg of 4 ’dimethylaminopyridine (DMAP)). This 
mixture was then mixed with 2.7 mg of N ,N’-dicyclohexylcarbodiimide (DCC) on a 
shaker for 2 hours at room temperature. The solution was diluted with 10 ml of 0.1 M 
NaOH and incubated for a further 10 minutes at room temperature. The precipitate was 
then collected by filtration and 1 ml of 3 M sodium acetate was added (pH 
approximately 4.5). This mixture was then incubated for 10 minutes at room 
temperature to allow a precipitate to form, and filtered through a glass filter. The 
precipitate was washed with 3x1 ml of 60 mM sodium acetate (pH 5), filtered again and 
air dried, giving biotin-x-PEAA as a product.
Biotin-x-PEAA (2.3 mg) was dissolved in 100 pi\ of DMSO. U937 cells were 
centrifuged (5 minutes, 300 g) and resuspended in 500 ml polymer buffer containing 
200 /*g/ml of biotin-x-PEAA and incubated for 30 minutes at 37°C. The cells were then 
centrifuged for 5 minutes at 300 g , resuspended in 0.4 ml of 4% (w/v) 
paraformaldehyde in phosphate buffered saline (PBS), pH 7.4, and incubated with 
shaking at room temperature for 30 minutes. The fixed cells were then washed with 
PBS and permeabilised by incubation with 0.4 ml of 0.5% (v/v) triton X-100 in PBS for
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15 minutes on ice. Fixed, permeabilised cells were washed with 0.1% (w/v) bovine 
serum albumin (BSA) in PBS (0.1% BSA/PBS), then suspended in 50 //I of anti-EEAl 
antibody (diluted 1:50 in 1%BSA/PBS) and incubated on ice for 1 hour. The cells were 
then washed with BSA/PBS, suspended in 50 //I of goat-anti-mouse Ig-Alexa 488 
(diluted 1:50 in 1% BSA/PBS) and streptavidin Ig-Alexa 546 (diluted 1:50 in 1% 
BSA/PBS). Cells were then incubated on ice for 1 hour. Finally the stained cells were 
washed with PBS and examined by confocal microscopy. Cells were excited at 488 and 
543 nm and fluorescence collected simultaneously using emission windows set at 500- 
540 nm and 550-600 nm.
3.2.2.3 Measuring Polymer-M ediated Release of Tracer Molecules from  
Intracellular Vesicles
Endocytosed molecules are transported within cells via a series of vesicular 
compartments, namely endosomes and lysosomes. Vesicular traffic can be traced using 
fluorescent markers. Calcein, a 622 Da membrane-impermeable fluor, was used as a 
tracer molecule to follow the uptake of external medium by constitutive endocytosis, 
and, in turn, trace the effects of synthetic pH-dependent polymers on internalised 
vesicles.
In these experiments, 2x l06 U937 cells were centrifuged for 5 minutes at 300 g. Cells 
were resuspended in 0.5 ml of polymer buffer (PB) containing 2 mg/ml calcein with or 
without the addition of polymers from stock solutions at 6 mg/ml in 0.1 M NaOH. 
Following the addition of the polymer, and prior to adding to cells, the pH of 
PB/calcein/polymer solution was re-adjusted to pH 7.4. Cell suspensions were 
incubated for 30 minutes at 37°C and then washed 3 times with DMEM:F12 before
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being resuspended in 10% FBS/DMEM:F12. Subsequently, the distribution of calcein 
within cells was examined by confocal microscopy. Cells were excited at 488 nm and 
fluorescence collected using an emission window set at 500-540 nm. In some 
experiments, calcein distribution was determined each hour over a 4 hour time period.
The TCS NT software was also used to calculate the average pixel intensity of calcein 
fluorescence within regions of interest (ROI) drawn onto collected images. In these 
cases, for each treatment, images of 15-25 individual cells were analysed as follows. 
For each cell, the mean fluorescence intensity was determined for three ROI drawn to 
represent (1) cytoplasm (these were drawn to exclude any calcein-containing vesicles), 
and (2) background (drawn outside the cell). The values for each set of three ROI were 
averaged. The mean background value was then subtracted from the mean value for 
cytoplasm and the results for each cell obtained in arbitrary fluorescence units. 
Differences between treatments were analysed using Oneway ANOVA (JMP software, 
v3.0.2, SAS Institute Inc., Cary, NC, USA).
3.2.2.4 Transient Transfection of Hek293 Cells with a Plasmid Encoding 
Cathepsin B-EGFP Fusion Protein
Cathepsin B (Cat B) is a 38 kDa lysosomal cysteine protease, primarily involved in 
protein degradation within lysosomes. Roberts et al. (1997) constructed a plasmid 
encoding a fusion protein comprised of rat Cat B fused at its C terminus to an enhanced 
green fluorescent protein (EGFP). A rat cDNA fragment containing the coding sequence 
for amino acids 1-334 of rat Cat B was excised from the pRSG-2A vector and ligated 
into the pEGFP-Nl expression vector, which has a multiple cloning site adjacent to its 
EGFP sequence (Cat-B-EGFP). Transfection of this plasmid DNA into mammalian
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cells was used to show that cat B is translocated to the nucleus during bile salt-induced 
apoptosis (Roberts et al., 1997).
To determine if synthetic polymers release macromolecules from endosomes, Hek293 
cells were transiently transfected with Cat-B-EGFP prior to polymer loading. Hek293 
cells were seeded into 6 well plates (2xl05 cells in 2 ml of 10% FBS/DMEM:F12 per 
well) and incubated for 24 hours at 37°C. Cells were then transfected with either 
pEGFP-Nl (used as a control) or Cat-B-EGFP, using lipofectAMINE, according to the 
manufacturer’s instructions (Invitrogen, Melbourne, Australia). Seeded cells were 
washed with 2 ml of serum-free medium (SFM). 200 /d of transfection mixture (24 //I 
plasmid DNA/transfection, 18 /d lipofectAMINE reagent and 158 /d SFM) was then 
added to each well. Cells were then incubated for 5 hours at 37°C in a 5% C 0 2 
incubator. The transfection mixture was subsequently removed and replaced with 2 ml 
of complete medium. Cells were assayed for gene expression by confocal and 
epifluorescence microscopy at 48 hours post transfection.
Once expression had been confirmed, complete medium was removed and replaced with 
500 /d of PB containing 50 /.<g/ml of PPAA. The cells were then returned to a 37 °C, 5% 
C 0 2 incubator and 2 and 4 hours later analysed by confocal microscopy for the release 
of Cat-B-EGFP to the cytosol.
3.2.2.5 Determining if Polymer-M ediated Endosomal Disruption is pH- 
Dependent
The ability of PAAAs to disrupt membranes in a pH-dependent manner was determined 
using three assays. Each assay is described below.
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1. Whole cell experiments were conducted to determine the ability of PAAAs to disrupt 
membranes in a pH-dependent manner. Cells were incubated in different buffers at 
various pH levels in the presence of 200 ^g/ml of polymer. The pH-dependence of 
membrane-lytic activity was determined by measuring the proportion of non-viable 
cells at different pHs. lxlO6 U937 cells were pelleted and resuspended in 400 /d of 100 
mM MES buffer (100 mM NaCl, 100 mM MES, 5 mM KC1) at various pH levels. The 
pHs used were 5, 5.5, 6, 6.5 and 7. PPAA, PEAA or PMAA was added from a 10 mg/ml 
stock solution in 0.1 M NaOH, to give a final concentration of 200 /^g/ml (no additions 
were made to the control tubes). The samples were then incubated at 37°C for 30 
minutes and stained with propidum iodide (PI) immediately before flow cytometric 
analysis. For each sample, FL3 (red fluorescence) was acquired for 10 000 cells.
2. Bafilomycin was then used to determine the ability of PAAAs to disrupt membranes 
in a pH -dependent manner. B afilom ycin is a specific inhib itor of the 
endosomal/lysosomal H+-ATPase (Ohkuma, 1993). H+-ATPase is responsible for the 
acidification of endosomes. In these experiments, 1 mM bafilomycin was added to cell 
suspensions during calcein uptake (section 3.2.2.3) and the subsequent 4 hour 
incubation.
3. Finally, the ability of PAAAs to disrupt membranes in a pH-dependent manner was
determined by increasing the concentration of Hepes buffer in the PB; this is known to
alkalinize the contents of endosomes (Sullivan, 1987). In these experiments calcein was
again constitutively endocytosed into cells as described in section 3.2.2.3. Control cells
were incubated in 0.5 mM Hepes-buffered PB (that had been adjusted to an equivalent
osmotic pressure by the addition of 75 mM sucrose) and PAAA-exposed cells were
incubated in 50 mM Hepes-buffered PB. Following uptake, cells were incubated for a
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further 4 hours. For these latter experiments, cells were analysed by confocal 
microscopy and flow cytometry.
3.2.2.6 Identification of Intracellular Vesicles Disrupted by PAAA Polymers
Immunofluorescence assays were used to examine the morphology and distribution of 
both early and late endosomes and lysosomes following endocytosis of polymers. This 
enabled determination of the specific intracellular vesicle/s that the polymer/s disrupted. 
Monoclonal antibodies reactive with early endosomal antigen 1 (EEA1), lysosomal- 
associated membrane protein-1 (Lamp-1), and Golgin-97 were used. EEA1 is thought to 
only be associated with early endosomes. Lamp-1 is associated with various vesicles, 
however, it seems to predominately accumulate in late endosomes and lysosomes 
(Akasaki, 1995). Anti-golgin-97 recognizes a 97 kDa protein called Golgin-97, which is 
a member of the granin family of proteins localised on the cytoplasmic face of the Golgi 
apparatus.
U937 cells were treated as described for measuring the release of calcein from 
endosomal vesicles (section 3.2.2.3), except that calcein was deleted from the initial 
incubation mixture. Following uptake, the cells were incubated for 4 hours at 37°C in 
10% FBS/DM EM :F12 before processing for im m unofluorescence. In some 
experiments, polymers were omitted from the initial incubation buffer but 70 jaM 
MSDH (an acidotropic detergent known to disrupt lysosomes (Li et al., 2000)) was 
added to the medium used for the subsequent 4 hour incubation. The cells were then 
centrifuged for 5 minutes at 300 g , resuspended in 0.4 ml of 4% (w/v) 
paraformaldehyde in PBS, pH 7.4, and incubated with shaking at room temperature for 
30 minutes. The fixed cells were then washed with PBS and permeabilised by
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incubation with 0.4 ml of 0.5% (v/v) triton X-100 in PBS for 15 minutes on ice. Fixed, 
permeabilised cells were washed with 0.1% (w/v) bovine serum albumin (BSA) in PBS 
(0.1% BSA/PBS), then suspended in 50 /a \ of either, anti-EEAl, anti-Lamp-1 or anti- 
golgin-97 antibodies (diluted 1:50 in 1%BSA/PBS) and incubated on ice for 1 hour. The 
cells were then washed with BSA/PBS, suspended in 50 //I of goat-anti-mouse Ig-Alexa 
488 (diluted 1:50 in 1% BSA/PBS) and incubated on ice for 1 hour. Finally the stained 
cells were washed with PBS and examined by confocal microscopy. Cells were excited 
at 488 nm and fluorescence collected using an emission window set at 500-540 nm.
In experiments analysing the effects of treatments on Lamp-1 immunofluorescence, 
TCS NT software was used to measure for 50 randomly chosen cells from each 
treatment, in a constant arbitrary plane, the diameter of globular areas of fluorescence 
within cells (see Figure 3.11). The measurement taken was used to score each cell as 
being in one of four categories: (1) no globular regions of fluorescence (i.e. diameter 
(grf) = 0 mm), (2) diameter (grf) = 0.1-1.5 mm, (3) diameter (grf) = 1.6-3.0 mm, or (4) 
diameter (grf) > 3.0 mm. Histograms were then plotted from these scorings. In the small 
number of cases in which there was more than one globular area of fluorescence within 
a cell, only the largest was measured.
3.2.2.7 Lysosomal Assays
To further test the effects of polym ers on lysosom es, in addition to the 
immunofluorescence assay with Lamp-1 antibody, cells were stained with the 
fluorescent acidotropic probes acridine orange and LysoTracker Yellow. Acridine 
orange accumulates to high concentrations in the lysosomal lumen where it forms red 
fluorescing dimers (Zelenin, 1999). An increase in dimer formation can be detected by
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flow cytometry. The LysoTracker dyes are thought to partition into lysosomal 
membranes. The morphology and distribution of lysosomes was determined, following 
staining, by confocal microscopy.
Polymers were loaded by constitutive endocytosis into U937 cells as previously 
described (section 3.2.2.3). Following the 4 hour incubation, cells were centrifuged for 
5 minutes at 300 g and resuspended in DMEM:F12 containing 5 /*g/ml acridine orange, 
incubated for 20 minutes at room temperature in the dark, and finally analysed by flow 
cytometry. The cells were excited with a 488 nm Argon laser and red fluorescence 
collected using a 650 nm long pass filter. For each sample, 10,000 events were 
acquired.
Similarly, for LysoTracker Yellow staining, cells were loaded with polymers by 
constitutive endocytosis and incubated in 1 ml of 10% FBS/DMEM:F12 for 4 hours at 
37°C. After 3 hours, LysoTracker Yellow (75 nM - from 1 mM stock) was added to the 
cell suspension and cells were incubated for a further hour. Cells were then centrifuged 
(5 minutes, 300 g), resuspended in DMEM:F12 and analysed by confocal microscopy. 
Cells were excited at 543 nm and fluorescence collected using an emission window set 
at 550-600 nm.
In experiments analysing the effects of treatments on LysoTracker fluorescence, the 
TCS NT software was used to draw a line in a constant arbitrary plane across the entire 
diameter of images of individual cells and the “profile” function used in each case to 
obtain a histogram plot of the level of fluorescence along the length of the line drawn. A 
constant arbitrary “baseline” level of fluorescence was selected and the number of
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continuous regions with fluorescence above this baseline was counted for each cell. For 





Following uptake of PPAA, PEAA or PMAA by constitutive endocytosis, cell viability 
was determined. During the ensuing 24 hour period, like control cells, more than 95% 
of cells treated with PPAA remained viable. Similar results were obtained for cells 
treated with PEAA and PMAA (data not shown).
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Figure 3.1: Line graph showing the viability of PPAA-treated (dashed line) and control 
U937 cells (solid line) over a 24 hour period following uptake of PPAA by constitutive 
endocytosis. Over the 24 hour time period, no significant change in cell viability was 
detected in either PPAA-treated or control cells. Each data point represents the mean of 
3 independent experiments. Error bars are too small to be seen.




3.3.2 Testing the pH-Dependent Lytic Activity of PPAA, PEAA 
and PMAA
Whole cell experiments were conducted to determine the pH-dependent lytic activity of 
the polymers; cell lysis was measured as a function of pH. Cytolysis was detected by 
flow cytometric analysis of Pi-stained cells (Figure 3.2). At all pH levels tested, little 
cell lysis (approximately 5%) was detected in control and PMAA-treated cells. In 
contrast, at some pHs, cell viability was significantly reduced following treatment with 
PPAA and PEAA. Following exposure to PPAA, the percentage of non-viable cells 
increased considerably between pH 7.0 and 6.5, but gradually decreased with further 
reductions in pH (Figure 3.2). At pH 7.0 neither PPAA nor PEAA induced significant 
loss of cell viability. However, at pH 6.5, exposure to PPAA lysed nearly 90% of cells 
(Figure 3.2). At progressively more acidic pH, the proportion of cells lysed by PPAA 
decreased slightly. In contrast, the proportion of cells lysed by PEAA did not increase 
significantly until the pH was reduced to 6.0 (where about 15% of the cells were lysed). 
At pH 5.5 and 5.0, PEAA lysed more than 90% of cells. For unknown reasons, PMAA 




Figure 3.2: Line graph showing the percentage of non-viable U937 cells following 
exposure to either 200 ^g/ml PPAA ( A ), PEAA (■ )  or PM A A (X ). Each data point 
represents the mean values for three independent experiments. Errors bars represent the 
standard errors of the mean in each case.
3.3.3 Polymers are Endocytosed and Release Calcein from 
Intracellular Vesicles
Following a 30 minute incubation in polymer buffer containing b-PEAA, U937 cells 
were stained with anti-EEAl antibody and Alexa 488-conjugated goat anti-mouse Ig; 
b-PEAA was detected using streptavidin-Alexa 546. Confocal microscopy showed the 
polymer (b-PEAA) in punctate structures, many at the periphery of the cell. Many of 
these punctate structures co-stained with anti-EEA l antibody. This pattern of 
fluorescence suggests that the polymer, which is hydrophilic at pH 7.4, enters the cell 
via the process of endocytosis (Figure 3.3).
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Figure 3 .3 : Confocal microscopy images of U937 cells incubated in PB containing b- 
PEAA (red fluorescence). Images show cells stained with (a) anti-EEA l antibody only 
(green fluorescence), (b) streptavidin-A lexa 546, and (c) an overlay o f the two 
fluorescence images. In many cells, vesicles show co-localisation of green and red 
fluorescence (white). This result is representative of four independent experiments. 40- 
50 cells were scanned to ensure reproducibility. Bar = 10 /<m.
When U937 cells were incubated in PB containing the membrane- impermeable fluor
calcein, they subsequently showed fluorescent intracellular vesicles, consistent with
constitutive endocytosis of the external medium. Numerous fluorescent intracellular
vesicles were detected (Figure 3.4). W hen PPAA was included in the buffer together
with calcein, there was a time-dependent release of calcein from vesicles to the cytosol.
The pattern of intracellular fluorescence significantly changed during a 4 hour period
following the initial uptake. Immediately following constitutive endocytosis of calcein
and polymer, intracellular fluorescence was punctate. Two hours after uptake, larger
fluorescent vesicles were clearly seen in many polymer-treated cells (Figure 3.4, panel
b, indicated by arrow) but were absent in control cells, suggesting that PPAA induced
vesicle fusion. At the same point in time, some cells showed partial release of calcein to
the cytosol (Figure 3.4, panel b). A t 4 hours follow ing loading, fluorescence was
considerably more diffuse, suggesting movement of calcein from vesicles to the cytosol
(Figure 3.4, panel c). A similar pattern of fluorescence was detected when PEAA was
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used. PEAA-treated cells also showed vesicle fusion and cytosolic calcein release, 
although this occurred later then in PPAA-treated cells. After 4 hours, calcein release 
was also detected in cells treated with PMAA, however the extent of this was less than 
in PPAA or PEAA-treated cells.
Figure 3.4: Confocal microscopy images of U937 cells incubated in PB containing 200 
Hg/ml of polymer and 2 mg/ml calcein. (a) Image of U937 cells immediately following 
PPAA treatment. Fluorescence is largely in punctate regions, (b) U937 cells 2 hours 
following PPAA-treatment. (c-e) Images of U937 cells 4 hours after loading of PPAA 
(c), PEAA (d), and PMAA (e) by constitutive endocytosis. In some cells vesicles have 
fused (arrows) and in others fluorescence is diffuse. This result is representative of six 
independent experiments. 40-50 cells were scanned to ensure reproducibility. Bar = 10 
pim.
These interpretations are supported by quantitative analysis. For all polymers tested 
there was an increase in cytosolic fluorescence over time. At 4 hours following PPAA 
exposure the average cytosolic fluorescence (in arbitrary units) was 107. The 
corresponding level of fluorescence was 96 for PEAA-treated cells and 58 for PMAA-
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Figure 3.5: Plot showing the cytosolic calcein fluorescence of U937 cells, following 
constitutive endocytosis of media containing 2 mg/ml calcein and either 200 jAg/ml 
PPAA, 200 fdglml PEAA or 200 fdg/m\ PMAA. Over time, cytosolic calcein 
fluorescence increased by 60-70 arbitrary units in all treatments. 50 randomly chosen 
cells were analysed for each treatment. Error bars represent the standard error of the 
mean cytosolic calcein fluorescence in each case.
The ability of polymers to mediate calcein release showed a biphasic dependence on 
polymer concentration (Figure 3.6). For any one polymer, the level of calcein release 
was comparable for polymer concentrations of 5-25 p g/ml but increased to a higher 
similar level at either 50 or 200 /<g/ml of polymer. The level of calcein release obtained 
following exposure of cells to either 50 or 200 //g/ml PPAA was significantly greater 
than that obtained with 25 //g/ml PPAA (P<0.001, F450=13.87, pairwise Tukey-Kramer 
comparisons). Significant differences between either of the higher concentrations of
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PEAA or PMAA (i.e. 50 /^g/ml or 200 //g/ml) were not observed. In further 
experiments, 50 or 200 /*g/ml of polymer was used.
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Figure 3.6: Dependence of endosomal calcein release on the concentration of poly(2- 
alkylacrylic acid)s. Plots show the level of cytosolic calcein fluorescence in U937 cells 
(determined as described in section 3.2.2.3), 4 hours after a 30 minute incubation in PB 
containing 2 mg/ml calcein and the indicated concentrations of PEAA, PPAA or 
PMAA. Each data point represents the mean values determined for 15 cells. The error 
bars shown are standard errors of the mean.
3.3.4 Polymers Release a Cathepsin B-GFP Fusion Protein from 
Intracellular Vesicles
Results in section 3.3.3 demonstrate that PAAAs can mediate release of a 622 Da fluor, 
calcein, from intracellular vesicles. To investigate whether the polymers could also 
Mediate the release of macromolecules from vesicles, Hek293 cells were transiently
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transfected with pCatB-EGFP plasmid encoding a fusion protein consisting of cathepsin 
B fused at its C-terminus to enhanced green fluorescent protein. Cathepsin B is an 
enzyme that is concentrated in lysosomes but is also found in early and late endsomes 
(Seaman, 2001). Control cells were transfected with control DNA (pEGFP-Nl). 
Cells expressing EGFP showed a homogeneous distribution of green fluorescence 
within the entire cell (Figure 3.7A, panel a). In contrast, cells expressing Cat B-EGFP 
showed a restricted distribution of intracellular fluorescence consistent with the fusion 
protein being localized within endosomes/lysosomes (Figure 3.7A, panel b). When 
these latter cells were incubated in PB containing 50 /^g/ml PPAA for 30 minutes, and 
subsequently examined by confocal microscopy, the intracellular fluorescence was more 
diffuse (Figure 3.7A, panel c), indicating partial release of cathepsin B-EGFP to the 
cytosol. Quantitative image analysis (as described in section 3.2.2.3) indicated that 
under the conditions tested, uptake of PPAA caused a statistically significant 2.4-fold 
increase in the cytosolic level of green fluorescence in pCatB-EGFP transfectants 
(p<0.001, Students t-test; Figure 3.7B). Similar changes in the distribution of 
fluorescence were also found when pCatB-EGFP-transfected cells were treated as above 
with PEAA or PMAA, but not when they were treated the same in the absence of any 
polymers (data not shown).
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Figure 3.7: A. Confocal microscopy images of transiently transfected Hek293 cells 
showing (a) diffuse cytoplasm ic fluorescence in cells transfected with a plasmid 
encoding (cytosolic) EGFP, (b) fluorescence restricted to intracellular vesicles in cells 
transfected with a plasmid encoding a cathepsin B-EGFP fusion protein, and (c) the 
same type of transfectants shown in (b) 4 hours after incubation in PB containing 50 
/<g/ml PPAA, showing release of cathepsin B-EGFP from vesicles to the cytosol. 
Release of cathepsin B-EGFP to the cytosol was also visible at earlier time points 
following polym er uptake (data not shown). PEAA and PMAA were also able to 
mediate release of cathepsin B-EGFP to the cytosol; this release did not occur in cells 
treated similarly but in the absence of PAAAs (images not shown). Bar = 10 ;/m. B. 
Histogram plots summarising the results of quantitative image analysis of cytosolic 
calcein fluorescence in Hek293 cells following transient transfection with (i) p-EGFP or 
(ii) pCatB-EGFP (with or without a subsequent 4 hour exposure to 50 //g/ml PPAA). 
Results are representative of 2 independent experiments and for each treatment 30 cells 
were analysed. Error bars represent the standard error of the mean cytosolic calcein 





































3.3.5 Polymer-Mediated Disruption of Intracellular Vesicles is 
pH-Dependent
Stayton (2000) previously reported that PAAAs disrupt membranes in a pH-dependent 
manner and their membrane disruptive ability is significantly enhanced at acidic pH. 
The intra-vesicular pH of the major vesicles involved in the endocytic pathway 
gradually decreases from approximately 6.5 (early endosomes) to 4.5 (lysosomes). 
The progressive acidification of these vesicles is achieved primarily by the operation of 
an H+-ATPase pump found in the vesicle membrane. Acidification can be inhibited by 
membrane-permeable vacuolar ATPase inhibitors such as bafilomycin (Vandeurs et al., 
1996; Schoonderwoert et al., 2000).
Results discussed in sections 3.3.3 and 3.3.4 suggest that PAAAs are able to mediate the 
release of small and macro-molecules from endosomes to the cytosol. Bafilomycin 
significantly inhibits the release of calcein from intracellular vesicles mediated by 
PPAA, PEAA or PMAA (Figure 3.8). In each case, the effect of bafilomycin was 
statistically significant (p<0.02, Student’s t-test). These result suggest that acidification 
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Figure 3.8: Plot showing that bafilomycin-mediated alkalinization of endosomes 
inhibits PAAA-mediated release of calcein to the cytosol. Quantitative results of 
confocal microscopy analyses of U937 cells measuring calcein release into the cytosol 
(see section 3.2.2.3 for details), 1.5 hours after a 30 minutes incubation in PB containing 
2 mg/ml calcein and (where indicated) other additions. The histogram plots show results 
for cells incubated only with calcein (control) or with calcein and other additions (e.g. 
PEAA, cells incubated with calcein and 200 /*g/ml PEAA). Where indicated (e.g. 
PEAA/BAF), cells were also treated with 1 bafilomycin to inhibit H+-ATPase- 
mediated acidification of endosomal vesicles. Data points represent the mean of 25 cells 
and error bars represent the SE of the mean in each case.
This result was confirmed by showing that strong buffering of the solution from which 
cells endocytosed calcein and polymers inhibited the subsequent release of calcein into 
the cytosol. A 50% decrease in calcein release was detected in cells incubated in the 
strongly buffered solution, containing 200 /^g/ml PPAA, compared to those incubated in 
the control buffer (Figure 3.9, p<0.001, Students t-test).
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Figure 3.9: Buffer-mediated alkalinization of endosomes inhibits PAAA-mediated 
release of calcein to the cytosol. Plots show quantitative results of confocal microscopy
details). Cells were analysed 1.5 hours after a 30 minute incubation in PB containing 2 
mg/ml calcein and where indicated (Hepes), the buffering of PB was increased from 0.5 
mM to 50 mM Hepes. The histograms show results for cells incubated with calcein only 
(control) and cells incubated with calcein and 200 J4g/m\ PPAA (PPAA). Where 
indicated (Control/Hepes and PPAA/Hepes), cells were incubated in PB containing 50 
mM Hepes. Pairwise comparisons indicated that 50 mM Hepes significantly inhibited 
the release of calcein (p<0.001, Student’s t-test): the small difference between 
Control/Hepes and Control is not statistically significant. This data are representative of 
three independent experiments and error bars represent the standard error of the mean in 
each case.
analyses of U937 cells measuring calcein release into the cytosol (see section 3.2.2.3 for
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3.3.6 Effects of Polymer Uptake on EEA1 and Lamp-1 
Immunofluorescence
Results thus far indicate that PAAAs, particularly PEAA and PPAA, disrupt 
intracellular vesicles in a pH-dependent manner. Immunofluorescence was used to 
examine the effects of individual polymers on the morphology and distribution of 
different vesicle populations. Early endosomes were identified by staining cells with 
anti-EEAl antibody. In both control and polymer-treated cells, fluorescence was in 
distinct punctate regions, generally towards the periphery of the cell (Figure 3.10), 
suggesting that the uptake of polymers did not affect the morphology or distribution of 
early endosomes. The lysosomal disruptive agent MSDH also had no effect on early 
endosomes (data not shown).
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Figure 3.10: Confocal microscopy images showing U937 cells stained with anti-EEAl 
antibody following constitutive endocytosis of PAAAs. A similar punctate pattern of 
fluorescence was detected in both control cells (a) and polymer-treated cells; PEAA (b), 
PPAA (c) and PMAA (d), suggesting that internalised polymers have no effect on early 
endosomes. These images are representative of cells analysed from 4 independent 
experiments. B ar=  10 //m.
Late endosomes and lysosomes were detected by staining cells with anti-Lamp-1 
antibody. In control cells, one or two regions of bright concentrated fluorescence were
81
Chapter 3 PAAAs
detected. These concentrated regions were approximately 2-4 ^m  in diameter and were 
surrounded by smaller fluorescent vesicles distributed throughout the cell (Figure 3.11A 
Panel a). In polymer-treated cells, these bright fluorescent globular regions were 
significantly reduced in size and in many cells these regions were not identifiable at all. 
Interestingly, the smaller fluorescent vesicles distributed throughout the cell were 
unaffected by polymers. This notable change in fluorescence was most obvious in cells 
treated with MSDH. In the majority of MSDH-treated cells, no globular regions of 
Lamp-1 specific fluorescence were detected (Figure 3 .11A). These interpretations were 
confirmed by quantitative image analysis (Figure 3.1 IB).
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Figure 3.11: A: Confocal microscopy images of U937 cells following uptake of PAAAs 
by constitutive endocytosis and staining with anti-Lamp-1 antibody. Images show: 
Lamp-1 positive globular regions of fluorescence (grf; arrow) in cells incubated with (a) 
no added polymer, (b) 70 //M MSDH (to disrupt lysosomes), or 200 piglm\ of (c) PEAA, 
(d) PPAA or (e) PMAA. B: Histogram plots summarising the results of quantitative 
image analysis of the diameter of grf of 50 randomly chosen cells from each treatment 
(see section 3.2.2.6 for more details regarding this analysis). Bar = 10 /<m.
3.3.7 Identifying the Specific Intracellu lar V esicle  
Compartment(s) Disrupted by PAAAs
Lamp-1 is a major lysosomal protein but is also found in the membranes of late 
endosomes and the trans Golgi network (Akasaki, 1995). Thus, the changes in the 
pattern of Lamp-1 immunofluorescence induced by uptake of PAAAs might result from 
changes to one or more of these compartments. To eliminate the possibility that PAAAs 
might be transported from endosomes to the trans-Golgi and there disrupt the Golgi, 
following uptake of polymer, U937 cells were stained with anti-golgin 97 antibody.
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Anti-golgin-97 antibody recognizes a 97 kDa protein called golgin-97 that is located on 
the trans-Golgi network. Golgin-97 is not located in any other compartment. Cells were 
analysed by confocal microscopy following polymer uptake and antibody staining. 
In both the control cells and polymer-treated cells, fluorescence was in distinct 
elongated clumps around the periphery of the cell (Figure 3.12), suggesting that the 
uptake of PAAAs did not affect the morphology or distribution of the trans-Golgi 
apparatus.
Figure 3.12: Confocal microscopy images of U937 cells showing Golgin-97 positive 
vesicles (trans-Golgi apparatus). Four hours after a 30 minutes incubation in PB alone 
(a) or PB containing 200 //g/ml PPAA (b), U937 cells were fixed, permeabilized and 
then stained with anti-golgin-97 antibody. Images are representative of two independent 
experiments. Bar = 5 //m.
To investigate the effects of polymer uptake on lysosomes, LysoTracker Yellow and 
acridine orange were used. Control cells stained with LysoTracker Yellow showed one 
or a small number of patches of peri-nuclear fluorescence (Figure 3.13, panel a). In cells 
treated with MSDH, the areas of fluorescence were smaller in size and more punctate 
(Figure 3.13, panel b), indicating changes in lysosomal morphology. However, the 
effects of the polymers were less pronounced. Polymer-exposed cells showed a more 
irregular pattern of staining with LysoTracker Yellow than control cells (Figure 3.13,
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panels c-d). Uptake of PEAA produced a pattern of fluorescence that was similar to that 
of MSDH-treated cells. Cells that had taken up PPAA or, particularly, PMAA showed 
lesser effects but the pattern of fluorescence was still more dispersed than that of the 
controls. Image analysis (see section 3.2.2.7) confirmed that MSDH and the polymers 
had induced changes in the pattern of LysoTracker fluorescence (Figure 3.13B). Flow 
cytometric analysis of cells treated with either MSDH or polymers and stained with 
acridine orange indicated that MSDH induced loss of lysosomal integrity but that 
uptake of any of the polymers did not (Figure 3.14). Collectively, these results suggest 
that polymers were causing changes in lysosomal morphology but were not causing 
physical disruption of the lysosomal membrane.
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panels c-d). Uptake of PEAA produced a pattern of fluorescence that was similar to that 
of MSDH-treated cells. Cells that had taken up PPAA or, particularly, PMAA showed 
lesser effects but the pattern of fluorescence was still more dispersed than that of the 
controls. Image analysis (see section 3.2.2.7) confirmed that MSDH and the polymers 
had induced changes in the pattern of LysoTracker fluorescence (Figure 3.13B). Flow 
cytometric analysis of cells treated with either MSDH or polymers and stained with 
acridine orange indicated that MSDH induced loss of lysosomal integrity but that 
uptake of any of the polymers did not (Figure 3.14). Collectively, these results suggest 
that polymers were causing changes in lysosomal morphology but were not causing 
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Figure 3.13 A: Confocal microscopy images of U937 cells loaded with PAAAs by 
constitutive endocytosis and stained with LysoTracker Yellow. U937 cells were 
incubated in PB containing various additions for 30 minutes. Cells were then washed 
and resuspended in com plete medium and incubated for a further 4 hours. 
LysoTracker Yellow was added directly to the cells 1 hour before confocal analyses 
(see section 3.2.2.7 for more details). Images show: (a) control cells (no added 
polymer); (b) MSDH-exposed cells (MSDH disrupts lysosomes); (c) PEAA-treated 
cells (200 (d) PPAA-treated cells (200 /*g/ml) and (e) PMAA-treated cells (200
I*g/ml). For each treatment, the images shown are representative of 40 cells analysed in 
three independent experiments. Bar = 10 //m. B: Each histogram plot summarises the 
results of quantitative image analysis (performed as described in section 3.2.2.7) of 25 




Figure 3.14: Overlay flow cytometry histograms showing U937 cells stained with 
acridine orange 4 hours after a 30 minute incubation in PB containing no additions (thin 
solid line) or 200 j<g/ml PEAA (dashed line), or after 4 hours incubation in culture 
medium containing 70 pM  MSDH (thick solid line). The results shown are 
representative of four independent experiments. In similar experiments, the uptake of 
PPAA and PMAA also had no effect on the level of red fluorescence associated with 




This chapter describes work in which PAAAs were introduced into cells via constitutive 
endocytosis and the effects on cells were characterised. No significant decrease in cell 
viability was detected over a 24 hour time period following polymer uptake. Whole cell 
experiments indicated that both PEAA and PPAA destabilize membranes at mildly 
acidic pH. The membrane-disruptive activity was greatest at pH 5.5 for PEAA and pH
6.5 for PPAA. Interestingly, the membrane-disruptive activity of PPAA appeared to 
decrease at pH<6.5. At these pHs, PPAA has a tendency to precipitate from aqueous 
solution. It has been suggested that at pH 5 and 5.5, PPAA may form micro-aggregates 
with a reduced ability to disrupt membranes (Jones et al., 2003). Thus, the greater 
hydrophobicity of PPAA may explain why it had reduced lytic efficiency at lower pH. 
Previous work has suggested that PAAAs are likely to deliver molecules into cells by 
endocytic uptake followed by low pH-induced disruption of endosomes/lysosomes to 
release their contents to the cytosol (Murthy et al., 1999). The membrane-disruptive 
activity results suggest that PPAA might achieve maximum membrane-disruptive 
activity during the earlier stages of endosomal acidification, whereas PEAA might only 
achieve this in the final most acidic endosomal compartments. In these whole cell 
experiments PMAA did not display any membrane-disruptive activity. The reason(s) for 
this are unknown.
Results displayed in Figure 3.3 show U937 cells with biotinylated PEAA (b-PEAA) in
punctate structures located primarily at the periphery of the cell; some of the punctate
structures are co-stained with anti-EEAl antibody. This suggests that PEAA (which is
hydrophilic at pH 7.4) is taken up by endocytosis and transits through early endosomes
before moving onto other vesicular compartments. Similarly, when U937 cells were
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incubated in buffer containing the membrane-impermeable fluor calcein, they 
subsequently showed fluorescent intracellular vesicles, consistent with constitutive 
endocytosis of the external medium (Figure 3.4). Uptake of PAAAs induced fusion of 
calcein-containing endosomes followed by release of calcein to the cytosol (Figure 3.4). 
This effect appears similar to the PEAA-induced fusion of phosphatidylcholine vesicles 
observed in vitro at mildly acidic pH (Linhardt and Tirrell, 1999).
Time course studies conducted over a 4 hour period showed a time dependent release of 
calcein from intracellular vesicles into the cytosol. PPAA produced more rapid 
disruption of vesicles than PEAA. PMAA produced the least disruption of vesicles and 
its effect was the slowest of the three polymers tested. The faster kinetics and greater 
extent of vesicle disruption mediated by PPAA and PEAA compared to PMAA may 
result from the greater hydrophobicity of PPAA and PEAA.
In contrast to the results reported here, Plank et al. (1994) previously showed that pH- 
sensitive endosomal disruptive peptides were able to induce significant release of 
fluorescent dextran from intracellular vesicles 15 minutes after endocytic uptake. 
However, in these experiments no measurements of the time dependence of release 
were reported. Both PPAA and PEAA mediated measurable release of calcein from 
vesicles im mediately after uptake, however, the extent of release increased 
progressively with time, reaching a maximum at approximately 4 hours after uptake. 
It appears that, once endocytosed, PAAAs may disrupt endosomes more slowly than 
pH-sensitive peptides. It has been suggested that endosomal-disruptive peptides only 
require protonation of a small number of side-chain groups (e.g. 3) to bring about 
transition to a membrane-disruptive conformation (Plank et a l ,  1994). In contrast,
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PAAA are polyanions at physiological pH: when internalised within endosomes they 
will act as polyvalent buffers and will require the transport of hundreds of H+ ions per 
polymer molecule before becoming membrane-disruptive. Another possible reason for 
the apparently slower kinetics of vesicle disruption mediated by PAAAs versus peptides 
may be that PAAAs appear unable to disrupt lysosomes (Figure 3.14). Mellman (1996) 
suggests that undegraded endocytosed material is continually recycled between late 
endosomes and lysosomes. Therefore, the PAAAs may only mediate the release of 
molecules when they are intermittently and transiently resident in late endosomes.
The default pathway for endocytosed materials is to be carried through vesicle 
compartments towards lysosomes for eventual degradation. During this trafficking the 
contents of the vesicles become progressively acidified, reaching a pH of less than 5.0 
in lysosomes. We reasoned that endocytosed PAAAs would probably follow this 
pathway and when the vesicle contents became sufficiently acidic, the polymers would 
adopt a conformation competent to disrupt membranes. Acidification of the lumen of 
endososomes/lysosomes is effected by an H+-ATPase found in the vesicle membrane, 
which can be specifically inhibited by bafilomycin (Vandeurs et al., 1996). Results 
shown in Figures 3.8 and 3.9 show that disruption of intracellular vesicles was 
significantly  decreased follow ing bafilom ycin-m ediated  inhib ition  of the 
endosomal/lysosomal H+-ATPase or strong buffering of the medium from which 
polymers were endocytosed. These results indicate that endocytosed PAAAs are 




The ability of PAAAs to mediate calcein release showed a biphasic dependence on 
concentration (Figure 3.6). Cytosolic calcein fluorescence was comparable when cells 
endocytosed PAAAs from concentrations of 5-25 /<g/ml increased significantly to a 
similar higher level when either 50 ^g/ml or 200 ^g/ml PAAA were used. The reason 
why this occurs is not known, however, it is possible that at higher concentrations in an 
acidic environment, individual polymer molecules may co-operate in some way to more 
efficiently disrupt membranes.
PAAAs disrupt intracellular vesicles to release both small molecules (e.g. 622 Da 
calcein) and macromolecules (e.g. a 64 kDa fusion protein) (Figure 3.4 and 3.7, 
respectively). In addition, Lackey et al. (2002) have shown that PPAA similarly 
mediated release of a large (approximately 264 kDa) polymer-antibody-streptavidin 
complex to the cytosol. These results suggest that PAAAs are capable of sufficiently 
disrupting intracellular vesicles to effect the indiscriminant release of their contents to 
the cytosol.
There are three major types of acidified intracellular vesicles through which most 
endocytosed materials pass through. These are early and late endosomes and lysosomes. 
These vesicles are thought to be the location of expressed Cat B-EGFP (Guicciardi et 
al., 2000). Results shown here indicate that Cat B-EGFP is released from intracellular 
vesicles following polymer treatment (Figure 3.7). Therefore, it was reasoned that one 
of these three compartments would be the site(s) disrupted by endocytosed PAAA 
polymers. There was no measurable effect of polymer uptake on the pattern of EEA1 
immunofluorescence, suggesting that early endosomes were unaffected (Figure 3.10). 
The early endosome is the first compartment that endocytosed materials are delivered to
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and its lumen is mildly acidic at pH 6.0-6.2 (Cain, 1989). Despite the fact that PPAA 
has potent haemolytic activity at this pH, it does not appear to disrupt early endosomes.
In contrast, Lamp-1 immunofluorescence was significantly affected following uptake of 
PAAAs (Figure 3.11). Lamp-1 proteins belong to a series of proteins that are located on 
the surface of late endosomes, lysosomes and the trans Golgi network. This suggests 
that the polymers were disrupting one or more of these compartments. To identify the 
precise com partment that the polymers disrupt, various other assays were performed. 
Changes in LysoTracker Yellow staining suggested that, 4  hours after uptake (when 
extensive release o f calcein from  vesicles could be m easured), the polym ers were 
effecting changes in the morphology of lysosomes. However, at this same time point, 
flow cytometric analysis of cells stained with acridine orange (which accumulates inside 
lysosomes (Zelenin, 1999)) indicated that lysosom es rem ained structurally intact 
(Figure 3.14). Extensive lysosomal bursting is known to induce cell death (Brunk et al., 
2001); we found that after continuous exposure of cells to 200 /ig/ml polymer for 24 
hours, >95% of cells remained viable (Figure 3.1). Collectively, these results suggest 
that the release of calcein and cathepsin B-EGFP fusion protein measured at 4 hours 
after polym er uptake was occurring from  a com partm ent other than lysosom es. 
Immunofluorescence analyses indicated that the morphology of the trans-Golgi network 
was not affected following polymer treatment (Figure 3.12). Therefore, we conclude 
that late endosom es are likely to be the intracellular com partm ent that becom es 
disrupted following constitutive endocytosis of PAAAs.
It is unclear why endocytosed PAAAs alter the morphology of lysosomes but do not 
Physically disrupt them. Two possible explanations are as follows: (1) The lysosomal
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membranes may be resistant to the disruptive effects of the polymers. It is known that 
the lumenal face of the lysosomal membrane is heavily coated with a family of 
glycoproteins that are thought to provide the membrane with protection from the many 
lytic enzymes in the lumen (Granger, 1990). This coating may also sterically shield the 
membrane from the actions of the protonated, hydrophobic polymers; (2) At a pH of 
less than 5 (which is found in lysosomes), if present at a sufficient concentration, the 
heavily protonated, hydrophobic polymers may precipitate and become ineffective as 
membrane disruptants. Supporting the latter possibility, as stated before, PPAA 
precipitates from aqueous solution at pH<5. The two above explanations may not be 
mutually exclusive.
Collectively, these results suggest that cells endocytose PAAAs and transport them to 
late endosomes, where acidification of the lumen by the membrane H+-ATPase triggers 
polymer-mediated vesicle disruption and release of endosomal contents to the cytosol. 





Investigation of Poly[l- 
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In recent years, many polymers have been tested for their ability to enhance delivery of 
anti-cancer agents to tumours. A few polymers show great potential and are now in 
stage I and II clinical trials. Unfortunately, progress is slow due to various limitations in 
vivo, for example, retaining polymer conjugates at tumour sites. Therefore, research 
continues to search for a suitable delivery agent. Initial investigations of PAAAs were 
discussed in the previous chapter. Results are promising and indicate that PAAAs 
disrupt late endosomes in a pH-dependent manner and deliver molecules into the 
cytosol.
The current chapter describes an investigation of another polymer, poly[ 1 - 
(dimethylamino)ethyl methacrylate) (pDMAEMA). pDMAEMA was analysed for its 
ability to (1) induce apoptotic cell death by disruption of lysosomal membranes and (2) 
deliver molecules into the cytosol of cancer cells. The chemical structure of 
pDMAEMA is schematically represented in Figure 4.1.
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Figure 4 .1 : Schematic representation of the 
chemical structure of poly(2-(dimethylamino)- 
ethyl methacrylate (pDMAEMA). Adapted from 




Van de W etering and colleagues (1999) suggested that pDMAEMA may have 
properties, similar to PAAAs, which enable it to disrupt endosomal membranes. 
Currently there is no direct evidence that pDMAEMA disrupts endosomes. Van de 
Wetering et al. (1999) have suggested that at physiological pH, pDMAEMA is partially 
protonated but at lower pH it becomes completely protonated (i.e. acts as a ‘proton 
sponge’). They have hypothesised that at low pH, the proton sponge action of 
pDMAEMA causes massive ATPase-driven proton accumulation within endosomes 
that is followed by passive chloride ion influx to prevent the build up of a charge 
gradient. The influx of the protons and chloride ions would increase the osmolarity of 
the endosomal contents and cause water influx resulting in osmotic swelling and 
subsequent disruption of endosomes (Boussif et al., 1995; van de Wetering et al., 1999, 
Funhoff et al., 2003).
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pDMAEMA, and derivatives thereof, have previously been used as delivery agents in 
gene therapy to kill cancer cells (Fonseca et al., 1999). In these experiments, 
pDMAEMA was complexed with plasmids encoding a therapeutic toxin and then used 
to transfect cancer cells. The pDMAEMA-plasmid complex has shown some favourable 
results in vitro, however, like many other potential cancer therapies, unfavourable 
complications such as lack of cell specificity have arisen (van Steenis et al., 2003).
Previously, relatively few studies of pDMAEMA have been performed. It has only been 
characterised in terms of m olecular modelling, pKa values, cytotoxicity, and 
transfection efficiency (Van de Wetering et al., 1999; Arigitia et al., 1999). Therefore, 
experiments described in the current chapter further characterise pDMAEMA by 
determining (1) its mechanism of entry into cells, (2) the mode of cell death it induces 
(i.e. apoptosis or necrosis) and (3) its ability to disrupt endosomes and release molecules 
into the cytosol of cells. These investigations were intended to identify whether 
pDMAEMA might by used in the development of novel cancer therapeutics such as a 
trimolecular construct (section 1.10).
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4.2 Materials and Methods
4.2.1 Materials
pDMAEMA (Mw = 22 kDa) and pDMAEMA/AEMA (Mw = 31 kDa; a copolymer of 
pDMAEMA and aminoethylmethacrylate, polymerised in the ratio 19:1) were gifts 
from Dr. Wim E. Hennink, Department of Pharmaceutics, Utrecht Institute for 
Pharmaceutical Sciences (UIPS), Utrecht University, The Netherlands. Propidium 
iodide and calcein were from Sigma (MO, USA). Annexin V-FITC was purified and 
conjugated to FITC within the laboratory (see section 2.2.5). CaspACE FITC-VAD- 
FMK was from Promega (WI, USA). Monoclonal antibodies reactive with early 
endosomal antigen 1 (EEA1), lysosomal-associated membrane protein-1 (Lamp-1) and 
cytochrome c were from Pharmingen-Transduction Laboratories (CA, USA). Alexa 
488-conjugated goat-anti-mouse Ig and 3,3’-dihexyloxacarbocyanine iodide (DiOC6(3)) 
were from Molecular Probes (OR, USA).
4.2.2 Methods
4.2.2.1 Determining Cell Viability Following Introduction of pDMAEMA
U937 cells were incubated in polymer buffer (PB; 145 mM NaCl, 5 mM KC1, 0.5 mM 
HEPES) containing pDMAEMA and constitutive endocytosis allowed to proceed before 
determining cell viability. U937 cells (2xl06) were centrifuged for 5 minutes at 300 g. 
Cells were resuspended in 0.6 ml of PB, with or without the addition of pDMAEMA to 
give a final concentration of 1 //g/ml or 2 //g/ml (added from a stock solution at 4 
mg/ml). Cell suspensions were incubated for 1 hour at 37°C; at 15, 30 and 60 minutes,
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200 ]A of the cell suspension was removed. Cell viability was then determined by 
staining cells with PI as described in section 3.2.2.1.
4.2.2.2 Confirming the Mode of Entry of pDMAEMA into Cells
Previous experiments involving pDMAEMA have presumed that the mode of entry of 
the polymer into cells was via endocytosis, however, this was not conclusively shown. 
Endocytosis is a process by which cells internalise material from their external 
environment (Mellman, 1996). Internalised material is then transported through the cell 
in a series of compartments called endosomes. Like PAAAs (Chapter 3), we predicted 
that pDMAEMA, internalised by endocytosis, would pass through the early endosomal 
compartment. To confirm this, we traced the initial movements of pDMAEMA through 
the cell. This was achieved by biotinylating pDMAEMA/AEMA (which contains free 
amine groups), and staining fixed permeabilised cells with anti-EEAl antibody (EEA1 
is used for the detection of early endosomes). Biotinylated pDMAEMA/AEMA (b- 
pDMAEMA/AEMA) was detected using streptavidin-Alexa 546 and anti-EEA l 
antibody was detected using Alexa 488-conjugated goat anti-mouse Ig antibody. 
Biotinylation, cell fixation and permeabilisation, and confocal analyses were performed 
as described in section 3.2.2.2.
To further test the hypothesis that pDMAEMA enters cells via endocytosis, the 
dependence of its cytotoxicity on temperature was determined. Endocytosis works most 
efficiently at 37 C and is inhibited at lower temperatures, for example, 4 C. Two 
parallel experiments were performed; one at 37 C and the other at 4 C. For each 
experiment, cytotoxicity assays were performed as described above (section 4.2.2.1). A
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decrease in cytotoxicity at 4 C was expected if the mode of entry of pDMAEMA into 
cells was by endocytosis.
4.2.2.3 Staining Cells with Annexin V-FITC to Measure Phosphatidylserine 
Exposure
Phosphatidylserine (PS) is a phospholipid, normally confined to the inner leaflet of the 
plasma membrane. However, during apoptosis, and in some necrotic cell systems, it is 
exposed on the outer leaflet of the plasma membrane (Kerr, 1995; Martin et al., 1996). 
The exposure of PS on the surface acts as a trigger for the recognition of apoptotic cells 
by phagocytes. Phagocytes contain specific receptors for exposed PS, thereby allowing 
rapid removal of the cells (Martin et al., 1996). PS externalisation is most commonly 
measured using a protein known as annexin V. Annexin V has high affinity for 
aminophospholipids such as PS (Meers and Mealy; 1993, Meers and Mealy, 1994; 
Martin et al., 1996). Fluorescent conjugates of annexin V (e.g. FITC conjugates) can be 
used to detect PS exposure on the surface of cells by flow cytometry (Kroemer et al., 
1995).
Annexin V labelling solution was made by diluting annexin V-FITC (1 mg/ml) 1:100 in 
annexin V buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, 5 mM CaCl2). 2 x l06 cells 
were centrifuged at 300 g and resuspended in 500 ji\ of PB containing either 1 pig/ml or 
2 ng/m\ polymer. Cells were incubated for 30 minutes at 37°C to allow constitutive 
endocytosis to occur. The cells were resuspended in 1 ml of lx PBS and re-centrifuged 
as above. The supernatant was removed and cells were resuspended in 50 /,i\ of the 
annexin V labelling solution, followed by a 15 minute incubation at room temperature 
ln the dark. Immediately before flow cytometric analysis, 500 n\ of annexin V buffer
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was added and cells stained with PI (see section 3.2.2.1). FSC, SSC, FL1 and FL3 
signals were acquired. Increased PS exposure on the cell surface was measured as an 
increase in FL1 fluorescence. Non-viable (i.e. PI positive) cells were excluded from all 


































Figure 4.2: FL1 histograms of U937 cells exposed to 2 //g/ml pDMAEMA for 30 
minutes and stained with annexin V-FITC. The margins used for the control cells were 
the same as those used for cells treated with pDMAEMA. M l is the population of cells 
that had not bound annexin V-FITC to their surface. The percentages of cells that bound 
annexin V-FITC to their surface (M2) are shown under each histogram. Histogram A 
represents the control cells. Histogram B represents cells exposed to pDMAEMA. Non- 
viable cells were excluded from all analyses.
4.2.2.4 Staining Cells with 3,3’-Dihexylo\acarbocyanine Iodide (DiOC6(3))
to Measure Mitochondrial Depolarisation
DiOC6(3) is a cationic lipophilic fluor that accumulates in the matrix of mitochondria. 
The negative charge of the matrix attracts the positive charge of the fluor, while the
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lipophilic properties allow the fluor to diffuse across membranes and enter the matrix. 
When there is reduced m itochondrial m em brane potential (m itochondrial 
depolarisation), accumulation of the fluor is reduced and is measured by flow cytometry 
as a decrease in cell-associated fluorescence (Kroemer et al., 1997).
Following loading of polymers by constitutive endocytosis (section 4.2.2.1) cells were 
centrifuged at 300 g for 5 minutes. The supernatant was discarded and the pellet was 
resuspended in 1 ml of complete medium containing 40 nM DiOC6(3). This was 
prepared from a 1 M stock, which was diluted to 1 mM in 500 //I of lx PBS and then 
diluted to 40 nM in complete medium. The cells were incubated at 37°C for 15 minutes 
in the dark. Immediately before flow cytometric analysis, cells were stained with PI (see 
section 3.2.2.1). FSC, SSC, FL1 and FL3 signals were collected. Non-viable cells were 














Figure 4.3 : FL1 histograms of U937 cells exposed to 2 /^g/ml pDMAEMA for 30 
minutes and stained with DiOC6(3). The margins used for the control cells were the 
same as those used for cells treated with polymer. M l is the population of cells with 
depolarised mitochondria. The percentages of cells with depolarised mitochondria are 
shown under each histogram. Histogram A represents control cells. Histogram B 
represents cells exposed to pDMAEMA. Non-viable cells were excluded from all 
analyses.
4.2.2.5 Measuring Caspase Activation Following Exposure to pDMAEMA
Several caspases, in particular caspase 3, are known to be involved in apoptosis. 
Caspase 3 has been implicated in virtually all apoptotic systems tested. Caspases 
interact with proteins normally stored within mitochondria and other intracellular 
proteins to regulate apoptosis. Following exposure to pDMAEMA, caspase activation 
was determined using CaspACE™ FITC-V AD -FM K (carbobenzoxy-valyl-alanyl- 
aspartyl-|0-methyl]-fluormethylketone). CaspACE™ FITC-VAD-FM K is a cell 
Permeable probe that irreversibly binds to a number of activated caspases (Flores and
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Macklin, 2000; Perkins et al., 2003). pDMAEMA was loaded by constitutive 
endocytosis into 2 x l0 6 U937 cells (as previously described in section 4.2.2.1). 
Following loading, cells were washed with DMEM:F12 and resuspended in 
DMEM:F12 containing 10 CaspACE™ FITC-VAD-FMK. Cells were then 
incubated for 20 minutes at 37°C in the dark. Immediately before flow cytometric 
analysis, cells were stained with PI (see section 3.2.2.1). FSC, SSC, FL1 and FL3 
signals were collected. Caspase activation was measured by an increase in FL1 
fluorescence. Non-viable cells were excluded from all analyses.
4.2.2.6 M easuring C ytochrom e c R elease Follow ing Exposure to
pDMAEMA
Cytochrome c is an extrinsic membrane protein, normally associated with the outer 
surface of the inner membrane of mitochondria (Gastman, 2001). Cytochrome c release 
from mitochondria to the cytosol has been reported in many different systems of 
apoptosis (Kluck et al., 1997; Zhaung and Cohen, 1998). Immunofluorescence staining 
of cells allows the release of cytochrome c from mitochondria to be visualised by 
fluorescence microscopy as a change from punctate regions of intensely concentrated 
fluorescence (corresponding to mitochondrial localisation), to diffuse fluorescence 
located throughout the cell cytosol.
U937 cells (2xl06) were centrifuged (300 g, 5 minutes) in a 15 ml tube. Cells were fixed 
and permabilised as described in section 3.2.2.2. Cells were then diluted with ice-cold
0.1% (w/v) BSA/PBS to pre-block non-specific binding sites and to minimise cell loss 
during centrifugation. Cells were centrifuged again (900 g, 10 minutes), drained and 
resuspended in 50 /vl of 1% (w/v) BSA/PBS containing 2.5 |/g/m l mouse anti­
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cytochrome c primary antibody. Cell suspensions were transferred to pre-chilled 1.5 ml 
tubes and incubated on ice for 1 hour. Cells were then diluted to 1.5 ml with 0.1% 
BSA/PBS, centrifuged (900 g, 10 minutes) and thoroughly drained. Cells were then 
resuspended in 50 jil of goat-anti-mouse Ig-Alexa 488 (diluted to 2 ^g/ml in 1% 
BSA/PBS) and incubated in the dark, on ice, for 1 hour. Cells were subsequently 
washed twice with PBS, resuspended in 1% PF/PBS and examined by confocal 
microscopy. Cells were excited at 488 nm and fluorescence collected using an emission 
window set at 500-540 nm. All signals collected were adjusted to remain within the 
linear range of the detectors.
4.2.2.7 Determining if pDMAEMA Causes Rupture of Endosomes or 
Lysosomes
Similar to studies conducted with PAAAs (Chapter 3), a variety of assays were 
conducted to determine if pDMAEMA disrupted endosomes and/or lysosomes and 
released their contents to the cytosol. Initially, calcein was simultaneously loaded with 
pDMAEMA into cells to determine if pDMAEMA induced calcein release from 
endosomes. Other polymers, such as PAAAs (section 3.2.2.2), have the ability to 
release molecules from endosomes into the cytosol. pDMAEMA (at 1-2 fig/ml) was co­
loaded into cells with calcein as described for PAAAs in section 3.2.2.2. 
Immunofluorescence assays were then used to examine the morphology and distribution 
of both early and late endosomes and lysosomes following uptake of pDMAEMA by 
constitutive endocytosis. Anti-EEAl and anti-Lamp-1 antibodies were used to visualize 
early endosomes and late endosomes/lysosomes, respectively. Immunofluorescence 
assays were conducted as previously described in section 3.2.2.6. Globular regions of 
fluorescence were measured and scored as before (see section 3.2.2.6). For each
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treatment, 50 randomly chosen cells were analysed. To further test the effects of 
pDMAEMA on lysosomes, cells were stained with the fluorescent acidotropic probes 
acridine orange and LysoTracker Yellow. This was done as described in section 3.2.2.7, 
except in these experiments cells were only incubated for 1 hour (as opposed to 4 
hours). For each treatment, 50 randomly chosen cells that had been stained with 




4.3.1 Effects of pDMAEMA on U937 Cells
Cell viability was initially tested following exposure of cells to 1 or 2 /^g/ml 
pDMAEMA for 15, 30 and 60 minutes. Non-viable cells were detected by staining with 
PI. Poniris (2001) previously showed that 80-90% of cells exposed to 10-100 nglm\ 
pDMAEMA for 15 minutes died. Likewise, substantial cell death was apparent 
following exposure of cells to 5 //g/ml polymer for 15 minutes (data not shown). At 
lower concentrations of pDMAEMA (e.g. 1 or 2 /<g/ml), the extent of cell death was 
significantly less. However, 1-2 ^g/ml pDMAEMA induced a time-dependent increase 
in cell death (Figures 4.4 and 4.5). Under these conditions, pDMAEMA caused the 
appearance of a population of cells that stained with PI to an intermediate level (Figure 
4.5, indicated by the rectangle). This population most likely represents cells with ‘leaky 
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Figure 4.4: Bar graph showing the percentage of non-viable U937 cells, as a function of 
time, during exposure to 1 /*g/ml or 2 //g/ml of pDMAEMA. Each data point represents 
the mean value from three independent experiments. Error bars represent the standard 
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Figure 4.5: Flow cytometry density plots of (a) untreated U937 cells and U937 cells 
exposed to 2 //g/ml pDMAEMA for (b) 15, (c) 30 and (d) 60 minutes. The elipses 
indicate dead cells and the rectangles indicate cells with 'leaky’ membranes. The results 
shown are representative of 4 independent experiments.
Cells were exposed to b-pDMAEMA/AEMA and stained with anti-EEAl to confirm 
that pDMAEMA is internalised by endocytosis. Cells were exposed to 1 or 2 j/g/ml b- 
pDMAEMA/AEMA for 30 minutes and then stained with anti-EEAl antibody and 
Alexa 488-conjugated goat anti-mouse Ig; b-pDMAEMA/AEMA was detected using 
streptavidin-Alexa 546. Confocal microscopy showed that the polymer was largely at 
the periphery of the cell. In approximately 40% of cells there was co-localization of the 
fluorescences associated with b-pDMAEMA/AEMA and early endosomes (Figure 4.6). 
Approximately 200 cells were analysed in these experiments.
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Figure 4 .6 : Confocal m icroscopy im ages o f U937 cells exposed to 2 //g/m l b- 
pDM AEM A/AEM A for 30 minutes. Images show cells stained with (a) anti-EEA l 
antibody only (green fluorescence), (b) streptavidin-Alexa 546, and (c) an overlay of the 
two fluorescence images. In most cells, vesicles show partial co-localisation of green 
and red fluorescence (white). This result is representative ot two independent 
experiments. 200 cells were scanned to ensure reproducibility. Bar = 10 fim.
The percentage of non-viable cells was reduced considerably when cytotoxic assays 
were performed at 4°C compared to 37°C. Approximately 50% of cells were non-viable 
following exposure to 1 //g/ml pDMAEM A for 1 hour at 37°C. In comparison, only 
20% of cells were non-viable following exposure to 1 fig/m\ pDMAEM A for 1 hour at 
4°C (Figure 4.7). Similar results were observed following exposure of cells to 2 fig/m \ 
pDMAEMA (results not shown).
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Figure 4.1: Bar graph showing the percentage of non-viable U937 cells, as a function of 
time, during exposure to 1 //g/ml of pDMAEMA. Parallel experiments were conducted 
at 37 C (grey bars) and 4 C (white bars). Each data point represents the mean value 
from three independent experiments. Error bars represent the standard error of the mean 
in each case.
To determine if death was via apoptosis, measurements of mitochondrial depolarisation, 
phosphatidylserine exposure, caspase activation and mitochondrial release of 
cytochrome c were made. Mitochondrial depolarisation was detected by staining 
control and polymer-exposed cells with DiOC6(3). Time course experiments were 
conducted over 60 minutes. Approximately 10% of cells had depolarised mitochondria 
following exposure of cells to either 1 //g/ml or 2 /^g/ml pDMAEMA for 15 minutes. At 
60 minutes, this increased to approximately 20% for cells treated with 1 /^g/ml 
pDMAEMA and to 30% in cells treated with 2 //g/ml pDMAEMA (Figure 4.8). Non- 
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Figure 4.8: The percentage of U937 cells with depolarised mitochondria, as a function 
of time, during a 60 minute exposure to pDMAEMA. Cells were either left untreated 
(black bars), or exposed to 1 /*g/ml (grey bars) or 2 pig/ml pDMAEMA (white bars) for 
15 to 60 minutes. Mitochondrial depolarisation was measured as described in section 
4.2.2.4. Each data point represents the mean value from three independent experiments. 
Error bars represent the standard error of the mean in each case.
Exposure of cells to pDMAEMA also resulted in PS exposure. Following 15 minutes 
exposure to 1 /<g/ml of pDMAEMA, approximately 25% of cells had surface-exposed 
PS. Approximately 60% of cells had surface-exposed PS following a 60 minute 
exposure to 2 /<g/ml pDMAEMA. The proportion of cells with surface-exposed PS was 
significantly different between treatments at all time points (p<0.001 F 14 = 447.55, 
pairwise Tukey-Kramer comparisons), however, the differences over time for any one 





Figure 4.9: Bar graph showing the percentage of cells with surface-exposed PS, as a 
function of time, following a 15 to 60 minute exposure to either 1 /Yg/ml or 2 /<g/ml 
pDMAEMA. Each data point represents the mean value from three independent 
experiments. Error bars represent the standard error of the mean in each case.
Caspase activation was also assayed following the exposure of U937 cells to 
pDMAEMA but none was detected (Figure 4.10). Caspase activation was detected in 
U937 cells induced to undergo apoptosis by exposure to TN Fa and cycloheximide 
(Figure 4.10, inset panel A).
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Figure 4.10: Bar graph showing the percentage of cells with bound CaspACE FITC- 
VAD-FMK, as a function of time, following a 15 to 60 minute exposure to 1 /<g/ml or 2 
fig/ml pDMAEMA. Panel A: Positive Control; U937 cells exposed to 10 ng/ml TN Fa 
and 10 /^g/ml cycloheximide for 4 hours. Each data point represents the mean value 
from three independent experiments. Error bars represent the standard errors of the 
mean in each case.
Cytochrome c was not released from mitochondria following exposure of cells to 1-2 
/<g/ml pDMAEMA for 30 minutes. Immunofluorescence staining of cytochrome c in 
untreated control cells showed a punctate distribution typical of mitochondrial 
localisation (Figure 4.11, panel a). A similar pattern of immunofluorescence to that of 
control cells was observed in cells treated with either 1 /^g/ml or 2 /<g/ml pDMAEMA 
(Figure 4.11, panels b and c). Diffuse cytosolic fluorescence was not observed in cells 
exposed to pDMAEMA. However, a diffuse cytosolic fluorescence was observed when 
cells were induced to undergo apoptosis by exposure to 10 ng/ml TN Fa and 10 /^g/ml 
cycloheximide (Figure 4.11, panel d).
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Figure 4.11: Immunofluorescence images obtained by confocal microscopy of U937 
cells stained with anti-cytochrom e c antibody. A sim ilar punctate pattern of 
fluorescence was detected in both untreated control cells (a) and cells exposed for 30 
minutes to either 1 /yg/ml (b) or 2 /<g/ml (c) pDMAEMA. However, in some cells 
exposed to 10 ng/ml TN Fa and 10 ^g/ml cycloheximide for 4 hours (positive control; 
d), fluorescence was more diffuse (arrows). These images are representative of cells 
analysed from two independent experiments. Bar = 5 //m.
Finally, light microscopy was used to examine cells for pDMAEMA-induced changes 
in the morphology of the cell membrane. Significant membrane blebbing occurs in 
apoptotic U937 cells (e.g. following exposure to TN Fa and cycloheximide). Membrane 
blebbing was not observed following exposure to pDMAEMA (results not shown).
4.3.2 Characterisation of the Morphology and Distribution of 
Intracellular Vesicles Following Exposure of Cells to 
pDMAEMA
A final series of assays, similar to those described in chapter 3, were completed to 
determine if endocytosed pDMAEMA disrupts endosomes or lysosomes. Following 
exposure to pDMAEMA, U937 cells were assayed by confocal microscopy for the 
release of calcein (a small tracer molecule) from endosomes to the cytosol. U937 cells 
were incubated for 30 minutes in medium containing 2 mg/ml calcein with or without
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the addition of 1-2 //g/ml pDMAEMA and subsequently assayed. In both control and 
polymer-treated cells, fluorescence was in punctate regions around the periphery of the 
cell (Figure 4.12A). This suggests that pDMAEMA did not induce release of calcein 
from intracellular vesicles. Results were also quantified by measuring the cytosolic 
calcein fluorescence of many cells from each treatment (see section 4.2.2.7). There was 
no significant difference in cytosolic calcein fluorescence of the control and polymer- 
treated cells (p>0.7154 F257=0.3369, pairwise Tukey-Kramer comparisons). In all 
treatments, the cytosolic calcein fluorescence was less than 10 arbitrary units (Figure 
4 .12B). Similar results were obtained when Jurkat cells were used (results not shown). 
Cytosolic calcein fluorescence of cells treated similarly with PAAAs (discussed in 
chapter 3) was 4-10 times greater than control cells (section 3.3.3). The level of 
cytosolic calcein fluorescence for the control cells was similar for these experiments and 
those described in section 3.3.3.
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Figure 4.12: A Confocal images of U937 cells incubated for 30 minutes in medium 
containing 2 mg/ml calcein and 1 ^g/ml or 2 //g/ml pDMAEMA. Panel a represents 
control cells (i.e. incubated in the absence of pDMAEMA) and panels b and c represent 
cells exposed to 1 j/g/ml or 2 /*g/ml pDMAEMA, respectively. Images are 
representative of three independent experiments. Bar = 10 //m. B Bar graph comparing 
cytosolic calcein fluorescence of U937 cells exposed for 30 minutes to 1-2 /^g/ml 
pDMAEMA or 200 //g/ml PPAA. Quantitative image analyses were performed as 
described in section 3.3.3. Data points represent means of values determined for 15-20 
cells and error bars shown are standard errors of the mean in each case.
Im m unofluorescence assays were conducted to determine the morphology of 
endosomes and lysosomes following a 30 minute exposure of cells to pDMAEMA.
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Anti-EEAl and anti-Lamp-1 antibodies were used to stain early endosomes and late 
endosomes/lysosomes, respectively. Following staining with anti-EEAl antibody, 
fluorescence within both control and polymer-treated cells was in punctate regions. 
Early endosomes appeared as roughly circular, bright fluorescent patches distributed 
mainly at the cell periphery (Figure 4.13). The pattern of fluorescence suggests that the 
morphology and distribution of early endosomes was not affected by exposure of cells 
to pDMAEMA.
• «.
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Figure 4.13: Confocal microscopy images showing U937 cells stained with anti-EEAl 
antibody following exposure to pDMAEMA. Cells were incubated for 30 minutes with 
(a) no additions, or 1 //g/ml (b) or 2 /<g/ml (c) pDMAEMA. Images are representative of 
two independent experiments. Bar = 5 /^m.
The pattern of Lamp-1 immunofluorescence in untreated control cells was different 
from that of cells exposed to pDMAEMA. Untreated control cells stained with anti- 
Lamp-1 antibody showed large globular regions of fluorescence (grf), with 
approximately 40% of these regions being greater than 3 ]Am in diameter. A similar 
pattern of fluorescence was evident in some cells following a 30 minute exposure to 1-2 
/<g/ml pDMAEMA, however the size of the grf was, on average, considerably smaller 








grf were not detected. Quantitative analysis (Figure 4.14B) showed a negative 
correlation between the concentration of pDMAEMA in which cells were incubated and 
the size of grf. This indicates that the morphology of late endosomes/lysosomes is 





Figure 4.14: A Confocal images of U937 cells stained with anti-Lamp-1 antibody 
following exposure to pDMAEMA. Images shown represent untreated control cells (a), 
and cells exposed for 30 minutes to 1 /^g/ml (b) or 2 /^g/ml (c) pDMAEMA. A large 
globular region of fluorescence (grf) is indicated by the white arrow. These images are 
representative of three independent experiments. Bar = 5 n m. B Histogram plots 
summarising the results of quantitative image analysis of the diameter of grf of 50 
randomly chosen U937 cells treated as in the panel above (see section 3.2.2.7 for more 
details regarding this analysis).
LysoTracker Yellow and acridine orange were used to further investigate the effects of
pDMAEMA on lysosomes. Fluorescence in control cells stained with LysoTracker
119
Chapter 4 pDM AEM A
Yellow was largely concentrated around the periphery of the cell (Figure 4 .15A, panel 
a). In contrast, following pDMAEMA uptake, cells showed a more diffuse pattern of 
LysoTracker fluorescence (Figure 4.15A: compare panels b and c), suggesting changes 
in lysosomal morphology. Image analysis (see section 3.2.2.7) confirmed that 
pDMAEMA (both at 1 //g/ml and 2 /<g/ml) had induced changes in the pattern of 
LysoTracker Yellow fluorescence (Figure 4.15B). Under the conditions tested, flow 
cytometric analysis showed that control cells and cells exposed to 1 /^g/ml pDMAEMA 
had similar level of red AO fluorescence (Figure 4.16). Similar results were obtained 
when cells were exposed to 2 ^g/ml pDMAEMA (data not shown). However, in cells 
exposed to MSDH (a known lysosomal disruptive agent) a population of cells with 
substantially decreased red AO fluorescence was detected (indicated by the arrow on 
Figure 4.16). The remaining MSDH-treated cells not in this population had red AO 
fluorescence slightly lower that that of control or pDMAEMA-treated cells. A 
substantial decrease in red AO fluorescence indicates lysosomal rupture. Collectively, 
these results indicate that (1) MSDH caused lysosomal bursting and (2) exposure of 
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Figure 4.15: A: Confocal microscopy images of U937 cells exposed to 1 /*g/ml 
pDMAEMA for 30 minutes and stained with LysoTracker Yellow. See section 4.2.2.7 
for details of methods. Images show: (a) control cells (no added polymer) and cells 
treated with 1 /*g/ml or 2 //g/ml pDMAEMA (panels b and c, respectively). The images 
shown are representative of three independent experiments. Bar = 10 ^ m . B: Each 
histogram plot summarises the results of quantitative image analysis, performed as 
described in section 3.2.2.7, for 50 cells treated as in the image above. For the purpose 




Figure 4.16: Overlay flow cytometry histograms of U937 cells stained with acridine 
orange following a 30 minute incubation in PB containing no additions (thin solid line) 
or 1 nglm\ pDMAEMA (dashed line), or after a 4 hour incubation in culture medium 
containing 70 //M MSDH (thick solid line). In some MSDH-treated cells a substantial 
decrease in red AO fluorescence was detected (arrow). The results shown are 




In the past few years, pDMAEMA has successfully been used in gene therapy 
(Foneseca et al., 1999). In these experiments, pDMAEMA was complexed with plasmid 
DNA to yield polymer/plasmid complexes (polyplexes). OVCAR-3 human ovarian 
carcinoma and COS-7 cells were then transfected with the polyplexes and the 
transfection efficiency and cell viability measured (van de Wetering et al., 1999). The 
most promising results were obtained when low concentrations of polymer, similar to 
those used in this study, were used. Based on these previous experiments and functional 
predictions about pDMAEMA, experim ents were performed to determ ine the 
mechanism of entry of pDMAEMA into cells, the mode of cell death following 
pDMAEMA internalisation, and finally, the ability of pDMAEMA to disrupt 
endosomes and release molecules into the cytosol of cells.
Following a 30 minute incubation of cells in 2 ^g/m l b-pDMAEMA/AEMA, the 
biotinylated polymer was detected inside U937 cells primarily at the cell periphery 
(Figure 4.6). In approximately 40% of the cells, a fraction of the b-pDMAEMA/AEMA 
co-localised with anti-EEAl stained vesicles (early endosomes). These results are 
similar to those from experiments using b-PEAA described in Chapter 3 and suggest 
that, like PAAAs, pDMAEMA is taken up by endocytosis and transits through early 
endosom es before m oving onto other vesicular com partm ents (e.g. late 
endosomes/lysosomes). Endocytic entry of pDMAEMA into cells is also consistent with 
the effects of temperature on its cytotoxicity. Endocytosis works most efficiently at 
37 C and is inhibited at 4 C (Mellman, 1996). Thus, the reduced number of non-viable 
cells following exposure of cells to pDMAEMA at 4 C compared to 37 C supports the 
conclusion that entry of pDMAEMA into cells occurs via endocytosis (Figure 4.7).
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These results are also supported by Zuidam et al. (2000); they showed that 
internalisation of pDMAEMA-polyplexes was inhibited at 4 C and that internalised 
pDMAEMA-polyplexes remained contained within what appeared to be endocytic 
vesicles.
The second aim of this study was to determine the mode of cell death following 
exposure of cells to pDMAEMA. There was a time-dependent increase in non-viable 
cells following exposure of cells to either 1 or 2 n g/ml pDMAEMA (Figure 4.4). Cell 
death did not occur immediately; the cell membranes first became ‘leaky’ -  a 
characteristic that is often associated with apoptosis (Figure 4.5). The detection of 
‘leaky cell membranes’ following the exposure of cells to pDMAEMA raises the 
possibility that it may affect cells by directly interacting with cell membranes. The cell 
surface contains many ion channels that fluctuate between open and closed 
conformations and that maintain the equilibrium of ions within the cell. The dissipation 
of ion gradients leads to impairment of essential processes in the cell and finally cell 
death (Ultee et al., 1999). For example, inappropriate accumulation of Ca2+ and Na+ ions 
within rat striatum cells causes abnormalities in energy metabolism by increasing (1) 
the activity of proteases, lipases and endonucleases, (2) the production of free radicals, 
and (3) DNA damage that ultimately leads to cell death (McLaughlin et al, 1998; 
Bordelon et al., 1998). Therefore, it is possible that in addition to (or in parallel with) its 
effects from within the cell following endocytosis, exogenous pDMAEMA may induce 
cell death by directly interacting with the cell membranes to result in the collapse of ion 
gradients. Arguing against this possibility is the observation that confocal images of 
cells incubated with b-pDMAEMA/AEMA do not show a concentration of the polymer
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at the cell membrane (Figure 4.6), which would be expected if it were directly exerting 
its cytotoxic effects at this site.
A series of assays were performed to determine the type of cell death induced by 
pDMAEMA. Following exposure of cells to pDMAEMA mitochondrial depolarisation 
(Figure 4.8) and PS exposure (Figure 4.9) were both detected. However, under these 
same conditions, caspase activation (Figure 4.10), cytochrome c release (Figure 4.11) 
and changes in cell morphology (data not shown) were not detected. Until recently, 
mitochondrial depolarisation and PS exposure were both thought to be hallmarks of 
apoptosis; however, both are now known to sometimes occur during necrosis. For 
example, mitochondrial depolarisation has been detected in cells induced to undergo 
necrosis with cyclosporin and trifluoperazine (Lemasters et a i ,  1999) and PS exposure 
has been detected in thymocytes (Waring et al., 1999) and mouse leukaemia cells 
(Bonneau and Poulin, 2000) undergoing death exclusively by necrosis. Therefore, 
collectively, the results suggest that cell death caused by exposure to pDMAEMA is via 
necrosis not apoptosis. The fact that cell death was very rapid also supports this 
conclusion. Following a 60 minute exposure to 2 /<g/ml of pDMAEMA, approximately 
50% of cells were non-viable (Figure 4.4). Apoptosis generally takes hours and in some 
cell systems it may take days; necrosis is generally much faster.
Lastly, experiments were performed to determine the ability of internalised pDMAEMA 
to disrupt endosomes, in particular lysosomes. If pDMAEMA disrupts endosomes it is 
possible that it could be used as a delivery agent in a novel cancer therapeutic (see 
section 1.0). The ability of pDMAEMA to disrupt endosomes and release a small 
membrane-impermeable fluor (calcein) into the cytosol of cells was investigated. When
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U937 cells were incubated in buffer containing calcein and pDMAEMA, they showed 
fluorescent intracellular vesicles (Figure 4.12). This pattern of fluorescence did not 
change over 60 minutes, suggesting that calcein was not released into the cytosol. Other 
characteristics associated with calcein release, such as vesicle fusion (Jones et al., 2003; 
Linhardt and Tirrell 1999), were also not observed. Similar results were obtained with 
Jurkat cells (data not shown). The results shown in this chapter suggest that 
pDMAEMA does not have the ability to disrupt endosomes and release small tracer 
molecules into the cytosol.
The morphology of early/late endosomes and lysosomes following exposure of cells to 
pDMAEMA was also investigated. It is possible that pDMAEMA may change the 
morphology of vesicles without physically disrupting their membranes. Similar to 
PAAAs (Chapter 3), there was no measurable effect of exposing cells to pDMAEMA 
on the pattern of EEA1 immunofluorescence, suggesting that early endosomes were 
unaffected (Figure 4.13). In contrast, Lamp-1 immunofluorescence was significantly 
affected following the exposure of cells to pDMAEMA. Lamp-1 proteins are primarily 
located on the surface of late endosomes and lysosomes. Results shown in Figure 4.14 
suggest that pDMAEMA caused morphological changes to one or both of these 
compartments. To further characterize the compartment affected following exposure to 
pDMAEMA, cells were stained with LysoTracker Yellow and AO. Changes in the 
pattern of LysoTracker Yellow staining were observed following the exposure of cells 
to pDMAEMA, suggesting that pDMAEMA caused changes in lysosomal morphology 
(Figure 4.15). However, flow cytometric analysis of cells stained with acridine orange 
indicated that lysosomes remained structurally intact (Figure 4.16). Therefore, the 
results suggest that exposure of cells to pDMAEMA changes the morphology of late
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endosomes or lysosomes but does not physically disrupt them. This latter result is 
supported by Zuidam et al. (2000); they showed that a large percentage of polyplexes 
(pDMAEMA bound to DNA) were retained within endosomes following a 24 hour 
post-transfection incubation.
Results presented in chapter 3 showed that the uptake of PAAAs by constitutive 
endocytosis disrupted late endosomes in a pH-dependent fashion and released both 
small and large molecules into the cytosol. Results presented in this chapter demonstrate 
that exposure of cells to pDMAEMA induced changes in the morphology of 
endosomes/lysosomes but did not disrupt them. The exposure of cells to pDMAEMA 
resulted in rapid necrotic death. In contrast, cell viability was maintained following the 
uptake of PAAAs. The most appropriate polymer to use as a delivery agent for a 
proposed cancer therapeutic (see section 1.10) must have the ability to disrupt 
endosomes and release their contents into the cytosol. Results presented in this chapter 
indicate that pDMAEMA lacks this ability. In addition, the very high toxicity of 
pDMAEMA could pose a significant risk of bystander cell damage in cancer therapies. 
Collectively, these results indicate that, of the polymers tested, PAAAs appear to be the 
best suited to deliver molecules into the cell cytosol.
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Chapter 5
Synthesis and Functional Assays of 
PAAA-X-Bad(140-165) Conjugates
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5.1 Introduction
Chapters 3 and 4 describe the effects of two different polymers (PAAA and 
pDMAEMA) on cells. A variety of assays were performed to determine if these 
polymers disrupted endosomes/lysosomes and induced apoptosis, and if they might be 
used as part of a novel cancer therapeutic (see section 1.10). Many morphological and 
biochemical changes were evident following uptake of PAAAs and pDMAEMA. 
However, the results obtained suggest that, of the polymers tested, PAAAs are the most 
suitable to be used as endosomal disruptive agents.
As previously described in chapter 1, the proposed novel cancer therapeutic is 
comprised of a synthetic polymer conjugated to both a targeting ligand and, via a pH- 
sensitive linker, to a pro-apoptotic peptide. For several years now, synthetic polymers 
have been conjugated to anti-tumour agents using a variety of linking mechanisms 
(Kratz et al., 1999). The linkers that show the greatest potential for in vivo cancer 
therapy are those that are stable in plasma and only cleave within tumours to release the 
anti-tumour agent. The most promising linkers recently used are pH-sensitive. These 
linkers are stable at physiological pH (i.e. pH 7.4) but trigger the release of the anti­
cancer drug at acidic pH, such as that found in late endosomes and lysosomes (Duncan 
et al., 1996). Synthesis of such linkers has been slow because the chemistry involved is 
complicated. More recently, carboxcyclic-hydrazide pH-sensitive linkers have been 
developed. These linkers are stable at pH 7.4 but not at lower pH values. The chemistry 
involved in the synthesis of these linkers is considerably simpler than that required for 
other linkers. Synthesis of a carboxcyclic-hydrazide linker and experiments involving 
its conjugation to PEAA and PPAA are described in this chapter. Conjugation of the
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carboxcyclic-hydrazide linker involves a chemical reaction between the amine group on 
the linker and a carboxyl group on the polymer.
This chapter also describes a series of assays that were performed to:
1. Determine the percentage of derivatized carboxyls on the polymer (i.e. the 
number of linkers attached to the polymer). Collaborators from the University of 
Washington (USA) have previously conjugated specific anti-tumour agents to 
PAAAs. They found that derivatization of more than 3-5% of carboxyls on the 
polymers resulted in loss of polymer function (C. Cheung, 2002, p ers. 
commun.).
2. Confirm that derivatized PAAAs retained their ability to disrupt endosomes in a 
pH-dependent manner. One of the greatest risks involved in conjugating 
molecules to pH-sensitive polymers is the potential loss of function of the 
polymers. Loss of polymer function would result in the construct being retained 
within acidic endosomes, risking degradation of the pro-apoptotic peptide by 
endosomal/ lysosomal proteases.
3. Determine the stability of the carboxcyclic-hydrazide bond joining the linker to 
the polymer. This bond must be stable at physiological pH to ensure that 
Bad( 140-165) is only released once inside the targeted cancer cells, thereby 
reducing bystander cell damage.
The final section of this chapter describes (1) the conjugation of Bad(140-165) to 
PEAA/PPAA via the carboxcyclic-hydrazide linker, and (2) the effects that 
PEAA/PPAA-linker-Bad(140-165) constructs (PAAA-X-Bad( 140-165)) have on cells 
following uptake by constitutive endocytosis. Assays similar to those described in
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chapters 3 and 4 were conducted to determine the morphological and biochemical 
effects on cells of the uptake of PAAA-X-Bad(140-165) constructs. Based on the results 
in chapter 3, we predicted that internalisation of PAAA-X-Bad(140-165) would disrupt 
the morphology of endosomes and release Bad(140-165), which would in turn induce 
apoptosis. Pro-apoptotic peptides, including Bad(104-182), Bak(82-94) and Bad(140- 
165)) have previously been shown to bind to Bcl-XL (an anti-apoptotic protein) and in 
turn elicit characteristic features of apoptosis, both in isolated mitochondria (Narita et 
al., 1998) and in intact cells (Kelekar et al., 1997).
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5.2 Materials and Methods
5.2.1 Materials
4-aminobenzoic acid, dichloromethane, isobutyl chloroformate, tert-butyl carbazate, 
triethylamine, maleic anhydride, trifluoroacetic acid (TFA), acetronitrile, fluorescamine, 
sodium phosphate, boric acid and ethylenediamine tetraacetic acid (EDTA) were from 
Sigma/Aldrich (MO, USA). Hexane and acetone were from Crown Scientific (Sydney, 
Australia). Anhydrous acetone was from Merck (NJ, USA). Silica gel 60 F254 pre-coated 
aluminium plates (0.2 mm thickness; used for analytical thin layer chromatography) and 
Silica gel 60 (230-400 mesh; used for flash chromatography) were also from Merck. 
Methanol, anhydrous sodium acetate, acetic anhydride, HC1 and magnesium sulfoxide 
w ere from  A jax ch em ica ls  (S y d n ey , A u stra lia ) . 5 -((2 -(a n d -3 )-S -  
(acetylm ercapto)succinoyl)am ino)fluorescein (SAM SA fluorescein) was from 
Molecular Probes (OR, USA). Biotin-X-NHS was from Calbiochem (CA, USA). 
Bad(140-165) was synthesised at the University of Notre Dame (USA) and was 
provided as a gift from Professor Martin Tenniswood. Bad(140-165) was synthesised 
with three additions at the C-terminus; firstly, a cathepsin cleavage sequence (Leu lie 
Val Arg Tyr Thr Arg), then a triple glycine spacer (Gly Gly Gly) and finally, at the 
extreme C-terminus, a cysteine residue. This modified peptide is subsequently referred 
to simply as Bad(140-165). Two strategies were adopted to favour intra- 
endosomal/lysosomal release of Bad(140-165); the cathepsin cleavage site was one, the 
acid-labile hydrazide linkers was the second.
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5.2.2 Methods
5.2.2.1 Synthesis of Hydrazide Cross Linker
The hydrazide cross linker was synthesised according to Lau et al. (1995a, b). 4- 
aminobenzoic acid (20 g) was suspended in 120 ml of anhydrous acetone. Distilled 
methanol (20 ml) was then added drop-wise and the suspension was stirred until 
completely dissolved (Solution A). Solution B was made by adding 40 ml of anhydrous 
acetone drop-wise to 16.49 g maleic anhydride. Solution B was then added drop-wise to 
solution A, under nitrogen and stirred at room temperature for 1 hour. The yellow 
precipitate was then filtered and washed with acetone and vacuum dried. Anhydrous 
sodium acetate (3.4 g) and 20 g of the yellow precipitate were added together and then 
treated with 40 ml of acetic anhydride at 50°C for 2 hours. The solution was then 
evaporated to dryness. Water (500 ml) was added to the solid and stirred at 70°C for 2 
hours. Again the solution was filtered off and the precipitate was vacuum dried to yield 
4-maleimidobenzoic acid (MBA).
MBA (2.68 g) was suspended in 60 ml of dichloromethane and cooled to 0°C before the 
addition of 1.89 ml of triethylamine and 1.76 ml of isobutyl chloroformate. The mixture 
was stirred for 1 hour at 0°C and then 1.26 g of te rt-butyl carbazate in 10 ml of 
dichloromethane was added drop-wise. Stirring was continued for 3 hours at room 
temperature. The reaction mixture was diluted with 150 ml of acetic acid and washed 
with saturated N aH C03 (2x50 ml), 0.1 M HCL (2x50 ml), saturated NaCl (2x50 ml), 
H20  (50 ml) then dried using M gS04 and evaporated to give crude protected hydrazide 
product. The product was purified by flash chromotography, using silica gel 60 (230- 
400 mesh) and a mixture of solvents: initially 1:2 and then 2:3 Me2CO:hexane. Thin
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layer chromotography (TLC) was then performed on Kieselgel 60 F254 pre-coated 
aluminium plates (0.2 mm) for all samples, using standard techniques. Comparable 
samples were then pooled, evaporated to produce a solid and analysed by one­
dimensional H NMR. A Mercury 300 MHz Fourier Transform spectrometer was used 
for all NMR analyses. Chemical shifts are reported in parts per million (ppm).
Protected hydrazide (Fraction 3; 500 mg) was dissolved in 5 ml of ice-cold TFA and 
stirred for 30 minutes in an ice bath. The TFA was then removed under vacuum at room 
temperature to give the final product. This was again analysed by NMR. Figure 5.1 
schematically depicts the chemical reactions and the synthesis of the intermediates and 
final product.
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H2N
\\ / -COOH










- f in a l product
Figure 5.1: Schematic representation of the hydrazide synthesis. The intermediate 
products are indicated in red.
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S.2.2.2 Coupling Polymer and Cross Linker
Previous results suggest that PEAA or PPAA are appropriate polymers to use as 
endosomal-disruptive agents. Therefore, PEAA and PPAA were conjugated to the 
hydrazide linker described in 5.2.2.1. Many small-scale experiments were conducted to 
determine ideal conjugation ratios. This was done to ensure that the ability of the 
polymer to disrupt membranes in a pH-dependent manner was maintained. The amounts 
used are summarised in Table 5.1. Once the optimum ratios were determined, the 
reactions were scaled up.
A basic summary of the conjugation procedure follows. The polymer and the hydrazide 
linker were dissolved in anhydrous methanol with the addition of TFA and stirred at 
room temperature, protected from light, for 24 hours. The solution was evaporated 
under a stream of N2 gas until a precipitate was formed. The precipitate was 
resuspended in acetronitrile and allowed to stand at 4°C, protected from light, for a 
further 24 hours. The precipitate was then centrifuged (800 g, 10 minutes), dried under 
vacuum and analysed by NMR.
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PEAA (23 kDa) 4.8 10.3 2 0.75 1
PEAA (23 kDa) 5.1 3.8 2 0.75 1
PEAA (23 kDa) 5.0 1.28 2 0.75 1
PPAA (43 kDa) 31.4 2.9 3 1.5 2.5
PEAA (32 kDa) 49.2 3.2 4 2.5 2.5
PEAA (43 kDa) 12.8 2.0 3 1.5 2.5
PPAA (105 kDa) 8.6 2.6 3 1.5 2.5
Table 5.1: Quantities of starting materials used in the small-scale conjugation reactions 
between PAAAs (PPAA and PEAA, various molecular weights) and hydrazide linker 
(synthesised as described in section 5.2.2.1).
5.2.2.3 Determining the Number of Hydrazide Linkers Attached to PAAAs 
Using SAMSA Fluorescein
The number of hydrazide linkers attached to PEAA or PPAA was calculated using 
SAMSA fluorescein. Activated SAMSA fluorescein reacts with the free malemide 
group on the linker. The degree of labelling was determined from the absorbance at 495 
nm. SAMSA fluorescein was activated by removal of the acetyl-protecting group. This 
was achieved by dissolving 10 mg of SAMSA in 1 ml of 0.1 M NaOH and incubating 
the mixture at room temperature for 15 minutes. Following activation, the solution was 
neutralised with 14 ^1 of 6 M HC1 and buffered with the addition of 0.2 ml of 0.5 M 
sodium phosphate, pH 7.
To determine the number of derivatized carboxyl groups on the PAAAs, a 200X molar 
excess of activated SAMSA fluorescein was added to the polymer-linker mixture (200 
Hg/ml polymer-linker in sodium phosphate buffer containing 0.05 M EDTA). This was
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then incubated at room temperature on an orbital shaker for approximately 2 hours to 
allow conjugation to take place. Samples were then dialysed overnight in the dark 
against 0.5 M phosphate buffer to remove unbound SAMSA fluorescein. Following 
dialysis, the degree of labelling was determined from the absorbance of the labelled 
polymer at 495 nm. The extinction co-efficient of SAMSA fluorescein is approximately 
80,000 cm 'M 1 at 495 nm (Molecular Probes, OR, USA).
5.2.2.4 Determ ining if the pH-Dependent Lytic Ability of PAAAs is 
Retained Following Conjugation with Hydrazide Linker
Following conjugation of the hydrazide linker to PEAA and PPAA, the ability of 
PEAA-X and PPAA-X to disrupt membranes in a pH-dependent manner was tested by 
conducting whole cell experiments (as described in section 3.2.2.5). Maintaining this 
function was crucial (see introduction for more details). Derivatized polymer and 
control samples (underivatized polymer) were compared in the same assays.
5.2.1.5 Determining the Stability of the Carboxcyclic-Hydrazide Bond 
Joining the Linker to the Polymer
It was expected that the polymer-linker construct (PAAA-X) would be stable at 
physiological pH but that the hydrazide bond within the linker would cleave at mildly 
acidic pH. The stability of PAAA-X was determ ined using fluorescam ine. 
Fluorescamine is a non-fluorescent molecule that reacts with primary amines to form 
fluorescent products. The spontaneous cleavage of the hydrazide bond that occurs at 
mildly acidic pH results in the formation of two primary amine groups. Thus, 
fluorescamine can be used to measure the extent of hydrazide linker cleavage.
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A stock solution of fluorescamine was made (15 mg / 50 ml acetone). PAAA-X was 
added to 1 ml of 0.2 M phosphate buffer to give a final concentration of 200 ^ig/ml 
(from a 6.5 mg/ml stock in 0.1 M NaOH). The pH was then adjusted to either 5 or 7.4 
and the samples incubated on a rocker at room temperature for 48 hours. At 0, 24 and 
48 hours, 300 pil was removed from each sample and added to 1200 pil of 0.2 M borate 
buffer (pH 8.5). This was then vortexed and while vortexing, 500 (j,l of the stock 
fluorescamine solution was added. Samples were mixed for 5 minutes and allowed to sit 
for 1 minute. Several 100 pil aliquots were then placed in a black 96-well plate and read 
on a Biolumin 960 fluorescence plate reader (Molecular Dynamics, Sydney, Australia) 
with an excitation wavelength of 390 nm and an emission wavelength of 475-490 nm. 
Negative (polymer only) and positive controls (glycine) were also assayed. All samples 
were assayed in triplicate.
5.2.2.6 Conjugating Bad(140-165) Peptide to Polymer-Linker Constructs
Bad(140-165) was conjugated to three derivatized polymers (PEAA 23 kDa, PEAA 32 
kDa and PPAA 43 kDa). Conjugation was achieved through the spontaneous reaction of 
the maleimide group on the linker with the C-terminal thiol group on Bad( 140-165). 
PAAA-X (2 mg) and approximately 1.5 mg of Bad(140-165) were dissolved in 460 //I 
of DM F (d im ethyl form am ide) and 40 }i\ o f 100 mM TAPS (N - 
tris[H ydroxym ethyl]m ethyl-3-am inopropane-sulfonic acid) buffer (pH 8.5). This 
mixture was then incubated for 3 hours at room temperature under nitrogen. Following 
this, the sample was dialysed for 48 hours at room temperature against 100 mM TAPS 
buffer (pH 9.5). Dialysis caused some of the conjugate to precipitate; following dialysis 
the sample was centrifuged (300 g , 5 minutes) to pellet the precipitate. The supernatant 
(containing PAAA-X-Bad(140-165)) was then stored at -2 0  C. Conjugation of
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Bad(140-165) to PAAA-X was confirmed using fluorescamine (see section 5.2.2.5). 
Bad(140-165) contains 7 free amine groups; successful conjugation of Bad(140-165) to 
PAAA-X was confirm ed by measuring a significant increase in fluorescam ine 
fluorescence compared to that of PAAA-X alone.
A standard curve plotting fluorescamine fluorescence verses the concentration of free 
amine groups was produced using methylamine. This was the used to calculate the 
number of Bad(140-165) molecules attached to each of the PAAA-X-Bad( 140-165) 
conjugates.
52 .2 .1  Functional Assays of PAAA-X-Bad(140-165) Constructs
PAAA-X-Bad(140-165) constructs were introduced into U937 cells via constitutive 
endocytosis. Subsequently, a series of assays were conducted to determine the effects 
on cells of the uptake of the constructs.
U937 cells (lx lO 6) were centrifuged at 300 g for 5 minutes. Cells were drained 
thoroughly and resuspended in 1 ml of DMEM:F12 containing 200 /<g/ml of PAAA-X- 
Bad(140-165). Following a 30 minute incubation at 37°C, cells were washed with 
DMEM:F12 and resuspended in 2 ml of complete medium. Cells were then transferred 
to a 6-well plate and incubated for a further 4 hours at 37°C. Following this incubation, 
4 ml of complete medium was added to each of the cell cultures, which were then 
incubated for up to 72 hours at 37°C. Cytotoxicity assays were performed (as described 
in section 3.2.2.1) at 24, 48 and 72 hours.
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To determine if PEAA/PPAA-X-Bad(140-165) were internalised and co-localised with 
early endosomes, immunofluorescence assays were performed. PAAA-X-Bad(140-165) 
was firstly labelled with biotin. A stock solution of biotinylation reagent (biotin-X- 
NHS) (40 mg/ml in DMSO) was initially made. 0.25 mg of the stock biotin reagent was 
added to 1 ml of sodium carbonate buffer (pH 8.5) containing 3 mg of PAAA-X- 
Bad(140-165). This was then incubated on a rocker for 2 hours at room temperature. 
Biotinylated PAAA-X-Bad(140-165) (PAAA-X-Bad(140-165)-biotin) was dialysed 
against PBS for 24 hours and then introduced into U937 cells as described in section 
3.2.2.3. Cells were fixed, permeabilised and stained with anti-EEAl antibody and goat- 
anti-mouse Ig-Alexa 488 (as described in 3.2.2.6). Cells were also stained with 
steptavidin-Alexa 546 (as described in 3.2.2.2). Finally, cells were analysed by confocal 
microscopy (see section 3.2.2.2).
Lastly, experiments similar to those described in section 3.2.2.3 were performed to 
determine if PAAA-X-Bad( 140-165) constructs disrupted endosomes and released their 
contents into the cytosol. U937 cells were incubated for 30 minutes in PB containing 2 
mg/ml of calcein and 200 /^g/ml of PAAA-X-Bad(140-165). Cells were analysed 2 and 
4 hours after incubation with PAAA-X-Bad(140-165).
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5.3 Results
5.3.1 Synthesis of the Hydrazide Linker
Synthesis of the hydrazide linker involved the synthesis of 2 intermediates (see Figure
5.1). Table 5.2 shows the colour and yields of each product. Intermediate 2 was purified 
by flash chromatography and resulted in several different fractions. These fractions 
were analysed by TLC. The Rf values were determined for each fraction (Table 5.3). 
Fractions 1, 2, and 4 contained unwanted by-products. Fraction 3 contained the desired 
product.
Following TLC, fractions were pooled and then analysed by one-dimensional H NMR. 
The pattern of resonance peaks for each fraction was analysed; the purified hydrazide 
was confirmed to be in fraction 3. The spectrum of fraction 3 showed two doublets in 
the aromatic region (7.998 and 7.969 ppm and 7.614 and 7.586 ppm). These 
represented the benzene group. A singlet was evident at 7.011 ppm and represented the 
maleimide group. Other peaks were visible, however these were attributed to either the 
blocking group (r-but) or the solvent. The one-dimensional H NMR spectrum for 
fraction 3 is shown in Figure 5.2.
The final step in the synthesis involved the removal of the blocking group, which was 
achieved by the addition of ice cold TFA. The yield of purified hydrazide was 0.79 g 
(Table 5.2).
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Intermediate 1 (MBA) 15.31 Beige




Table 5.2: Summary of the hydrazide synthesis. Synthesis involved the production of 
two intermediates and the removal of a protecting group.
Fraction 1 0.222, 0.349, 0.539, 0.603
Fraction 2 0.285, 0.428
Fraction 3 0.253
Fraction 4 0.126
Table 5.3: Rf values of the crude hydrazide linker mixture following flash and thin layer 
chromatography (see section 5.2.2.1). Fractions 1, 2 and 4 contain various by-products 
of the synthesis. Fraction 3 contained the purified hydrazide linker.
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Aromatic region
Figure 5.2: One-dimensional H NMR of fraction 3. The two doublets in the aromatic 
region (7.998 /7.969 ppm and 7.614 /7.586 ppm) represent the benzene group. The 
singlet at 7.011 ppm represents the maleimide group. Other peaks were visible, however 
these were attributed to either the blocking group (4.95 ppm) or the solvent (3.36 ppm).
5.3.2 Conjugation of the Hydrazide Linker to PAAAs
Purified hydrazide linker (X) was conjugated to five different PAAAs using the method 
described in section 5.2.2.2. Three conjugation reactions were successful. These were 
PEAA(23 kDa), PEAA(32 kDa) and PPAA(43 kDa). The H NMR spectrum obtained 
for PEAA(23 kDa)-X was similar to that observed for the linker alone, however a 
downward chemical shift was evident (Figure 5.3). The spectrum of PEAA(23 kDa)-X 
showed a doublet in the aromatic region (at 7.942 and 7.913 ppm and 7.569 and 7.541 
ppm), representing the derivatized benzene ring, and a singlet at 7.000 ppm representing
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the maleimide group. A broad range peak was evident at approximately 2 ppm, 
representing the polymer. This peak was considerably broader than other peaks, due to 
the heterogeneous mass of PAAA molecules (i.e. PAAAs are a collection of polymers 
with close but not identical molecular weights). Similar spectra were also obtained for 
samples of both PEAA(32 kDa)-X and PPAA(43 kDa)-X (results not shown).
Aromatic Region
~8 7 6 5 4 3 2 1 0 ppm
Figure 5.3: One-dimensional H NMR spectrum obtained for PEAA(23 kDa)-X. Two 
doublets are evident in the aromatic region. These represent the benzene group. A 
singlet is seen at ~7.000 ppm representing the malemide group. A broad range peak is 
seen at approximately 2 ppm, representing the polymer. A distinct chemical downward 
shift is evident for both the doublet and the singlet compared to the linker alone (Figure
5.2). This is caused by conjugation of the polymer to the hydrazide linker. Other peaks 
were visible, however, these were attributed to either the blocking group, the solvent or 
the polymer.
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5.3.3 Determining the Number of Hydrazide-Linkers 
Conjugated to PA A As
At acidic pH, PAAAs are thought to cause membrane rupture by inserting themselves 
directly into membranes. This is thought to occur following a conformational change of 
the PAAA from an expanded coil shape to a more complex shape. This conformational 
change is most likely related to the increased hydrophobic character when the many 
carboxylate ions become protonated at low pH (Murthy et al., 1999). Therefore, when 
conjugating the hydrazide linker to a PAAA, a sufficient fraction of carboxylate ions 
must remain unmodified to ensure that the PAAA retains its ability to disrupt 
membranes. It was suggested that the ability of these polymers to lyse membranes may 
be lost if more than 3-5% of carboxyl groups are altered (C. Cheung, 2002, pers. 
commun.). The number of hydrazide linkers attached to the polymers was determined 
using SAMSA fluorescein (see section 5.2.2.3 for details). Table 5.4 summarises the 




No. of linkers 
attached per PAAA 
molecule
% of COOH derivatized
PEAA (23 kDa) 4 2
PEAA (32 kDa) 6 2
PPAA (43 kDa) 13 3
Table 5.4: Number of carboxcyclic-hydrazide linkers conjugated to three PAAAs. These 
numbers were calculated on the basis of results from an assay using SAMSA 
fluorescein (see section 5.2.2.3 for methods).
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5.3.4 Determining the pH-Sensitive Membrane-Lytic Ability of 
PAAAs Derivatized with Hydrazide Linker
Whole cell experiments, similar to those described in section 3.2.2.5, were performed to 
determine if the derivatized polymers (PAAA-X) retained their ability to disrupt 
membranes in a pH-sensitive manner. Three derivatized polymers, with molecular 
weights ranging from 23 kDa to 43 kDa were tested. Cytolysis was detected by flow 
cytometric analysis of Pi-stained cells.
At pH 7, 6.5 and 6, approximately 5% of cells were non-viable following exposure to 
either PEAA(23 kDa) or PEAA(23 kDa)-X. At pH 5.5, both PEAA(23 kDa) and 
PEAA(23 kDa)-X lysed approximately 97% of cells; in both cases the extent of cell 
lysis increased slightly at pH 5 to about 99%. At all pH values tested, there were no 
significant differences in the extent of cell lysis induced by PEAA(23 kDa) or PEAA(23 
kDa)-X (Figure 5.4 A). Similar results were obtained when PEAA(32 kDa) and 
PEAA(32 kDa)-X were tested, except that at pH 6, both PEAA(32 kDa) and PEAA(32 
kDa)-X lysed more cells (15% and 28%, respectively) (Figure 5.4 B). The difference 
between the percentage of cells lysed by PEAA(32 kDa)-X and PEAA(32 kDa) at pH 6 
was not significant (p> 0.05 F u = 5.2943, Students t-test). The results shown in this 
chapter indicate that derivatization of PEAA with a hydrazide linker had no significant 
effect on its ability to lyse cells at pH 5-5.5.
Previously, PPAA was shown to disrupt RBC at pH 6.5 and below (Stayton et al., 
2000). Similarly, in whole cell experiments described in this chapter, cell lysis induced 
by PPAA (43 kDa) occurred at pH 6.5 and below. At pH 6.5, PPAA(43 kDa) lysed 
approximately 90% of cells; this increased to approximately 95% at pH 6. However, at
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pH 5.5 and below the percentage of cells lysed by PPAA(43 kDa) decreased. This 
extent of cell lysis was similar when PPAA(43 kDa)-X was used. Like PEAA polymers, 
there was no significant difference in the extent of cell lysis induced by either PPAA(43 
kDa) or PPAA(43 kDa)-X (Figure 5.4 C).
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Figure 5.4: Histogram plots showing the percentage of non-viable cells following a 30 
minute exposure of U937 cells to either PAAA or PAAA-X. Cytolysis was detected by 
flow cytometric analysis of Pi-stained cells. (A) Cells exposed to 200 (j,g/ml PEAA(23 
kDa) (white bars) or PEAA(23 kDa)-X (black bars). (B) Cells exposed to 200 iig/ml 
PEAA(32 kDa) (white bars) or PEAA(32 kDa)-X (black bars). (C) Cells exposed to 200 
[ig/ml PPAA(43 kDa) (white bars) or PPAA(43 kDa)-X (black bars). Each data point 
represents the mean value from three independent experiments. Error bars represent the 
standard error (SE) of the mean in each case. In some cases the SE are too small to be 
visible.
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5.3.5 Testing the Effects of pH on the Stability of the 
Carboxcyclic-Hydrazide Bond in the Linker Used to 
Derivatize PAAAs
Theoretically, at physiological pH, the carboxcyclic-hydrazide bond within the linker is 
stable. However at acidic pH, the linker is expected to be cleaved from the polymer, 
generating free primary amine groups. Stability of the PAAA-X constructs was 
determined using fluorescamine, a non-fluorescent molecule that reacts with free 
primary amines to produce a fluorescent product. Stability tests were conducted on three 
types of PAAA-X, formed from PEAA(23 and 32 kDa) and PPAA(43 kDa). 
Derivatized polymers were incubated in phosphate buffers at either pH 7 or 5. At 0, 24 
and 48 hours, aliquots of these samples were assayed for free amine groups using 
fluorescamine (see section 5.2.2.5).
In all cases, the resulting fluorescence for aliquots taken from the pH 7 buffer was 
significantly lower than those obtained for corresponding aliquots taken from the pH 5 
buffer (Figure 5.5 A, B and C). For the PAAA-X samples incubated at pH 7, the 
fluorescence ranged between 2000 and 2500 arbitrary units. Fluorescence did not 
change significantly during the 48 hour time period for these samples. The fluorescence 
obtained from aliquots taken from the pH 7 buffer was similar to that of the controls 
(i.e. buffer containing PAAA plus fluorescamine (data not shown) or fluorescamine 
alone). These results suggest that the carboxcyclic-hydrazide bond in the linker is stable 
at pH 7.
For PEAA(23 kDa)-X incubated at pH 5, the level of fluorescence measured for the 0
hour sample was approximately 6000 arbitrary units. Surprisingly, a significantly lower
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Figure 5.5: Bar graphs showing the level of fluorescamine fluorescence measured for 
PAAA-X samples incubated in either pH 5 or pH 7 buffers for up to 48 hours. PAAAs 
were conjugated to a hydrazide linker (X) as described in section 5.2.22. Data is shown 
for (A) PEAA(23 kDa)-X, (B) PEAA(32 kDa)-X, and (C) PPAA(43 kDa)-X incubated 
in pH 5 or pH 7 buffer. The level of fluorescence measured for samples containing only 
fluorescamine are also shown. Each data point represents the mean of the values from 
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5.3.6 Conjugation of Bad(140-165) to PAAA-X
Bad(140-165) was conjugated to both PPAA-X and PEAA-X. Bad(140-165) has 7 free 
amines; conjugation of Bad(140-165) to PAAA-X was confirmed by measuring an 
increase in primary amine groups associated with the conjugate (by fluorescamine 
assay; section 5.2.2.5). The fluorescence obtained for PPAA(43 kDa)-X alone was 
approximately 14000 arbitrary units. The fluorescence obtained for PPAA-X-Bad(140- 
165) was significantly higher (~17000 arbitrary units) than that obtained for PPAA(43 
kDa)-X alone (p<0.0001, F, 14 = 93.54, Student’s t-test; Figure 5.6). These results 
suggest that conjugation between PPAA-X and Bad(140-165) was successful. 
Conjugation of Bad(140-165) to PEAA-X was also successful (results not shown). 
(Note: In these experiments the sensitivity settings on the Biolumin fluorescence plate 
reader were different from those used in previous experiments, hence the fluorescence 
values shown in Figure 5.6 are considerably higher than those previously displayed in 
Figure 5.5). The number of Bad(140-165) molecules attached per PAAA molecule were 
calculated using the results of fluorescamine assays and are shown in Table 5.5.
*
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Figure 5.6: Bar graph showing the results of fluorescamine assays testing PPAA-X- 
Bad(140-165) (white bar), PPAA-X (grey bar) and fluorescamine only (black bar). Each 
data point represents the mean of values from three independent experiments. Error bars 




No. of linkers attached 
per PAAA molecule
No. of Bad(140-165) 
molecules attached per 
PAAA molecule
PEAA (23 kDa) 4 2
PEAA (32 kDa) 6 2
PPAA (43 kDa) 13 5
Table 5.5: Number of Bad( 140-165) molecules conjugated to PAAA-X.
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5.3.7 Introduction of PPAA/PEAA-X-Bad(140-165) into U937 
Cells by Constitutive Endocytosis
PEAA(23 kDa)-X-Bad(140-165), PEAA(32 kDa)-X-Bad(140-165) and PPAA(43 kDa)- 
X-Bad( 140-165) were introduced into U937 cells by constitutive endocytosis, using 
methods described in section 3.2.2.1 (except that, following the initial incubation, cells 
were incubated in 4 ml of complete medium containing the constructs for 3 days). Cell 
viability was determined after 24, 48 and 72 hours. Over this time, there was a small, 
but insignificant, increase in the proportion of dead cells in both control and PAAA-X- 
Bad(140-165)-treated cells. An increase in cell density over the 72 hours (due to normal 
cell multiplication) may have resulted in the increase in non-viable cells. Results 
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Figure 5.7: Bar graph showing the viability of U937 cells following uptake of PEAA(32 
kDa)-X-Bad(140-165) by constitutive endocytosis. Graph shows the percentage of non- 
viable cells in: control (white bars) and cells incubated with PEAA(32 kDa)-X- 
Bad(140-165) (grey bars). Each data point represents the mean value from three 
independent experiments. Error bars represent the standard errors of the mean in each 
case and in some cases are too small to be seen.
PAAAs are internalised into cells by constitutive endocytosis and transit through early 
endosomes. To determine if this is also true for PAAA-X-Bad(140-165) constructs, 
cells were incubated for 30 minutes in PB containing PPAA-X-Bad( 140-165)-biotin. 
U937 cells were then stained with anti-EEAl antibody and Alexa 488-conjugated goat 
anti-mouse Ig; PPAA-X-Bad( 140-165)-biotin was detected using streptavidin-Alexa 
546. Confocal microscopy showed PPAA-X-Bad(140-165)-biotin located primarily at 
the periphery of the cell. In approximately 50% of cells there was partial overlap of the 
fluorescences attributable to PPAA-X-Bad(140-165)-biotin and EEA1. This pattern of 
fluorescence suggests that, like PPAA alone, PPAA-X-Bad( 140-165)-biotin enters cells
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via endocytosis and transits through early endosomes (Figure 5.8). A similar pattern of 
fluorescence was observed when PEAA-X-Bad(140-165)-biotin was introduced into 
U937 cells (data not shown).
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Figure 5.8: Confocal microscopy images of U937 cells incubated for 30 minutes in PB 
containing PPAA-X-Bad(140-165)-biotin. Images show cells stained with (a) anti- 
EEA1 antibody only (green fluorescence), (b) streptavidin-Alexa 546, and (c) an 
overlay of the two fluorescence images. In approximately 50% of cells, vesicles show 
partial co-localisation of green and red fluorescence (arrows). This result is 
representative of two independent experiments. Approximately 240 cells were scanned 
to ensure reproducibility. Bar = 10 n m.
To determine if the membrane disruptive ability of PAAAs is retained following 
conjugation of Bad(140-165), U937 cells were incubated in PB containing the 
membrane-impermeable fluor calcein and PEAA(32 kDa)-X-Bad(140-165) (see section 
5.2.2.7). There was a time dependent release of calcein from vesicles to the cytosol 
when cells were incubated in the presence of PEAA(32 kDa)-X-Bad(140-165). Two 
hours after uptake, fluorescent vesicles were still clearly seen in some PEAA(32 kDa)- 
X-Bad(140-165)-treated cells while in others the fluorescence was considerably more 
diffuse (Figure 5.9, panel b). At 4 hours following loading, fluorescence was diffuse in 
most cells, indicating release of calcein from vesicles to the cytosol (Figure 5.9, panel
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c). A similar pattern of fluorescence was detected when cells were incubated in the 
presence of PPAA-X-Bad(140-165) (data not shown).
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Figure 5.9: Confocal microscopy images of U937 cells incubated in PB containing 200 
^ig/ml of PEAA(32 kDa)-X-Bad(140-165) and 2 mg/ml calcein. Images show U937 
cells immediately after uptake of PEAA(32 kDa)-X-Bad( 140-165) and 2 and 4 hours 
after uptake (b and c, respectively). This result is representative of three independent 
experiments. 50 cells were scanned to ensure reproducibility. Bar = 10 /im .
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5.4 Discussion
This chapter described the synthesis of a pH-sensitive hydrazide linker, the structure of 
which was confirmed by one-dimensional H NMR. The hydrazide linker was 
conjugated to various PAAAs. Results presented in this chapter show that 
approximately 2-3% of the carboxyl groups were conjugated to the linker (Table 5.4). 
Cheung and colleagues have previously conjugated anti-tumour agents to PAAAs. They 
found that derivatization of more than 3-5% of the carboxyl groups on the polymers 
inhibited their ability to disrupt membranes in a pH-sensitive manner (C. Cheung, pers. 
com m un.). Therefore, in experiments conducted, the percentage of derivatized 
carboxylate ions was kept to a minimum.
The ability of the polymer to disrupt membranes in a pH-dependant manner was not 
affected by the conjugation of hydrazide linker (X) to the polymer (Figure 5.4). In all 
cases, the cytolytic efficiencies of underivatized PAAAs and the corresponding PAAA- 
X derivatives were not significantly different (Figure 5.4). The maximum cytolysis for 
both PPAA and PPAA-X occurred at pH 6.0, while that for PEAA and PEAA-X 
(irrespective of molecular weight) occurred at pH 5.0-5.5. The efficiency of cytolysis of 
PPAA and PPAA-X decreased at pH 5.5 and below. The reason for this is not known, 
however, Stayton and colleagues have recently shown a similar trend in experiments 
involving PPAA and RBCs. They showed that the haemolytic activity of PPAA was 
lower at pH 5.5 than at pH 6.5 or 6. At pH 5.5 and below, PPAA has a tendency to 
precipitate from solution. Stayton et al. (2000) have suggested that the greater 
hydrophobicity of PPAA may explain why it had reduced haemolytic efficiency at pH 
<6. It is possible that at pH <6, PPAA (and PPAA-X) form micro-aggregates which 
reduces their cytolytic activity.
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To determine the stability of the carboxcyclic-hydrazide bond, PAAA-X samples were 
incubated in buffer at either pH 5 or pH 7 for up to 48 hours and then assayed using 
fluorescamine. Fluorescamine reacts with primary amine groups to produce a 
fluorescent product. Cleavage of the carboxcyclic-hydrazide bond generates two 
primary amines that are otherwise absent from the structure of PAAA-X. For PAAA-X 
samples incubated at pH 7, the level of fluorescence measured in the fluorescamine 
assay was not expected to change over 48 hours; this was found to be the case for all 
PAAA-X samples tested (Figure 5.5). In contrast, for PAAA-X samples incubated at pH 
5, it was expected that the level of fluorescence measured in the fluorescamine assay 
would increase at each consecutive time point. This was found to be the case for 
PEAA(32 kDa)-X but not for the other two PAAA-X constructs tested. For PEAA(23 
kDa)-X, the fluorescence obtained for the 24 hour sample was about 15% lower than the 
values obtained for 0 or 48 hours, which were similar (Figure 5.5 A). The anomalously 
low value for the 24 hour sample may have resulted from the use of an aged stock 
solution of fluorescamine; several stock solutions were used in these experiments and in 
some cases they may have been of different ages (up to several days old, stored at 4 C; 
fluorescamine is known to oxidise slowly in solution). In the case of PPAA(43 kDa)-X, 
the values obtained for the 24 and 48 hour samples were not significantly different from 
each other but these values were slightly higher than the value obtained for the 0 hour 
sample. Overall, the levels of fluorescence measured for all PAAA-X samples incubated 
at pH 5, irrespective of the time of incubation, were significantly higher than those 
measured for corresponding samples incubated at pH 7. These results suggest that the 
carboxcyclic-hydrazide bond is stable at pH 7 (physiological pH) but at pH 5 (which is 
found inside late endosomes/lysosomes) is very unstable and under these conditions, in 
many cases, cleaves almost immediately.
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The final experiments described in this chapter involved conjugating Bad(140-165) to 
PAAA-X, and determining the effects on cells of the uptake of PAAA-X-Bad(140-165) 
conjugates by constitutive endocytosis. Conjugation of PAAA-X and Bad(140-165) was 
confirmed using fluorescamine (Figure 5.6). Quantitative analyses showed that the 
number of Bad(140-165) molecules attached per PAAA ranged from 2 to 5, depending 
on the polymer used (Table 5.5). These results indicate that approximately one third of 
the linkers attached to the polymer conjugated with Bad(140-165). The reason why 
Bad(140-165) did not conjugate to all of the attached linker molecules is currently 
unknown but may be a result of the instability of the reactive maleimide group in 
aqueous solution.
Surprisingly, uptake of PAAA-X-Bad(140-165) did not induce cell death (Figure 5.7). 
We expected that endocytosis of PAAA-X-Bad( 140-165) would result in apoptosis. 
This expectation was based on the following:
1. Results shown in chapter 3 demonstrate that PAAAs are taken up by endocytosis 
and disrupt endosomes to release both small and macro-molecules to the cytosol.
2. Results shown in Figure 5.8 suggest that PPAA-X-Bad(140-165) is taken up by 
endocytosis and transits through early endosomes before moving onto other 
vesicular compartments.
3. Results shown in this chapter demonstrate that the pH-sensitive membrane 
disruptive ability of PAAAs is not affected following conjugation of the linker 
and Bad(140-165). Results shown in Figure 5.9 demonstrate that uptake of 
PEAA-X-Bad(140-165) induced physical disruption of endosomes sufficient to 
release calcein into the cytosol. These results are consistent with those reported 
by Lackey and colleagues (1999) who demonstrated that PPAA retains its ability
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to lyse RBCs following conjugation with streptavidin. They also showed that 
PPAA-streptavidin complexes have similar haemolytic activity to that of 
unmodified PPAA (Lackey et al., 1999).
4. Results presented in this chapter show that the linker is stable at physiological 
pH but not at the pH found in endosomes (Figure 5.5).
5. Work previously performed in this laboratory showed that pinocytic loading 
(described in section 6.2.2.1) of Bad(140-165) alone into U937 cells induced 
characteristics of apoptosis (Woods, 2000). Immediately after pinocytic loading 
of Bad(140-165), approximately: 25% of cells had depolarised mitochondria 
(compared to 2% of control cells), 40% of cells had PS exposure (compared to 
6% of control cells), and 76% of cells showed a diffuse pattern of fluorescence 
following staining with anti-cytochrome c antibody, suggesting cytochrome c 
release (only 11% of control cells showed a diffuse pattern of fluorescence). In 
addition, it was shown that caspase inhibition significantly reduced the extent of 
cell death induced by pinocytic loading of Bad(140-165). These results 
demonstrated that cytosolic Bad(140-165) induces apoptosis. Several other 
research groups have also shown that apoptosis is induced following cytosolic 
delivery of a variety of pro-apoptotic peptides similar to the one used in this 
study (Kelekar et al., 1997; Narita et al., 1998).
Collectively, the above results suggest that PA A A-X-Bad( 140-165) constructs are 
internalised by cells into endosomes where the low pH of the lumen would (1) 
rapidly cleave the carboxcyclic-hydrazide bond in the linker, releasing Bad(MO- 
165), and (2) trigger the polymer to disrupt the endosomal membrane and release its 
contents (including Bad(140-165)) to the cytosol. So, the question is why did uptake
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of PAAA-X-Bad(140-165) not induce apoptosis? The reason(s) for this are not yet 
known but could include the following:
1. In vivo, the linker may not have been completely cleaved from the construct, 
thereby limiting the amount of Bad(140-165) released into the cytosol.
2. Regardless of the extent of linker cleavage, the amount of Bad(140-165) 
released may not have been enough to induce apoptosis. To estimate the amount 
of Bad(140-165) theoretically delivered into cells in the experiments described 
here, the ratio of the intracellular concentration of a constitutively endocytosed 
fluorescently-labelled protein to its concentration in the external medium was 
determined. A standard curve plotting fluorescence versus concentration was 
produced for FITC-insulin. U937 cells were then allowed to constitutively 
endocytose FITC-insulin for a period of 20 minutes from an external 
concentration of 200 //g/ml (as described in section 3.2.2.1). Subsequently, 
lOxlO6 U937 cells were disrupted using a series of five freeze/thaw cycles and 
the lysate centrifuged (16,000 g, 6 minutes) to pellet cell debris. The level of 
fluorescence in the supernatant was then determined and used to calculate the 
amount of FITC-insulin internalised by the cells. Assuming that U937 cells are 
spheres of 24 nm  in diameter (estimated from confocal microscopy), it was 
calculated that the final intracellular concentration of FITC-insulin was only
0.08% of that in the external medium (results not shown). Using this value, it is 
possible to estimate that after 20 minutes of endocytosis, the concentration of 
PAAA-X-Bad(140-165) within U937 cells would be about 3.06 x 10 10 M. 
Assuming complete cleavage of Bad(140-165) from the polymer, and knowing 
that each PAAA molecule had 2-5 Bad(140-165) peptides attached (Table 5.5),
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this predicts that under these conditions the final intracellular concentration of 
Bad( 140-165) would be in the range 0.61 -1 .5 3  x 109 M.
The in vitro binding affinity (KD) of Bad(140-165) for Bcl-XL is 6.0x109 M 
(Kelekar et al., 1997); this binding interaction is thought to be involved in 
exerting the pro-apoptotic effect of Bad. Thus, the calculations outlined above 
(with all their assumptions), indicate that after 20 minutes of endocytosis from 
an external concentration of PAAA-X-Bad(140-165) of 200 /^g/ml, the 
intracellular concentration of Bad(140-165) would be, at most, approximately 4 
fold lower than that required for significant interaction with Bcl-XL. Therefore, it 
is quite feasible that the concentration of PAAA-X-Bad(140-165) released into 
the cytosol may not have been enough to induce apoptosis.
3. Cleavage of the linker occurs at a double bond (Figure 5.10). This results in the 
bulk of the structure of the linker remaining attached to the released peptide. 
Pro-apoptotic peptides interact with anti-apoptotic proteins in a specific manner 
(see sections 1.3.2.1 and 1.6). Thus, it is possible that the linker structure that 
remains attached to Bad(140-165) prevents its interaction with Bcl-xL (an anti- 
apoptotic protein, see section 1.3.2.1) and inhibits its ability to induce apoptosis. 
Alternatively, or in addition, it is also possible that the cathepsin cleavage site 
incorporated into Bad(140-165) may also prevent its interaction with anti- 
apoptotic proteins.
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Figure 5.10: Schematic representation of the cleavage of PAAA-X-Bad(140-165) at 
acidic pH. Cleavage occurs at the double bond (indicated by the arrow) and results in 
the bulk of the linker structure remaining associated with the released Bad(140-165).
In conclusion, results presented in this chapter describe initial work directed towards the 
development of a novel cancer therapeutic. Additional experiments (described in 
chapter 7) will be needed to determine why PAAA-X-Bad(140-165) did not induce 
apoptosis following uptake by constitutive endocytosis. However, results thus far are 
positive and show great potential for further development.
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Chapter 6
Detection of Mitochondrial Permeability 
Transition in Intact Cells
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6.1 Introduction
Traditional cancer therapeutics don’t directly manipulate apoptosis but instead kill 
cancer cells by indirect methods (e.g. by interfering with DNA replication). However, 
new cancer therapeutics in development, are now focusing on targeting apoptosis 
directly. Apoptosis is an ideal mode of killing because apoptotic cells are naturally 
engulfed and degraded by phagocytes, preventing the release of toxic cellular contents 
into adjacent healthy tissue. To confirm that the new therapeutics induce apoptosis in 
intact cells it will be necessary to accurately measure apoptotic process, such as MPT.
MPT has been studied in isolated mitochondria for decades (Zoratti and Szabo, 1995) 
and more recently in intact cells. In in vitro studies, MPT is associated with loss of 
electrical potential difference across the inner mitochondrial membrane (i.e. the loss of 
Axj)mjt) and mitochondrial swelling resulting from an increase in the permeability of 
mitochondria to solutes up to 1500 Da in mass (Zoratti and Szabo, 1995). MPT is 
thought to result from the sustained opening of permeability transition pores (PTP) that 
form at points of contact between the inner and outer mitochondrial membranes. Other 
studies of mitochondria, both in intact cells and as isolated organelles in vitro, have 
provided evidence that PTP can also undergo rapid transient openings that do not result 
in MPT (Petronilli et al., 1999; Ichas et al., 1997; H userera/., 1998).
The precise biological role(s) of MPT have yet to be established. However, it has been 
implicated as being important in several aspects of cell physiology and pathology, 
including:
1. Control of mitochondrial calcium homeostasis (Zoratti and Szabo, 1995).
2. Initiation of autophagy (Lemasters et al., 1998).
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3. Triggering necrosis in cells undergoing ischemia- and reperfusion-induced 
injury (Lemasters et al., 1998; Di Lisa et al., 2001).
4. Triggering apoptosis (Loeffler and Kroemer, 2000).
Given the likelihood that MPT performs critical biological functions, it is important to 
develop a valid technique for measuring this phenomenon in intact cells. Two previous 
approaches for doing this have been described, however, both have significant 
limitations. Both of these techniques utilize the membrane-permeable acetoxymethyl 
ester of calcein (calcein-AM) to stain the cytosol (Nieminen et al., 1995) or the 
mitochondrial matrix (Petronilli et al., 1999).
The first reported technique measured MPT in hepatocytes by tracing the movement of 
cytosolic calcein into mitochondria. The movement of calcein into mitochondria was 
imaged using confocal microscopy. This technique involved introducing calcein-AM 
into cells via diffusion and subsequently staining them with TMRM (TMRM labels 
polarised mitochondria with bright red fluorescence). Theoretically, once inside the 
cytosol, the ester bond is cleaved by non-specific esterases to release free calcein, which 
is membrane-impermeable. Using this technique, polarised mitochondria fluoresced red 
due to the accumulation of TMRM and, when viewing calcein fluorescence, appeared as 
dark voids within a brightly green fluorescent cytosol (Nieminen et al., 1995). In this 
technique, MPT is detected by a loss of mitochondrial staining with TMRM and an 
increase in calcein fluorescence inside mitochondria.
Minamikawa et al. (1999a) described a second technique for measuring MPT in intact 
cells. In this technique, calcein-AM is loaded into cells (by diffusion) and stained with
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TMRM. Cells are also simultaneously incubated with Co2+ ions, which enter the cytosol 
but not mitochondria to complex with calcein and thereby quench its fluorescence. This 
technique detects MPT by a loss of mitochondrial staining with TMRM and a decrease 
in calcein fluorescence inside mitochondria (Minamikawa et al., 1999 a and b).
The following chapter describes the development of an alternative confocal microscopy 
technique for the detection of MPT in intact cells that is free of the disadvantages 
associated with the other techniques described above (see discussion for more details). 
In this new approach, unconjugated calcein is simultaneously introduced into the 
cytosol of millions of cells by the process of pinocytic loading and, to identify the 
position of individual mitochondria and to measure Atjjmit, the cells are counter-stained 
with TMRM. A variety of cells types were used and results show that cytosolic calcein, 
which is initially excluded from polarized mitochondria, gradually enters them in 
response to transient openings of the MPT pore and that induction of sustained MPT 
produces a rapid net movement of calcein into mitochondria. Figure 6.1 schematically 
represents the three techniques for measuring MPT in intact cells.
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Figure 6.1: Schematic representations of three confocal microscopic techniques for 
measuring MPT in intact cells. In all cases, cells are stained with TMRM, which label 
polarised mitochondria with bright red fluorescence, (a) Calcein-AM is loaded into cells 
via diffusion (straight dotted arrow). Once inside, the ester bond is cleaved by non­
specific esterases (thin solid arrow) to release free calcein that is membrane 
impermeable (thick solid arrow), (b) Calcein is loaded into cells as in (a) but cells are 
simultaneously incubated with 1 mM Co2+ ions, which enter the cytosol but not 
mitochondria to complex with calcein and thereby quench its fluorescence, (c) Calcein 
is directly introduced into cells by pinocytic loading (PL) and is largely excluded from 
the mitochondrial matrix. In these methods, MPT is detected by a loss of mitochondrial 
staining with TMRM and either an increase (a and c) or a decrease (b) in calcein 
fluorescence inside mitochondria.
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6.2 Materials and Methods
6.2.1 Materials
Polyethylene glycol (molecular mass 1000 Da: PEG1000), sucrose, and 13-ds-retinoic 
acid (RA) were from Sigma (Sydney, Australia). N-(2-hydroxyethyl)piperazine-N’-(2- 
ethanesulfonic acid ) (HEPES) was from United States Biochemical Corp. (OH, USA). 
Calcein-AM and tetramethylrhodamine methyl ester (TMRM) were from Molecular 
Probes Inc. (OR, USA). Bongkrekic acid (BA) was a gift from Prof J Duine (University 
of Delft, the Netherlands). All other chemicals were of analytical reagent grade and 
were from Ajax Chemicals (Sydney, Australia).
6.2.2 Methods
6.2.2.1 Pinocytic Loading of Intact Cells
Pinocytic loading is a technique that was developed for the introduction of 
macromolecules into mammalian cells and is a convenient, rapid and simple procedure. 
Unlike other cell loading methods, such as microinjection and electroporation, pinocytic 
loading provides a more gentle cell-loading method and does not significantly alter cell 
function. The pinocytic loading technique is based on the osmotic lysis of pinocytic 
vesicles (Okada and Rechsteiner, 1982). Macromolecules are firstly taken up by cells 
via pinocytosis. The cells are then placed in a hypotonic medium, which results in the 
bursting of pinosomes within the cells and release of their contents to the cytosol 
(Figure 6.2). Pinocytic loading has previously been used to load macromolecules such 
as monoclonal antibodies (Chakrabarti et al., 1989), fluoresceinated dextran and 
horseradish peroxidase (Okada and Rechsteiner, 1982) into intact cells. Cell viability is 
maintained throughout the procedure.
173
Chapter 6 MPT in Intact Cells
Figure 6.2: Schematic representation of the process of pinocytic loading, (a) Cells are 
incubated in a hyper-osmotic buffer containing the molecule to be loaded. This causes a 
loss of water from the cells and the simultaneous uptake of pinocytic vesicles containing 
the target molecule, (b) During the subsequent incubation in a mildly hypo-osmotic 
buffer, water re-enters the cells and the hyper-osmolar pinocytic vesicles causing them 
to burst, (c) Release of macromolecules into the cytosol of the cell.
Cells (2 x l0 6) were centrifuged for 5 minutes at 300 g and washed in 1 ml of 
DMEM:F12. Cells were re-centrifuged as above and the supernatant was thoroughly 
drained. The cells were then gently resuspended in 100 (.il of hyper-osmotic buffer (10 
mM HEPES, 10% (w/v) polyethylene glycol (PEG), 0.5 M sucrose, pH 7.4) containing 
the compound to be loaded at a concentration of 2 mg/ml. The cell suspension was 
incubated for 10 minutes at 37°C and diluted with hypo-osmotic buffer (60% 
DMEM:F12 and 40% water (v/v)) to make up a final volume of 10 ml. Cells were then 
incubated for 2 minutes at 37°C and centrifuged as above. Cells were washed twice with 
DMEM:F12. For immediate analysis by confocal microscopy, cells were resuspended in 
200 n\ of complete medium.
In some experiments, pharmacological inhibitors of MPT (100 /^M bongkrekic acid or 
10 /yM cyclosporin A) were added to the calcein/hyper-osomotic buffer solution during
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cell loading and to the medium in which cells were incubated for up to 1 hour prior to 
confocal microscopic analysis. In other experiments, cells were treated with 0.5 mM 13- 
c/s-retinoic acid (to induce MPT) immediately before confocal analysis.
6.2.2.2 Staining Cells with a Cationic Fluorescent Dye to M easure 
Mitochondrial Membrane Potential
Tetramethylrhodamine methyl ester perchlorate (TMRM) is a cationic flurophore that 
accumulates inside mitochondria in response to the Aipmit (Heiskanen et al., 1999), thus 
enabling changes in Aipmit to be monitored. Depolarisation results in mitochondrial 
release of TMRM and reduced mitochondrial red fluorescence.
Cells (lx lO 6) were centrifuged for 5 minutes at 300 g. The supernatant was discarded 
and cells were resuspended in 500 ^1 of 50 nM TMRM in complete medium. TMRM 
was added by diluting 1 mM stock (in DMSO) to 1 //M in complete medium and then 
diluting the 1 //M stock 1:50 in complete medium. Samples were incubated at 37°C for 
15 minutes in the dark and then immediately analysed by confocal microscopy and/or 
flow cytometry.
6.2.2.3 Confocal Microscopy, Flow Cytometry and Image Analysis
Following cell labelling, cells were immediately loaded onto glass slides and examined 
by a Leica DMIRBE inverted microscope coupled to a Leica TCS SP confocal system 
(Leica Microsystems, Sydney, Australia). Cells were sequentially excited at 488 nm 
(calcein) and 543 nm (TMRM) and fluorescence collected using emission windows set 
at 500-540 nm (calcein) and 560-610 nm (TMRM). All signals collected were adjusted 
to remain within the linear range of the detectors. Images were collected using TCS NT
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software (Leica Microsystems, Sydney, Australia). In some experiments, this software 
was also used to calculate the average pixel intensity of calcein fluorescence within 
regions of interest (ROI) drawn onto collected images. In these cases, for each 
treatment, images of 10-14 individual cells were analysed as follows. For each cell, the 
mean fluorescence was determined for three ROI drawn to represent (1) mitochondria 
(these were drawn to be contained within regions stained with TMRM), (2) cytosol 
(drawn inside the cells but outside those regions stained with TMRM), and (3) 
background (drawn outside the cell). The values for each set of three ROI were 
averaged, then the mean background value was subtracted from each of the mean values 
for mitochondria and cytosol. Finally the background corrected value for mitochondria 
was divided by the corresponding value for the cytosol and expressed as a percentage. 
Differences between treatments were analysed using Oneway ANOVA (JMP software, 
SAS Institute INC, Cary, NC, USA). Images to be incorporated into figures were 
exported as TIFF files and figures were assembled using Adobe Photoshop v5.0 
software (Adobe Systems, Sydney, Australia).
In some experiments, cells stained with 50 nM TMRM (as previously described) were 
subsequently analysed using a FACSort flow cytometer (Becton Dickinson, Sydney). 
The cells were excited with a 488 nm Argon laser and fluorescence collected using a 
585 +/- 21 nm band pass filter. Acquired data was analysed using CellQuest (v.3.1f) 
software (Becton Dickinson, Sydney).
176
Chapter 6 M PT in Intact Cells
6.3 Results
6.3.1 Imaging Mitochondria by Staining Cells with Calcein-AM 
and TMRM
Results shown in section 6.3.1 were obtained by Alison Smail. They are included in this 
thesis because they complement other related work (sections 6.3.2 and 6.3.3).
Jurkat cells were loaded with calcein-AM and stained with TMRM. Calcein-AM was 
loaded into the cytosol and also, to a lesser extent, mitochondria. In the absence of co- 
staining (Figure 6.3, panel a) mitochondria were detectable as areas of slightly lower 
fluorescence intensity within a field of bright cytosolic calcein fluorescence. This was 
also true for cells stained with 50 nM TMRM (Figure 6.3, panel b). The areas of 
reduced fluorescence levels in cytosolic calcein fluorescence corresponded to red 
fluorescent mitochondria stained with TMRM (Figure 6.3, panel b-d). However, under 
these conditions, because of the relatively small difference between the intensity of 
calcein fluorescence in mitochondria versus the cytosol, it was difficult to visually 
discriminate mitochondria solely on this basis. Higher concentrations of TMRM were 
also tested. In cells stained with 100 nM, 500 nM and particularly 2000 nM TMRM, the 
intensity of green calcein fluorescence detected within mitochondria visibly decreased 
and they became more easily discernable as darkened voids within the brightly 
fluorescent cytosol (Figure 6.3 panels e and h). Thus, it is possible that when calcein- 
AM-loaded cells were stained with TMRM (at 100 nM or 500 nM, but not at 50 nM), 
mitochondrially-accumulated TMRM caused quenching of intra-mitochondrial calcein 
fluorescence.
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This interpretation was confirmed by quantitative analysis of images collected for cells 
pinocytically loaded with calcein and stained with a range of concentrations of TMRM. 
When low concentrations of TMRM were used, the average intensity of calcein 
fluorescence in ROI drawn within mitochondria was approximately 90% of that in the 
cytosol, confirming that calcein-AM is poorly excluded by Jurkat cell mitochondria 
(Figure 6.4). Similar results were obtained for U937 cells (data not shown). As the 
concentration of TMRM used to stain cells was increased above 100 nM, calcein 
fluorescence within mitochondria decreased (Figure 6.4). The level of calcein 
fluorescence within mitochondria in cells stained with 1-2 //M TMRM was significantly 
reduced from that in cells stained with 10-100 nM TMRM (p<0.001, F363=37.0, Tukey 
Kramer HSD (Honestly Significant Difference)).
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Figure 6.3: Images acquired by confocal microscopy showing Jurkat cells incubated in 1 
fiM  calcein-AM and stained with 0-2000 nM TMRM. Images are representative of 
several independent experiments.
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Figure 6.4 : Plot showing the level of calcein fluorescence, in ROI drawn within 
TM RM-stained mitochondria, expressed as a percentage of the cytosolic calcein 
fluorescence for Jurkat cells loaded with 1 calcein-AM and stained with 0.01 -  2 
HM TMRM. For each data point, the error bars shown represent the standard errors of 
the mean of values determined for 10 cells.
6.3.2 Imaging Mitochondria by Pinocytic Loading of Calcein 
into Cells and Staining with TMRM
Mitochondria were imaged in both suspension-cultured (Jurkat cells) and adherent 
(HeLa cells) human cells following pinocytic loading of calcein and staining with 
TMRM. In HeLa cells, mitochondria excluded sufficient calcein to give them the 
appearance of darkened voids in a bright green background of cytosolic fluorescence 
(Figure 6.5, panel a). Polarised mitochondria stained with TMRM were clearly 
discerned by their bright red fluorescence (Figure 6.5, panel b) and corresponded in 
position to darkened areas in the calcein fluorescence (Figure 6.5, panel c). In some 
cells, the edges of the darkened areas excluding calcein appeared ‘blurred’. Petronilli et
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al. (1999) reported a similar staining pattern in cells loaded with calcein and suggest 
that this is probably the result of fluorescence spreading which magnifies the size of 
emitting objects, while reducing that of dark spots. Similar results were obtained when 
Jurkat cells were used (Figure 6.6 and Figure 6.7).
Figure 6.5: Confocal microscopy images showing HeLa cells pinocytically loaded with 
calcein and stained with 50 nM TMRM. Images show: calcein fluorescence (a), TMRM 
fluorescence (b), and fluorescence overlay (c). Images shown are representative of 
many acquired in two independent experiments.
Jurkat cells were pinocytically loaded with calcein and stained with TMRM before 
subsequently being analysed over a period of 1 hour; cells were analysed immediately 
after pinocytic loading and again 30 and 60 minutes later. Immediately after staining, 
calcein was evenly distributed throughout the cytosol and was partly excluded from 
mitochondria; mitochondria appeared as darkened areas in a background of bright green 
fluorescence (Figure 6.6). Polarised mitochondria stained with TMRM were clearly 
discerned by their bright red fluorescence and corresponded in position to darkened 
areas in the calcein fluorescence (data not shown). Quantitative image analysis indicated 
that immediately after pinocytic loading with calcein, the level of calcein fluorescence 
in ROI drawn within m itochondria (defined by staining with TMRM ) was
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approximately 60% of that of the cytosol (Figure 6.7). A gradual time-dependent in­
filling of mitochondria with calcein was observed over the hour time period (Figure 6.6, 
panels b and c). This was confirmed by quantitative image analysis, which indicated 
that over a 60 minute period immediately following pinocytic loading, for ROI drawn 
within mitochondria of control cells, the average intensity of calcein fluorescence 
increased steadily from 60% to approximately 80% of that in the cytosol (Figure 6.7). 
These changes in fluorescence were statistically significant (p<0.001, F239=24.99, 
Tukey-Kramer HSD) and occurred in the absence of any loss of TMRM staining 
(Figure 6.8).
The slow calcein influx was inhibited by treating cells for 1 hour with bongrekic acid 
(BA) or cyclosporin A prior to calcein loading and TMRM staining. Bongrekic acid and 
cyclosporin A are both pharmacological inhibitors of MPT (Marchetti et al., 1996). In 
contrast to control cells, over a 1 hour period following pinocytic loading of calcein, 
there was no significant change in the average intensity of calcein fluorescence within 
ROI drawn within mitochondria of BA-treated cells (Figure 6.7: p=0.156, F239=1.95, 
Tukey-Kramer HSD). Similar results were obtained using cells treated with cyclosporin 
A (data not shown).
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Figure 6.6: Confocal microscopy images showing calcein fluorescence in control (a-c) 
or BA-treated (d-f) Jurkat cells pinocytically loaded with calcein (and stained with 50 
nM TMRM), imaged either immediately after loading (a, d), or 30 minutes (b, e) or 60 
minutes (c, f) later.
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Figure 6.7: Line graph showing the levels of intra-mitochondrial calcein fluorescence in 
control cells (♦ )  and BA-treated cells (□ ) , expressed as a percentage of the level of 
cytosolic calcein fluorescence, as a function of time after pinocytic loading. The error 
bars shown represent standard errors of the mean of measurements made for 10-14 cells 
for each data point (see section 6.2.2.3 for more details).
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Figure 6.8: Overlay histograms showing the results of flow cytometric analysis of Jurkat 
cells pinocytically loaded with calcein. The dashed line (the single peak to the left) 
represents cells that were not stained with TMRM. The dotted and solid lines (which are 
nearly identical in position) represent cells that were stained with TMRM and analysed 
either im mediately or 60 minutes later, respectively. The results shown are 
representative of three independent experiments.
6.3.3 Detecting Mitochondrial Permeability Transition Induced 
by Retinoic Acid
Pinocytic loading of cells with calcein and staining with TMRM was also used to detect
MPT induced by brief incubation of cells with retinoic acid (RA). Previous research
indicates that RA acts as a mitochondrial uncoupler and induces MPT and cyctochrome
c release (Rigobello et al., 1999). Immediately after exposure to RA, calcein
fluorescence was uniform throughout the entire cell. Mitochondria were not discernable
as dark regions or regions of significantly lower green fluorescence and mitochondria
did not stain with TMRM, indicating collapse of (Figure 6.9). In control cells,
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most areas of reduced calcein fluorescence corresponded in position to TMRM-stained 
mitochondria (e.g. the region indicated by arrow no .l, Figure 6.9, panels a and c). 
However, occasionally, areas of lower calcein fluorescence did not correspond in 
position with TMRM-stained, polarised mitochondria (e.g. the region indicated by 
arrow no.2, Figure 6.9, panel c). This latter type of calcein void was previously reported 
in hepatocytes microinjected with calcein (Petronilli et al., 1999) but has not been 
identified. It is possible that such regions may correspond to transiently depolarised 
mitochondria that have not undergone MPT and that therefore still exclude calcein.
Calcein T M R M  Overlay
Control
+RA
Figure 6.9: Confocal images showing Jurkat cells pinocytically loaded with calcein and 
stained with 50 nM TMRM. Control cells (a-c) received no further treatment. Other 
cells (+ RA: d-f) were stained with TMRM in the presence of 0.5 nM RA to induce 
mitochondrial permeability transition. The arrow numbered 1 (panel a) indicates a ‘dark 
region’ that corresponds in position to TMRM-stained mitochondria (see panel c). The 
arrow numbered 2 (panel c) indicates a ‘dark region’ that does not correspond in 
position to TMRM-stained mitochondria.
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6.4 Discussion
Results presented here demonstrate that pinocytic loading of calcein into cells and 
staining with 50 nM TMRM can provide a useful technique for detecting MPT in intact 
cells. MPT was detected by a loss of mitochondrial staining with TMRM and an 
increase in calcein fluorescence inside mitochondria. Results show that, in a variety of 
cell types, cytosolic calcein is excluded from normal polarized mitochondria but enters 
them during MPT.
Minamikawa et al. (1999) and Nieminen et al. (1995) describe alternative techniques to 
measure MPT in intact cells (see section 6.1). The technique described in this chapter is 
a favourable alternative and avoids the disadvantages associated with the earlier 
approaches. The advantages of this new technique are:
1. It has successfully been applied to various cell lines including HeLa (human 
epitheloid carcinoma), Jurkat (human T cell leukemia) and U937 (human 
myelomonocytic), suggesting that it would be applicable to use in most cell 
types. The technique described by Nieminen et al. (1995) is only applicable to 
some cell types. Nieminen et al. (1995) and Lemasters et al. (1998) reported that 
when calcein-AM only is loaded (by diffusion) into rat hepatocytes and then the 
cells are stained with TMRM, there appeared to be little calcein fluorescence 
detected within mitochondria. However, results described in this chapter and 
those of others (Petronilli et al., 1999) show that this is not the case when other 
cell types, such as rat hepatoma MH1C1 and Jurkat cells, are loaded with 
calcein-AM. In these cases, the ability of the technique (described by Nieminen 
et al. (1995)) to image mitochondria as calcein-negative voids, and thereby 
measure MPT in intact cells, is significantly limited.
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2. It does not involve toxic substances. The technique of Minamikawa et al. (1999) 
to measure MPT (Figure 6.1, panel b) involves loading cells with calcein-AM 
but quenching cytosolic calcein fluorescence with Co2+ ions (Minamikawa et al., 
1999a; Minamikawa et al., 1999b). Co2+ is a heavy metal that is known to cause 
toxic and other effects on cells. For example Co2+ (1) completely stopped growth 
in murine osteoblast-like MC3T3-E1 cells (Okazaki et al., 1998), (2) had 
adverse effects on developmental stages of post-blastocyst mouse pre-embryos 
in vitro  (Nieminen et al., 1995), and (3) significantly increased lactate 
production by cultured rat Sertoli cells (Monsees et al., 1998). It is difficult to 
exclude the possibility that even short exposures of cells to Co2+ might induce 
subtle changes that impact upon mitochondrial physiology.
3. It avoids potential artefacts arising from quenching of intra-mitochondrial 
calcein fluorescence. The technique described by Nieminen et al. (1995), 
(Figure 6.1, panel a) which stains cells with TMRM at a concentration of 500 
nM or above, causes mitochondrially-accumulated TMRM to suppress intra- 
mitochondrial calcein fluorescence, probably by fluorescence quenching 
(TMRM has been shown to quench calcein fluorescence both in a mixture of the 
two fluors in solution and in dual-stained isolated mitochondria (Petronilli et al., 
1999)). Even in cell types which do not accumulate intra-mitochondrial calcein 
following loading from 1 ^M  calcein-AM, this quenching effect may have 
important implications. For example, if calcein-AM-loaded cells are stained with 
TMRM at a concentration of 500 nM or greater, TMRM-mediated quenching is 
likely to make detection of calcein entry into mitochondria more difficult. This 
would probably be most problematic when mitochondria remain polarised and 
therefore retain a high internal concentration of TMRM, as has been reported to
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occur when mitochondria undergo transient, reversible openings of the 
mitochondrial permeability transition pores (Petronilli et al., 1999). Thus, under 
these conditions, MPT might go undetected.
4. It unambiguously identifies the physical movement of calcein across the inner 
mitochondrial membrane barrier coincident with MPT. The technique described 
by Minamikawa and associates (Figure 6.1, panel b), relies on calcein-AM 
entering mitochondria within cells and being cleaved by esterases to entrap 
calcein within the matrix. This does not occur when rat hepatocytes are 
incubated in a solution containing 1 j/M calcein-AM (Lemasters et al., 1998). 
Thus, at least in this cell type, the technique is not successful or it may require 
cell-specific adjustments to the conditions used. Also Minamikawa’s technique 
can not discriminate between calcein release from mitochondria or Co2+ entry 
into mitochondria.
Importantly, cell viability was maintained when calcein was loaded into cells using the 
technique described in this chapter. To load calcein into the cytosol, cells were exposed 
for 10 minutes to a hyperosmotic buffer followed by a 7 minute exposure to a 
hypoosmotic solution (the effects of which would tend to counter the initial 
hyperosmotic stress). When measured up to 3 days after treatment, no effects of 
pinocytic loading on the viability of L929 cells were detected (Okada and Rechsteiner, 
1982). Furthermore, in studies of Jurkat and HeLa cells, results confirmed that at 5 
hours after pinocytic loading there was no decrease in cell viability (data not shown). 
Thus, pinocytic loading has no gross effects on cell viability. Furthermore, the 
demonstration that cytosolic hyperosmolarity induced by uptake of Na+-co-transported, 
non-metabolised amino acids did not affect either matrix volume, respiratory rate,
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NADH/NAD+ ratio or in mitochondria within intact hepatocytes (Devin et al., 
1998) suggests that the mild osmotic stress associated with pinocytic loading is unlikely 
to affect mitochondria. It has been shown that osmotic stress sustained for a minimum 
of 30-100 minutes can induce changes in general cellular metabolism (Brunmair et al., 
2000; Ouwens et al., 2001); however, there is no evidence that short (< 10 minutes) 
exposure to mild osmotic stress produces such changes. Using the technique described 
in this chapter, measurements of MPT are best performed within 30 minutes of 
pinocytic loading. Thus, the available information suggests that the brief, mild osmotic 
stress associated with the procedure is unlikely to result in any major, rapid changes in 
mitochondria or cell metabolism that would compromise the measurements taken.
Results presented in this chapter show that, when cells were imaged immediately after 
pinocytic loading of calcein, the level of calcein fluorescence in ROI drawn within 
TMRM-stained mitochondria of control cells was approximately 60% of that in the 
cytosol, and increased gradually thereafter. The high level of measured intra- 
mitochondrial calcein fluorescence is probably a consequence of the following two 
factors, which relate to features of mitochondrial ultrastructure and the physics of 
confocal imaging: (1) Electron microscopy indicates that mitochondria are 0.1-0.5 fxm 
thick and, when present as discrete structure, 1-2 |xm long (Frey and Mannella, 2000). 
Confocal imaging collects ‘optical sections’ through the specimen of about 1 //m in 
thickness. Mitochondrial ROI were drawn inside areas containing red (TMRM) 
fluorescence. In some planes, the 1 //m thickness of the confocal optical section would 
be greater than the dimensions of mitochondria. In these cases, three-dimensional 
spaces seen (in two-dimensions) on-screen as containing TMRM fluorescence might 
also contain calcein fluorescence coming from adjacent regions of intermembrane space
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or cytosol that have been captured in the same optical section. (2) Recent ultra-structural 
analysis indicates that the cristae, which may occupy a large fraction of the volume of 
the mitochondrial interior, are generally connected to the intermembrane space via short 
tubular junctions 28 nm in diameter (Frey and Mannella, 2000). Calcein would have 
free access (across the permeable outer mitochondrial membrane) to the intermembrane 
space and, via the cristae junctions, to the cristae. Confocal microscopy is unable to 
spatially resolve cristae within mitochondria. Therefore, using the technique described, 
optical sections through the TMRM-stained mitochondrial matrix will incorporate 
calcein-containing cristae, even though these are not discerned as discrete visible 
structures. Therefore, acting together, both these factors probably account for the level 
of calcein fluorescence measured in mitochondrial ROI immediately after pinocytic 
loading.
Studies of mitochondria, both in intact cells and as isolated organelles in vitro, have 
established that MPT pores constitutively undergo rapid transient openings (Petronilli et 
al., 1999; Ichas et al., 1997; Huser et al., 1998). The technique described in this chapter 
detected constitutive transient MPT as a gradual time-dependent entry of calcein into 
mitochondria. Furthermore, these results demonstrate that RA, a known inducer of MPT 
(Rigobello et al., 1999), elicited an influx of calcein into the matrix and a loss of 
mitochondrial staining with TMRM. Thus, the technique described here can be used to 
measure the occurrence of MPT ‘flickering’ and also the bulk entry of calcein into 
mitochondria associated with sustained MPT. The latter is most easily detected when 
cells are imaged soon after calcein loading.
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Although this new technique has many advantages over previously described methods, 
two limitations have been identified. These are: (1) the measurement of sustained MPT 
(detected as complete in-filling of mitochondria with calcein) is best performed within 
30 minutes of pinocytic loading, and, more importantly, (2) detection of MPT in cells 
undergoing apoptosis is not possible. When cells were pinocytically loaded with calcein 
several hours after induction of apoptosis, it was not possible to induce release of 
calcein from pinocytic vesicles by incubating cells in hypoosmotic media, even when 
conditions were varied to increase the osmotic gradient imposed. This result was 
obtained when apoptosis was induced in either (1) Jurkat cells with staurosporine or 
anti-Fas antibody, or (2) U937 cells with tumour necrosis factor a  and cycloheximide 
(results not shown). The reason(s) underlying the difference in behaviour between 
normal and apoptotic cells is unknown, but it may relate to an increase in the 
permeability of the cell membrane that occurs during apoptosis (Zamai et al., 1996). 
Unfortunately, due to this latter limitation, this technique would not be appropriate to 
determine if novel cancer therapeutics, including that described in section 1.10, induce 
apoptosis in intact cells. Despite these limitations, this technique will be valuable in 







Apoptosis is a highly regulated form of cell death. Minor changes in the process can 
result in diseases, such as cancer. For many years now, clinical treatment of cancer has 
involved chemotherapy, radiotherapy and surgery. However, despite the wide use of 
these conventional treatments, there are still many disadvantages associated with them. 
These disadvantages have led to development of novel cancer therapeutics some of 
which are now in stage I and II clinical trials. This thesis describes work directed 
towards the development of a novel cancer therapeutic comprised of an endosomal- 
disruptive polymer conjugated to both a targeting ligand and, via a pH-sensitive linker, 
to a pro-apoptotic peptide (Bad(140-165)).
Two different types of synthetic polymer (PAAAs and pDMAEMA) were investigated 
for their potential use as endosomal-disruptive agents. PAAAs were found to be 
endocytosed into cells and then transported to late endosomes, where acidification of 
the lumen by the membrane H+-ATPase triggered polymer-mediated vesicle disruption 
and release of endosomal contents to the cytosol. pDMAEMA was also found to be 
endocytosed into cells and transported to endosomes where it induced morphological 
changes in late endosom es/lysosom es (but did not physically disrupt them). 
pDMEAMA induced rapid necrotic death. PAAAs were chosen as the most appropriate 
endosomal-disruptive agents for use in the novel cancer therapeutic because (1) the very 
high toxicity of pDMAEMA could pose a significant risk of bystander cell damage in 
cancer therapies, and (2) under the conditions tested, pDMAEMA did not have the 
ability to disrupt endosomes.
A pH-sensitive hydrazide linker (X) was successfully synthesised and conjugated to 
PEAA and PPAA. Whole cell experiments indicated that the pH-sensitive membrane
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disruptive ability of the polymers was retained following conjugation with the hydrazide 
linker. The stability of the carboxcyclic-hydrazide bond incorporated into the linker was 
then determined. At pH 7, the bond was stable; however, at pH 5, it was very unstable 
and the linker was cleaved almost immediately from the polymer. Lastly, Bad( 140-165) 
was conjugated to PAAA-X and then introduced into cells by constitutive endocytosis. 
Following uptake, in approximately 50% of cells, PAAA-X-Bad(140-165) partially co­
localised with early endosomes. Also, uptake of PAAA-X-Bad(140-165) induced a 
time-dependent release of calcein from endosomes into the cytosol. These results 
showed that PAAA-X-Bad(140-165) was internalised by constitutive endocytosis and 
retained the ability to disrupt endosomes. Cells were expected to undergo apoptosis 
following uptake of PAAA-X-Bad(140-165), however, cell viability was retained. A 
number of possibilities (discussed in section 5.4) have been proposed to explain why 
apoptosis was not induced. Experimental strategies to investigate these possibilities are 
discussed in section 7.1.
Lastly, a new technique was developed to measure MPT in intact cells. Two techniques 
of measuring MPT in intact cells have previously been described (Nieminen et al., 
1995; M inamikawa et al., 1999). However, both these techniques have several 
disadvantages. The new technique involves loading cells with calcein using the process 
of pinocytic loading. This technique simultaneously loads millions of cells with calcein, 
and subsequently visualises mitochondria as darkened voids within a bright green 
fluorescent cytosol. MPT is measured as an in-filling of the dark voids. This new 
technique has several advantages compared to the other techniques, including (1) it is 
applicable to many types of cells, (2) it avoids the use of toxic substances, (3) it avoids 
potential artefacts arising from quenching of intra-mitochondrial calcein fluorescence,
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and (4) it unambiguously identifies the physical movement of calcein across the inner 
mitochondrial membrane barrier coincident with MPT.
This new technique was initially developed to allow accurate measurement of MPT in 
intact cells following uptake of PAAA-X-Bad(140-165). Unfortunately, technical 
limitations prevent the use of this method to measure MPT in cells undergoing 
apoptosis (see section 6.4). Despite this limitation, this technique will be useful in 
functional studies of MPT.
7.1 Contributions of this Work
We hypothesised that uptake of PAAA-X-Bad(140-165) into cells by constitutive 
endocytosis would induce apoptosis, however, this was not the case. Further 
experiments will be needed to determine why apoptosis was not induced. These 
experiments could include:
1. Dual staining of PAAA-X-Bad(140-165). PAAA-X could firstly be conjugated 
with a fluorescent molecule that reacts specifically with carboxyl groups (e.g. 5- 
(aminoacetamido) fluorescein). Bad(140-165) could then be conjugated to the 
fluorescently labelled PAAA-X and biotinylated (as described in this thesis). 
The dual labelled construct could then be introduced into cells by constitutive 
endocytosis and the location of PAAA and Bad(140-165) traced using confocal 
microscopy. These experiments would indicate if Bad(140-165) is cleaved from 
PAAA-X-Bad(140-165) following uptake.
2. Increasing the number of Bad(140-165) molecules released into the cytosol. 
Assuming complete intracellular cleavage of Bad(140-165) from PAAA-X- 
Bad( 140-165), calculations indicated that the maximum intracellular
196
Chapter 7 Conclusions
concentration of Bad( 140-165) delivered by a 20 minute period of constitutive 
endocytosis of PAAA-X-Bad(140-165) from an external concentration of 200 
ixg/ml was 4 fold less than the known KD for the in vitro binding of Bad(140- 
165) to Bcl-XL (see Discussion in Chapter 5). Increasing the number of 
hydrazide linkers and/or Bad(140-165) peptides conjugated to PAAA molecules 
might overcome this potential problem.
3. Determining if Bad(140-165) conjugated to the hydrazide linker alone (X- 
Bad(140-165)) induces apoptosis. These experiments would indicate if the linker 
conjugated to Bad(140-165) prevents the interaction of Bad(140-165) with Bcl- 
XL and in turn prevents apoptosis. X-Bad(140-165) could be introduced into 
cells by pinocytic loading (as described in section 6.2.2.1) or using PEP 1. PEP
1 is a 21-mer amphipathic peptide. It has the ability to efficiently deliver a 
variety of peptides and proteins into several cell types in a fully biological active 
form, without the need for prior chemical coupling or denaturing steps (Morris 
et al., 2001). Following introduction of X-Bad(140-165), a variety of assays for 
apoptosis could be performed, including measurements of mitochondrial 
depolarisation, MPT, caspase activation, PS exposure and cytochrome c release.
Once the factors(s) responsible for the inability of the initial PAAA-X-Bad(140-165) 
constructs to induce apoptosis are identified and resolved, the chosen targeting ligand 
could be conjugated to PAAA-X-Bad(140-165) to produce the desired novel cancer 
therapeutic (as described in section 1.10). The effects of receptor-mediated endocytosis 
of the trimolecular construct on cells could then be established using assays similar to 
those described in this thesis.
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At present, cancer is the second most common cause of death in highly developed 
countries (Szekeres and Novotny, 2002). The development of new cancer therapeutics, 
to be used in conjunction with traditional treatments, will be invaluable in treating 
cancer in the future. Hopefully, this thesis will provide information that will aid in the 
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